Method of treating diseases using an il-17 receptor antibody formulation

ABSTRACT

The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. 119(e) of U.S.patent application No. 61/295,387, filed Jan. 10, 2010 and U.S. patentapplication No. 61/422,059, filed Dec. 10, 2010, which are incorporatedherein by reference.

BACKGROUND

Interleukin-17 (IL-17A) is an inflammatory cytokine initially identifiedas a transcript selectively expressed by activated T cells. IL-17A andIL-17F bind and activate IL-17RA. IL-17RA has been shown to be importantin regulating immune responses. Activation of the IL-17RA leads toproduction of cytokines, chemokines, growth factors, and other proteinsthat contribute to the symptoms and/or pathology of numerous diseases.IL-17A is an inflammatory cytokine that induces the production ofcytokines and other mediators leading to diseases and physiologicaleffects such as inflammation, cartilage degradation, and boneresorption. IL-17A may play a role in a number of inflammatoryconditions including arthritis (rheumatoid arthritis), psoriasis,inflammatory bowel disease, multiple sclerosis, and asthma. (Li et al.,2004, Huazhong Univ. Sci. Technolog. Med. Sci. 24:294-296; Fujino etal., 2003, Gut. 52:65-70; Kauffman et al., 2004, J. Invest. Dermatol.123:1037-1044; Mannon et al., 2004, N. Engl. J Med. 351:2069-2079;Matusevicius et al., 1999, Mult Scler 5, 101-104; Linden et al., EurRespir J. 2000 May; 15(5):973-7; Molet et al., 2001, J. Allergy Clin.Immunol. 108:430-438). Recent studies have suggested that IL-17F plays arole in the induction of inflammatory responses (Oda et al., 2006,American J. Resp. Crit. Care Medicine, Jan. 15, 2006; Numasaki et al.,2004, Immunol Lett. 95:97-104).

IL-17 Receptor A (IL-17RA) has been shown to bind and be activated byIL-17A and IL-17F. Five additional IL-17-like ligands (IL-17B-IL-17F)and four additional IL-17RA-like receptors (IL-17RB-IL-17RE) have beenidentified (Kolls and Linden, 2004, Immunity 21:467-476; Gaffen, 2009,Nat Rev Immunol 8:556-568). IL-17 Receptor C (IL-17RC) has been shown tobind and be activated by IL-17A and IL-17F. IL-17RA and IL-17RC form afunctional heteromeric receptor complex (Toy et al., 2006, J. Immunol.177:36-39; McAllister et al., 2005, J. Immunol. 175:404-412). Inaddition, IL-17 Receptor B (IL-17RB) has also been shown to requireIL-17RA for IL-25 mediated activity (Rickel, et al., 2008, J. Immunol.181:4299-4310), and IL-17RD interacts with IL-17RA to mediate IL-17signaling (Rong, et al., 2009, Cell Research 19:208-215).

DESCRIPTION OF THE DRAWINGS

FIG. 1: A graph depicting the relationship between viscosity and shearrate for various AM-14 formulations. Various excipients were evaluatedin a 10 mM glutamate, pH 4.5 buffer with AM-14 held constant atapproximately 180 mg/ml.

FIG. 2: A graph illustrating the relationship between viscosity andshear rate for various AM-14 formulations. Various excipients wereevaluated in a 10 mM glutamate, pH 5.5 buffer with AM-14 held constantat approximately 180 mg/ml.

FIG. 3: A graph depicting the viscosity of AM-14 at different proteinconcentrations.

FIG. 4: A graph showing the relationship between the viscosity of anAM-14 formulation at 200 mg/ml as a function of varying pH.

FIG. 5: A graph showing the mean percent IL-17 receptor occupancy as afunction of time in healthy volunteers receiving AM-14 doses between 21and 700 mg.

FIG. 6: A graph showing the mean percent IL-17 receptor occupancy as afunction of time in psoriasis patients receiving AM-14 doses of 140, 210and 700 mg.

FIG. 7: A graph showing the mean percent IL-17 receptor occupancy as afunction of time in rheumatoid arthritis receiving AM-14 doses between50 and 210 mg.

FIG. 8: A graph showing monotonically increasing relationship betweenthe pEC50 shift measured by the whole blood stimulation assay and theconcentration of circulating AM-14 measured by the pharmacokineticassay. The concentration of AM-14 is on the x-axis and the pEC50 shiftis on the y-axis.

FIG. 9: A graphical depiction of the predicted mean AM-14pharmacokinetic profiles based on modeling of the single dose study

FIG. 10: A schematic of the PK-PD model used in some forms of analysis.The syringe indicates sites of dosing: a bolus to the depot (SC); aninfusion to the central compartment (IV); or initiation of a placeboeffect. Inflammation (as measured by PASI score) is represented by aninflammation compartment with endogenous rates of synthesis (ksyn) anddegradation (kdeg). Drug concentrations in the effect compartment act todecrease ksyn and thereby decreasing inflammation. The placebo effect ismodeled as a hypothetical compartment with its own kinetics. The placeboeffect acts to increase kdeg and thereby decreasing inflammation.

FIG. 11: A depiction of the mean model-predicted PASI (as percent ofbaseline) compared to mean (SD) observed PASI data (as percent ofbaseline by cohort) over time after single dose administration of AM-14or placebo.

FIG. 12: A graphical depiction of the predicted mean PASI response timecourse for multiple dose scenarios (including placebo).

FIG. 13: A graphical depiction of the predicted week 12 median percentPASI improvement (dose-response curve) for AM-14, with 90% confidenceinterval shaded; for various dose levels each administered SC at week 0,1, 2, 4, 6, 8, and 10.

FIG. 14: A graph depicting changes in epidermal thickness over time insubjects receiving AM-14 (filled object) compared to placebo (emptycircles). Administration of AM-14 led to significant reductions inepidermal thickness in psoriasis subjects compared to placebo.

FIG. 15: A graph depicting changes in Keratin-16 (KRT16) over time insubjects receiving AM-14 (filled object) compared to placebo (emptycircles). Administration of AM-14 led to significant reductions in KRT16mRNA in psoriasis subjects compared to placebo.

FIG. 16: A graph depicting changes in Ki67 counts over time in subjectsreceiving AM-14 (filled object) compared to placebo (empty circles).AM-14 led to significant reductions in Ki67 counts in psoriasis subjectscompared to placebo.

DETAILED DESCRIPTION

It is understood that any and all of the various attributes of theembodiments provided herein that are described in separate paragraphsand are later combined in a specific embodiment or the selection of aspecific embodiment from a list of embodiments does not constitute addedor new matter. Applicants affirmatively state that all such combinationsare specifically envisioned and are specifically encompassed by thisdisclosure.

IL-17 Receptor “A”

“IL-17 receptor A” or “IL-17RA” (interchangeably used herein, as well asIL-17 receptor and IL-17R all refer to the same receptor) is the cellsurface receptor known in the art (see for example Yao, et al., 1997,Cytokine Vol. 9, No. 11:794-800). The cloning, characterization ofIL-17RA is described, for example, in U.S. Pat. No. 6,072,033, which isincorporated herein by reference in its entirety. IL-17RA binds, at aminimum, IL-17A and/or IL-17F and is activated by IL-17A and/or IL-17For other IL-17 ligands, as well as heteromeric forms of one or moreIL-17 ligands, such as but not limited to, IL-17A/IL-17F heteromers.

IL-17RA Antibody Biopharmaceutical Formulations

Aspects of the present invention are directed to biopharmaceuticalformulations (also referred to herein as simply “formulation”)incorporating the AM-14 antibody, as variously defined herein. AM-14 isdescribed in detail in WO 2008/054603, U.S. Ser. No. 11/906,094, U.S.Pat. Nos. 7,786,234, 7,833,527, and 7,767,206 which are hereinincorporated by reference in their entirety. AM-14 specifically binds tohuman IL-17RA and inhibits the biological activity of IL-17A, IL-17F,and IL-17A/IL-17F heterodimers, and/or the activation of IL-17RA as wellas a heteromeric complex of IL-17RA and IL-17RC (IL-17 Receptor “C”).AM-14 also has the unique property of inhibiting IL-17RB (IL-17 Receptor“B”) activation through its ligand IL-25, while not being bound by thistheory, presumably by affecting the heteromeric receptor complexcomprising IL-17RA and IL-17RB. The IL-17RA-RB complex and the use ofAM-14 in inhibiting the biological activity of IL-25 are described inPCT/US2009/001085 and is herein incorporated by reference in itsentirety.

AM-14 comprises a heavy chain sequence comprising SEQ ID NO:1 (oralternatively the heavy chain sequence comprising SEQ ID NO:12 which hasthe COOH-terminus Lys removed from SEQ ID NO:1) and a light chainsequence comprising SEQ ID NO:2, or a human IL-17RA binding fragmentthereof. AM-14 comprises a heavy chain variable region sequencecomprising SEQ ID NO:3 and a light chain variable region sequencecomprising SEQ ID NO:4, or a human IL-17RA binding fragment thereof,wherein said AM-14 antibody binds human IL-17RA. AM-14 comprises a heavychain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ IDNO:6 (or alternatively the heavy chain CDR2 comprising SEQ ID NO:7), aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, or a human IL-17RA binding fragmentthereof, wherein said AM-14 antibody binds human IL-17RA.

As used herein, the term “biopharmaceutical” is intended to mean amacromolecule such as a polypeptide, nucleic acid, carbohydrate orlipid, or building block thereof, that is intended for use as apharmaceutical, which in this instance is the antibody AM-14. A“biopharmaceutical formulation” refers to a pharmaceutically acceptablemedium that is compatible with a biopharmaceutical and is safe andnon-toxic when administered to humans.

The term “a” or “an”, refers to one or more, for example, “animmunoglobulin molecule,” is understood to represent one or moreimmunoglobulin molecules. As such, the terms “a” (or “an”), “one ormore,” and “at least one” can be used interchangeably herein.

It is understood that when describing a range of values, thecharacteristic being described can be an individual value found withinthe range. For example, “a pH from about pH 4 to about pH 6,” can be,but is not limited to, pH 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8,4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, etc. and anyvalue in between such values. Additionally, “a pH from about pH 4 toabout pH 6,” should not be construed to mean that the pH of aformulation in question varies 2 pH units in the range from pH 4 to pH 6during storage, but rather a value may be picked in that range for thepH of the solution, and the pH remains buffered at about that pH.

A formulation comprising a buffering solution and AM-14 is provided. Thebuffering solution may comprise a glutamic acid or an acetic acidbuffer. The buffering solution comprises a glutamic acid buffer. Thespecification also provides a method of preparing the formulation,methods of treating a condition using the formulated AM-14, and a kitcontaining components of the formulation.

A highly significant advance has been made in the formulation of AM-14(i.e., biopharmaceutical formulations of AM-14) in that highconcentrations of AM-14 in solution have been achieved. Therefore,embodiments include highly concentrated AM-14 formulations. Highconcentration AM-14 formulations are desirable in that this allows lowervolume administration and/or fewer administrations and consequently lessdiscomfort to the patient.

An additional highly significant advance is that AM-14 formulations havecomparatively low viscosity at high protein concentrations. AM-14formulations having lower viscosity are highly desirable, in that thisfacilitates manufacturability (such as but not limited to processing,filtering, and filling), the use standard syringe and needleconfigurations (as appropriate for the route of administration),adaptability to art-known auto-injector and microinfusion devices, easeof administration, and reducing shear forces to AM-14 uponadministration. An added benefit of lower viscosity AM-14 formulationsis less discomfort to the patient upon administration.

A further highly significant advance over the art is that AM-14formulations described herein having high concentration of AM-14(i.e., >100 mg/ml) are surprisingly stable, as described in thestability studies in Example 1.

In addition, it has been surprisingly found that glutamate-basedformulations at 10 mM glutamate do not induce unacceptable stinging/painupon subcutaneous injection, as described in Example 5.

Embodiments of AM-14 formulations include a biopharmaceuticalformulation of AM-14 having a concentration range of AM-14 in solutionof 60 to 250 mg/ml, 60 to 240 mg/ml, 60 to 230 mg/ml, 60 to 220 mg/ml,60 to 210 mg/ml, 60 to 200 mg/ml, 60 to 190 mg/ml, 60 to 180 mg/ml, 60to 170 mg/ml, 60 to 160 mg/ml, 60 to 150 mg/ml, 60 to 140 mg/ml, 60 to130 mg/ml, 60 to 120 mg/ml, 60 to 110 mg/ml, 60 to 100 mg/ml, 70 to 250mg/ml, 70 to 240 mg/ml, 70 to 230 mg/ml, 70 to 220 mg/ml, 70 to 210mg/ml, 70 to 200 mg/ml, 70 to 190 mg/ml, 70 to 180 mg/ml, 70 to 170mg/ml, 70 to 160 mg/ml, 70 to 150 mg/ml, 70 to 140 mg/ml, 70 to 130mg/ml, 70 to 120 mg/ml, 70 to 110 mg/ml, 70 to 100 mg/ml, 80 to 250mg/ml, 80 to 240 mg/ml, 80 to 230 mg/ml, 80 to 220 mg/ml, 80 to 210mg/ml, 80 to 200 mg/ml, 80 to 190 mg/ml, 80 to 180 mg/ml, 80 to 170mg/ml, 80 to 160 mg/ml, 80 to 150 mg/ml, 80 to 140 mg/ml, 80 to 130mg/ml, 80 to 120 mg/ml, 80 to 110 mg/ml, 80 to 100 mg/ml, 90 to 250mg/ml, 90 to 240 mg/ml, 90 to 230 mg/ml, 90 to 220 mg/ml, 90 to 210mg/ml, 90 to 200 mg/ml, 90 to 190 mg/ml, 90 to 180 mg/ml, 90 to 170mg/ml, 90 to 160 mg/ml, 90 to 150 mg/ml, 90 to 140 mg/ml, 90 to 130mg/ml, 90 to 120 mg/ml, 90 to 110 mg/ml, 90 to 100 mg/ml, 100 to 250mg/ml, 100 to 240 mg/ml, 100 to 230 mg/ml, 100 to 220 mg/ml, 100 to 210mg/ml, 100 to 200 mg/ml, 100 to 190 mg/ml, 100 to 180 mg/ml, 100 to 170mg/ml, 100 to 160 mg/ml, 100 to 150 mg/ml, 100 to 140 mg/ml, 100 to 130mg/ml, 100 to 120 mg/ml, 100 to 110 mg/ml, 110 to 250 mg/ml, 110 to 240mg/ml, 110 to 230 mg/ml, 110 to 220 mg/ml, 110 to 210 mg/ml, 110 to 200mg/ml, 110 to 190 mg/ml, 110 to 180 mg/ml, 110 to 170 mg/ml, 110 to 160mg/ml, 110 to 150 mg/ml, 110 to 140 mg/ml, 110 to 130 mg/ml, 110 to 120mg/ml, 120 to 250 mg/ml, 120 to 240 mg/ml, 120 to 230 mg/ml, 120 to 220mg/ml, 120 to 210 mg/ml, 120 to 200 mg/ml, 120 to 190 mg/ml, 120 to 180mg/ml, 120 to 170 mg/ml, 120 to 160 mg/ml, 120 to 150 mg/ml, 120 to 140mg/ml, 120 to 130 mg/ml, 130 to 250 mg/ml, 130 to 240 mg/ml, 130 to 230mg/ml, 130 to 220 mg/ml, 130 to 210 mg/ml, 130 to 200 mg/ml, 130 to 190mg/ml, 130 to 180 mg/ml, 130 to 170 mg/ml, 130 to 160 mg/ml, 130 to 150mg/ml, 130 to 140 mg/ml, 140 to 250 mg/ml, 140 to 240 mg/ml, 140 to 230mg/ml, 140 to 220 mg/ml, 140 to 210 mg/ml, 140 to 200 mg/ml, 140 to 190mg/ml, 140 to 180 mg/ml, 140 to 170 mg/ml, 140 to 160 mg/ml, 140 to 150mg/ml, 150 to 250 mg/ml, 150 to 240 mg/ml, 150 to 230 mg/ml, 150 to 220mg/ml, 150 to 210 mg/ml, 150 to 200 mg/ml, 150 to 190 mg/ml, 150 to 180mg/ml, 150 to 170 mg/ml, 150 to 160 mg/ml, 160 to 250 mg/ml, 160 to 240mg/ml, 160 to 230 mg/ml, 160 to 220 mg/ml, 160 to 210 mg/ml, 160 to 200mg/ml, 160 to 190 mg/ml, 160 to 180 mg/ml, 160 to 170 mg/ml, 180 to 250mg/ml, 180 to 240 mg/ml, 180 to 230 mg/ml, 180 to 220 mg/ml, 180 to 210mg/ml, 180 to 200 mg/ml, 180 to 190 mg/ml, 190 to 250 mg/ml, 190 to 240mg/ml, 190 to 230 mg/ml, 190 to 220 mg/ml, 190 to 210 mg/ml, 190 to 200mg/ml, 200 to 250 mg/ml, 200 to 240 mg/ml, 200 to 230 mg/ml, 200 to 220mg/ml, 200 to 210 mg/ml, 210 to 250 mg/ml, 210 to 240 mg/ml, 210 to 230mg/ml, 210 to 220 mg/ml, 220 to 250 mg/ml, 220 to 240 mg/ml, 220 to 230mg/ml, 230 to 250 mg/ml, 230 to 240 mg/ml, or 240 to 250 mg/ml.

Embodiments of AM-14 formulations include a biopharmaceuticalformulation of AM-14 having a concentration of at least 70, 71, 72, 73,74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91,92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107,108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121,122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135,136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149,150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163,164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177,178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191,192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205,206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219,220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233,234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247,248, 249, or 250 mg/ml. Embodiments of AM-14 formulations include abiopharmaceutical formulation of AM-14 having a concentration of 100-150mg/ml±0.01-5%. Embodiments of AM-14 formulations include abiopharmaceutical formulation of AM-14 having a concentration of 140mg/ml±0.01-5%.

Embodiments of AM-14 formulations comprise an acetic acid or glutamicacid buffer wherein the acetic acid or glutamic acid bufferconcentration is from about 5 to 30±0.2 mM, including 5±0.2, 6±0.2,7±0.2, 8±0.2, 9±0.2, 10±0.2, 11±0.2, 12±0.2, 13±0.2, 14±0.2, 15±0.2,16±0.2, 17±0.2, 18±0.2, 19±0.2, 20±0.2, 21±0.2, 22±0.2, 23±0.2, 24±0.2,25±0.2, 26±0.2, 27±0.2, 28±0.2, 29±0.2, or 30±0.2 mM. Embodiments ofAM-14 formulations comprise a glutamic acid buffer wherein the glutamicacid buffer concentration is 10±0.2 mM.

As used herein, the term “acetic acid buffer” is intended to mean abuffer comprising acetic acid. The buffer can be made from an acetatesalt, for example, sodium acetate. Other salts can be used, for example,potassium, ammonium, calcium or magnesium salts of acetate. “Acetic acidbuffer” and “acetate buffer” are used interchangeably.

As used herein, the term “glutamic acid buffer” is intended to mean abuffer comprising glutamic acid. The buffer can be made from a glutamatesalt, for example, sodium glutamate. Other salts can be used, forexample, potassium, ammonium, calcium or magnesium salts of glutamate.“Glutamic acid buffer” and “glutamate buffer” are used interchangeably.In other embodiments, the glutamic acid and/or the acetic acid bufferscan be used in combination with proline as an excipient (includingL-proline).

Embodiments of AM-14 formulations comprise an acetic acid or glutamicacid buffer having a pH of 4.5 to 5.5±0.2, or a range of 4.8 to 5.2±0.2,including a pH of 4.6±0.2, 4.7±0.2, 4.8±0.2, 4.9±0.2, 5.0±0.2, 5.1±0.2,5.2±0.2, 5.3±0.2, 5.4±0.2, and 5.5±0.2. Embodiments of AM-14formulations comprise a glutamic acid buffer having a pH of 4.8±0.2.

As used herein, the term “excipient” is intended to mean atherapeutically inactive substance. Excipients can be included in abiopharmaceutical formulation for a wide variety of purposes including,for example, as a diluent, vehicle, buffer, stabilizer, tonicity agent,bulking agent, surfactant, cryoprotectant, lyoprotectant, anti-oxidant,metal ion source, chelating agent and/or preservative. Optimalexcipients also are chosen to enhance or provide stabilization withreference to the mode of administration for an aqueous biopharmaceuticalformulation of the invention. For example, parenteral routes ofintravenous (IV), subcutaneous (SC) or intramuscular (IM) administrationcan be more safe and efficacious when all components of the formulationmaintain physical and chemical stability during manufacture, storage andadministration. The excipients exemplified herein for use in abiopharmaceutical formulation exhibit these and other characteristics.Excipients are well known in the art and can be found described in, forexample, Wang W., Int. J. Pharm. 185:129-88 (1999) and Wang W., Int. J.Pharm. 203:1-60 (2000).

Excipients include, for example, polyols such as sorbitol or mannitol;sugars such as sucrose, lactose or dextrose; polymers such aspolyethylene glycol; salts such as NaCl, KCl or calcium phosphate, aminoacids such as glycine, methionine or glutamic acid, surfactants, metalions, buffer salts such as propionate, acetate or succinate,preservatives and polypeptides such as human serum albumin, as well assaline and water. Other excipients useful in either a liquid orlyophilized biopharmaceutical formulation of the invention include, forexample, fucose, cellobiose, maltotriose, melibiose, octulose, ribose,xylitol, arginine, histidine, glycine, alanine, methionine, glutamicacid, lysine, imidazole, glycylglycine, mannosylglycerate, Triton X-100,Pluoronic F-127, cellulose, cyclodextrin, dextran (10, 40 and/or 70 kD),polydextrose, maltodextrin, ficoll, gelatin, hydroxypropylmeth, sodiumphosphate, potassium phosphate, ZnCl2, zinc, zinc oxide, sodium citrate,trisodium citrate, tromethamine, copper, fibronectin, heparin, humanserum albumin, protamine, glycerin, glycerol, EDTA, metacresol, benzylalcohol and phenol. Sugar alcohols, also known as a polyols, polyhydricalcohols, or polyalcohols, are hydrogenated forms of carbohydrate havinga carbonyl group reduced to a primary or secondary hydroxyl group.Polyols can be used as stabilizing excipients and/or isotonicity agentsin both liquid and lyophilized formulations. Polyols can protectbiopharmaceuticals from both physical and chemical degradation pathways.Preferentially excluded co-solvents increase the effective surfacetension of solvent at the protein interface whereby the mostenergetically favorable structural conformations are those with thesmallest surface areas. Specific examples of sugar alcohols includesorbitol, glycerol, mannitol, xylitol, maltitol, lactitol, erythritoland threitol. Reducing sugars include, for example, sugars with a ketoneor aldehyde group and contain a reactive hemiacetal group, which allowsthe sugar to act as a reducing agent. Specific examples of reducingsugars include fructose, glucose, glyceraldehyde, lactose, arabinose,mannose, xylose, ribose, rhamnose, galactose and maltose. Non-reducingsugars contain an anomeric carbon that is an acetal and is notsubstantially reactive with amino acids or polypeptides to initiate aMaillard reaction. Specific examples of non-reducing sugars includesucrose, trehalose, sorbose, sucralose, melezitose and raffinose. Sugaracids include, for example, saccharic acids, gluconate and otherpolyhydroxy sugars and salts thereof.

Embodiments of AM-14 formulations include sucrose, glycine, proline,glycerol, and/or sorbitol as excipients, which can be included atconcentration ranges of about 1 to 20% (w/v)±0.2% (w/v), or a range of 5to 10% (w/v)±0.2% (w/v), or a range of 3 to 9% (w/v)±0.2% (w/v),including a concentration of 1±0.2, 2±0.2, 3±0.2, 4±0.2, 5±0.2, 6±0.2,7±0.2, 8±0.2, 9±0.2, 10±0.2, 11±0.2, 12±0.2, 13±0.2, 14±0.2, 15±0.2,16±0.2, 17±0.2, 18±0.2, 19±0.2, or 20%±0.2% (w/v).

As used herein, the term “surfactant” is intended to mean a substancethat functions to reduce the surface tension of a liquid in which it isdissolved. Surfactants can be included in a biopharmaceuticalformulation for a variety of purposes including, for example, to preventor control aggregation, particle formation and/or surface adsorption inliquid formulations or to prevent or control these phenomena during thelyophilization and/or reconstitution process in lyophilizedformulations. Surfactants include, for example, amphipathic organiccompounds that exhibit partial solubility in both organic solvents andaqueous solutions. General characteristics of surfactants include theirability to reduce the surface tension of water, reduce the interfacialtension between oil and water and also form micelles. Surfactants of theinvention include non-ionic and ionic surfactants. Surfactants are wellknown in the art and can be found described in, for example, Randolph T.W. and Jones L. S., Surfactant-protein interactions. Pharm Biotechnol.13:159-75 (2002). Non-ionic surfactants include, for example, alkyl poly(ethylene oxide), alkyl polyglucosides such as octyl glucoside and decylmaltoside, fatty alcohols such as cetyl alcohol and oleyl alcohol,cocamide MEA, cocamide DEA, and cocamide TEA. Specific examples ofnon-ionic surfactants include the polysorbates including, for example,polysorbate 20, polysorbate 28, polysorbate 40, polysorbate 60,polysorbate 65, polysorbate 80, polysorbate 81, polysorbate 85 and thelike; the poloxamers including, for example, poloxamer 188, also knownas poloxalkol or poly(ethylene oxide)-poly(propylene oxide), poloxamer407 or polyethylene-polypropylene glycol and the like, and polyethyleneglycol (PEG). Polysorbate 20 is synonymous with TWEEN 20®, sorbitanmonolaurate and polyoxyethylene sorbitan monolaurate. Ionic surfactantsinclude, for example, anionic, cationic and zwitterionic surfactants.Anionic surfactants include, for example, sulfonate-based orcarboxylate-based surfactants such as soaps, fatty acid salts, sodiumdodecyl sulfate (SDS), ammonium lauryl sulfate and other alkyl sulfatesalts. Cationic surfactants include, for example, quaternaryammonium-based surfactants such as cetyl trimethylammonium bromide(CTAB), other alkyltrimethylammonium salts, cetyl pyridinium chloride,polyethoxylated tallow amine (POEA) and benzalkonium chloride.Zwitterionic or amphoteric surfactants include, for example, dodecylbetaine, dodecyl dimethylamine oxide, cocamidopropyl betaine and cocoampho glycinate.

Embodiments of AM-14 formulations include polysorbate 20(polyoxyethylene sorbitan monolaurate) as a surfactant, which can beincluded at concentration ranges of about 0.003 to 1% (w/v), or a rangeof about 0.008 to 0.02% (w/v) including 0.003, 0.004, 0.005, 0.006,0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08,0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1% (w/v).Embodiments of AM-14 formulations comprise glutamate based bufferscomprising polysorbate 20 (polyoxyethylene sorbitan monolaurate) as asurfactant at concentration of about 0.005-0.02% (w/v). Embodiments ofAM-14 formulations comprise polysorbate 20 (polyoxyethylene sorbitanmonolaurate) as a surfactant at concentration of about 0.01% (w/v).

An AM-14 formulation can be prepared to be isotonic relative to areference solution or fluid (i.e., blood serum). An isotonic solutionhas a substantially similar amount of dissolved solute in it compared tothe things around it so that it is osmotically stable. Unless expresslycompared to a specific solution or fluid, isotonic or isotonicity isexemplary used herein by reference to human blood serum (e.g., 300mOsmol/kg). Therefore, an isotonic AM-14 formulation will contain asubstantially similar concentration of solutes or exhibit substantiallysimilar osmotic pressure as human blood. In general, an isotonicsolution contains about the same concentration of solutes as normalsaline for humans and many other mammals, which is about 0.9 weightpercent (0.009 g/ml) salt in aqueous solution (e.g., 0.009 g/ml NaCl).Embodiments of AM-14 formulations include those that are isotonic ornear isotonic and have an osmolarity range of about 250 to 400 osm/L or275 to 325 osm/L, including an osmolarity of 250, 251, 252, 253, 254,255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268,269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282,283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296,297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310,311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324,325, 326, 327, 328, 329, 330, 331, 332, 334, 335, 336, 337, 338, 339,340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353,354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367,368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381,382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395,396, 397, 398, 399, or 400 osm/L.

Embodiments of AM-14 formulations include those described herein thathave low viscosity despite having a high concentration of antibody insolution. Embodiments of AM-14 formulations, such as those listed in thenext paragraph, include AM-14 formulations having a viscosity of between4 and 10 cP at 25 degrees C. Embodiments of AM-14 formulations, such asthose listed in the next paragraph, include AM-14 formulations having aviscosity of between 5 and 7 cP at 25 degrees C. Embodiments of AM-14formulations, such as those listed in the next paragraph, include AM-14formulations having a viscosity of 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6,4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0,6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4,7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8,8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or 10 cP at 25degrees C. Of course it is understood that these ranges and values arenot limited to the enumerated numbers and includes further fractionalincrements (for example 4.11, 4.12, 4.13, etc.).

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid, 7-9% (w/v)sucrose, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2. Embodimentsof AM-14 formulations include about 105 mg/mL AM-14, formulated with 10mM glutamic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 110 mg/mLAM-14, formulated with 10 mM glutamic acid, 8% (w/v) sucrose, 0.01%(w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulationsinclude about 120 mg/mL AM-14, formulated with 10 mM glutamic acid, 8%(w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. Embodiments ofAM-14 formulations include about 130 mg/mL AM-14, formulated with 10 mMglutamic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.Embodiments of AM-14 formulations include about 140 mg/mL AM-14,formulated with 10 mM glutamic acid, 8% (w/v) sucrose, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 150 mg/mL AM-14, formulated with 10 mM glutamic acid, 8% (w/v)sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid, 1-3% (w/v)glycine, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2. Embodimentsof AM-14 formulations include about 105 mg/mL AM-14, formulated with 10mM glutamic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 110 mg/mLAM-14, formulated with 10 mM glutamic acid, 2% (w/v) glycine, 0.01%(w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulationsinclude about 120 mg/mL AM-14, formulated with 10 mM glutamic acid, 2%(w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. Embodiments ofAM-14 formulations include about 130 mg/mL AM-14, formulated with 10 mMglutamic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.Embodiments of AM-14 formulations include about 140 mg/mL AM-14,formulated with 10 mM glutamic acid, 2% (w/v) glycine, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 150 mg/mL AM-14, formulated with 10 mM glutamic acid, 2% (w/v)glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid, 2-4% (w/v)proline, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2. Embodimentsof AM-14 formulations include about 105 mg/mL AM-14, formulated with 10mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 110 mg/mLAM-14, formulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulationsinclude about 120 mg/mL AM-14, formulated with 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. Embodiments ofAM-14 formulations include about 130 mg/mL AM-14, formulated with 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 140 mg/mLAM-14, formulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulationsinclude 140 mg/mL AM-14, formulated with 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8. Embodiments of AM-14formulations include about 150 mg/mL AM-14, formulated with 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 1-3% (w/v)glycine, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2. Embodimentsof AM-14 formulations include about 105 mg/mL AM-14, formulated with 10mM acetic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 110 mg/mLAM-14, formulated with 10 mM acetic acid, 2% (w/v) glycine, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 120 mg/mL AM-14, formulated with 10 mM acetic acid, 2% (w/v)glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14formulations include about 130 mg/mL AM-14, formulated with 10 mM aceticacid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.Embodiments of AM-14 formulations include about 140 mg/mL AM-14,formulated with 10 mM acetic acid, 2% (w/v) glycine, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 150 mg/mL AM-14, formulated with 10 mM acetic acid, 2% (w/v)glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v)proline, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2. Embodimentsof AM-14 formulations include about 105 mg/mL AM-14, formulated with 10mM acetic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 110 mg/mLAM-14, formulated with 10 mM acetic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulationsinclude about 120 mg/mL AM-14, formulated with 10 mM acetic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. Embodiments ofAM-14 formulations include about 130 mg/mL AM-14, formulated with 10 mMacetic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.Embodiments of AM-14 formulations include about 140 mg/mL AM-14,formulated with 10 mM acetic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 150 mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 7-9% (w/v)sucrose, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2. Embodimentsof AM-14 formulations include about 105 mg/mL AM-14, formulated with 10mM acetic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 110 mg/mLAM-14, formulated with 10 mM acetic acid, 8% (w/v) sucrose, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 120 mg/mL AM-14, formulated with 10 mM acetic acid, 8% (w/v)sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14formulations include about 130 mg/mL AM-14, formulated with 10 mM aceticacid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.Embodiments of AM-14 formulations include about 140 mg/mL AM-14,formulated with 10 mM acetic acid, 8% (w/v) sucrose, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 150 mg/mL AM-14, formulated with 10 mM acetic acid, 8% (w/v)sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v)glycerol, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2. Embodimentsof AM-14 formulations include about 105 mg/mL AM-14, formulated with 10mM acetic acid, 3% (w/v) glycerol, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 110 mg/mLAM-14, formulated with 10 mM acetic acid, 3% (w/v) glycerol, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 120 mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v)glycerol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14formulations include about 130 mg/mL AM-14, formulated with 10 mM aceticacid, 3% (w/v) glycerol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.Embodiments of AM-14 formulations include about 140 mg/mL AM-14,formulated with 10 mM acetic acid, 3% (w/v) glycerol, 0.01% (w/v)polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulations includeabout 150 mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v)glycerol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 3.5-5.5% (w/v)sorbitol, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2. Embodimentsof AM-14 formulations include about 105 mg/mL AM-14, formulated with 10mM acetic acid, 4.5% (w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 110 mg/mLAM-14, formulated with 10 mM acetic acid, 4.5% (w/v) sorbitol, 0.01%(w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulationsinclude about 120 mg/mL AM-14, formulated with 10 mM acetic acid, 4.5%(w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. Embodiments ofAM-14 formulations include about 130 mg/mL AM-14, formulated with 10 mMacetic acid, 4.5% (w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH4.8±0.2. Embodiments of AM-14 formulations include about 140 mg/mLAM-14, formulated with 10 mM acetic acid, 4.5% (w/v) sorbitol, 0.01%(w/v) polysorbate 20, pH 4.8±0.2. Embodiments of AM-14 formulationsinclude about 150 mg/mL AM-14, formulated with 10 mM acetic acid, 4.5%(w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid, 7-9% (w/v)sucrose, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25degrees C. Embodiments of AM-14 formulations include about 105 mg/mLAM-14, formulated with 10 mM glutamic acid, 8% (w/v) sucrose, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 110 mg/mL AM-14, formulated with 10 mMglutamic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C. Embodiments of AM-14 formulations include about120 mg/mL AM-14, formulated with 10 mM glutamic acid, 8% (w/v) sucrose,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.Embodiments of AM-14 formulations include about 130 mg/mL AM-14,formulated with 10 mM glutamic acid, 8% (w/v) sucrose, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14formulations include about 140 mg/mL AM-14, formulated with 10 mMglutamic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C. Embodiments of AM-14 formulations include about150 mg/mL AM-14, formulated with 10 mM glutamic acid, 8% (w/v) sucrose,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid, 1-3% (w/v)glycine, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25degrees C. Embodiments of AM-14 formulations include about 105 mg/mLAM-14, formulated with 10 mM glutamic acid, 2% (w/v) glycine, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 110 mg/mL AM-14, formulated with 10 mMglutamic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C. Embodiments of AM-14 formulations include about120 mg/mL AM-14, formulated with 10 mM glutamic acid, 2% (w/v) glycine,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.Embodiments of AM-14 formulations include about 130 mg/mL AM-14,formulated with 10 mM glutamic acid, 2% (w/v) glycine, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14formulations include about 140 mg/mL AM-14, formulated with 10 mMglutamic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C. Embodiments of AM-14 formulations include about150 mg/mL AM-14, formulated with 10 mM glutamic acid, 2% (w/v) glycine,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid, 2-4% (w/v)proline, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25degrees C. Embodiments of AM-14 formulations include about 105 mg/mLAM-14, formulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 110 mg/mL AM-14, formulated with 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14 formulationsinclude about 120 mg/mL AM-14, formulated with 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25degrees C. Embodiments of AM-14 formulations include about 130 mg/mLAM-14, formulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 140 mg/mL AM-14, formulated with 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14 formulationsinclude about 150 mg/mL AM-14, formulated with 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25degrees C.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 1-3% (w/v)glycine, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25degrees C. Embodiments of AM-14 formulations include about 105 mg/mLAM-14, formulated with 10 mM acetic acid, 2% (w/v) glycine, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14formulations include about 110 mg/mL AM-14, formulated with 10 mM aceticacid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cPat 25 degrees C. Embodiments of AM-14 formulations include about 120mg/mL AM-14, formulated with 10 mM acetic acid, 2% (w/v) glycine, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 130 mg/mL AM-14, formulated with 10 mMacetic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C. Embodiments of AM-14 formulations include about140 mg/mL AM-14, formulated with 10 mM acetic acid, 2% (w/v) glycine,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.Embodiments of AM-14 formulations include about 150 mg/mL AM-14,formulated with 10 mM acetic acid, 2% (w/v) glycine, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v)proline, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25degrees C. Embodiments of AM-14 formulations include about 105 mg/mLAM-14, formulated with 10 mM acetic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 110 mg/mL AM-14, formulated with 10 mMacetic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C. Embodiments of AM-14 formulations include about120 mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.Embodiments of AM-14 formulations include about 130 mg/mL AM-14,formulated with 10 mM acetic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14formulations include about 140 mg/mL AM-14, formulated with 10 mM aceticacid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cPat 25 degrees C. Embodiments of AM-14 formulations include about 150mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 7-9% (w/v)sucrose, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25degrees C. Embodiments of AM-14 formulations include about 105 mg/mLAM-14, formulated with 10 mM acetic acid, 8% (w/v) sucrose, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14formulations include about 110 mg/mL AM-14, formulated with 10 mM aceticacid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cPat 25 degrees C. Embodiments of AM-14 formulations include about 120mg/mL AM-14, formulated with 10 mM acetic acid, 8% (w/v) sucrose, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 130 mg/mL AM-14, formulated with 10 mMacetic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C. Embodiments of AM-14 formulations include about140 mg/mL AM-14, formulated with 10 mM acetic acid, 8% (w/v) sucrose,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.Embodiments of AM-14 formulations include about 150 mg/mL AM-14,formulated with 10 mM acetic acid, 8% (w/v) sucrose, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v)glycerol, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at25 degrees C. Embodiments of AM-14 formulations include about 105 mg/mLAM-14, formulated with 10 mM acetic acid, 3% (w/v) glycerol, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14formulations include about 110 mg/mL AM-14, formulated with 10 mM aceticacid, 3% (w/v) glycerol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cPat 25 degrees C. Embodiments of AM-14 formulations include about 120mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v) glycerol, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 130 mg/mL AM-14, formulated with 10 mMacetic acid, 3% (w/v) glycerol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C. Embodiments of AM-14 formulations include about140 mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v) glycerol,0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.Embodiments of AM-14 formulations include about 150 mg/mL AM-14,formulated with 10 mM acetic acid, 3% (w/v) glycerol, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.

Embodiments of AM-14 formulations include, but are not limited to100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 3.5-5.5% (w/v)sorbitol, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at25 degrees C. Embodiments of AM-14 formulations include about 105 mg/mLAM-14, formulated with 10 mM acetic acid, 4.5% (w/v) sorbitol, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 110 mg/mL AM-14, formulated with 10 mMacetic acid, 4.5% (w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14 formulationsinclude about 120 mg/mL AM-14, formulated with 10 mM acetic acid, 4.5%(w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25degrees C. Embodiments of AM-14 formulations include about 130 mg/mLAM-14, formulated with 10 mM acetic acid, 4.5% (w/v) sorbitol, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. Embodiments ofAM-14 formulations include about 140 mg/mL AM-14, formulated with 10 mMacetic acid, 4.5% (w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH4.8±0.2, 5-7 cP at 25 degrees C. Embodiments of AM-14 formulationsinclude about 150 mg/mL AM-14, formulated with 10 mM acetic acid, 4.5%(w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25degrees C. The term “about” means±0.01 to 5.0%.

Stability of an AM-14 biopharmaceutical formulation of the inventionrefers to the retention of structure and/or function of abiopharmaceutical within a formulation. A biopharmaceutical in aformulation of the invention will exhibit attributes such as resistanceto change or deterioration that affect stability or function andtherefore maintain consistent functional characteristics over time.Accordingly, AM-14 formulations will exhibit, for example, reliabilityand safety with respect to activity per volume or activity units.

In one embodiment, the stability of an AM-14 biopharmaceutical within aformulation of the invention includes, for example, the retention ofphysical and/or chemical stability. Biopharmaceutical stability of AM-14can be assessed by, for example, determining whether the AM-14 has beensubjected to physical and/or chemical degradation, including chemicalmodification of its structure. Stability may be measured by any meansknown in the art, such as measuring protein aggregates and/or proteinbreak-down products by photometric and/or chromatographic methods.Retention in stability of a AM-14 in a formulation includes, forexample, retention of physical and/or chemical stability between about80-100%, including retention of stability at least about 99%, 98%, 97%,96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%,82%, 81% or 80% compared to the stability of AM-14 at an initial timepoint. Example 1 describes such stability studies and exemplary meansfor measuring physical and/or chemical stability.

Embodiments include AM-14 formulations such as: 100-150 mg/mL AM-14,formulated with 5-15 mM glutamic acid, 7-9% (w/v) sucrose, 0.003-0.02%(w/v) polysorbate 20, pH 4.5-5.5±0.2; such as 140 mg/mL AM-14,formulated with 10 mM glutamic acid, 8% (w/v) sucrose, 0.01% (w/v)polysorbate 20, pH 4.8±0.2; 100-150 mg/mL AM-14, formulated with 5-15 mMglutamic acid, 1-3% (w/v) glycine, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, such as 140 mg/mL AM-14, formulated with 10 mM glutamicacid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2; 100-1500mg/mL AM-14, formulated with 5-15 mM glutamic acid, 2-4% (w/v) proline,0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, such as about 140mg/mL AM-14, formulated with 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2, and 140 mg/mL AM-14, formulatedwith 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2; 100-150 mg/mL AM-14, formulated with 5-15 mM aceticacid, 1-3% (w/v) glycine, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, such as 140 mg/mL AM-14, formulated with 10 mM acetic acid,2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2; 100-150 mg/mLAM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v) proline,0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, such as 140 mg/mLAM-14, formulated with 10 mM acetic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2; 100-150 mg/mL AM-14, formulated with5-15 mM acetic acid, 7-9% (w/v) sucrose, 0.003-0.02% (w/v) polysorbate20, pH 4.5-5.5±0.2, such as 140 mg/mL AM-14, formulated with 10 mMacetic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2;100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v)glycerol, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, such as 140mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v) glycerol, 0.01%(w/v) polysorbate 20, pH 4.8±0.2; 100-150 mg/mL AM-14, formulated with5-15 mM acetic acid, 3.5-5.5% (w/v) sorbitol, 0.003-0.02% (w/v)polysorbate 20, pH 4.5-5.5±0.2, such as 140 mg/mL AM-14, formulated with10 mM acetic acid, 4.5% (w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH4.8±0.2; 100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid,7-9% (w/v) sucrose, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2,4-10 cP at 25 degrees C., such as 140 mg/mL AM-14, formulated with 10 mMglutamic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C.; 100-150 mg/mL AM-14, formulated with 5-15 mMglutamic acid, 1-3% (w/v) glycine, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, 4-10 cP at 25 degrees C., such as 140 mg/mL AM-14,formulated with 10 mM glutamic acid, 2% (w/v) glycine, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.; 100-150 mg/mLAM-14, formulated with 5-15 mM glutamic acid, 2-4% (w/v) proline,0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25 degreesC., such as 140 mg/mL AM-14, formulated with 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25degrees C.; 100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid,1-3% (w/v) glycine, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2,4-10 cP at 25 degrees C., such as 140 mg/mL AM-14, formulated with 10 mMacetic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C.; 100-150 mg/mL AM-14, formulated with 5-15 mMacetic acid, 2-4% (w/v) proline, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, 4-10 cP at 25 degrees C., such as 140 mg/mL AM-14,formulated with 10 mM acetic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.; 100-150 mg/mLAM-14, formulated with 5-15 mM acetic acid, 7-9% (w/v) sucrose,0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25 degreesC., such as 140 mg/mL AM-14, formulated with 10 mM acetic acid, 8% (w/v)sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degreesC.; 100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v)glycerol, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at25 degrees C., such as 140 mg/mL AM-14, formulated with 10 mM aceticacid, 3% (w/v) glycerol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cPat 25 degrees C.; 100-150 mg/mL AM-14, formulated with 5-15 mM aceticacid, 3.5-5.5% (w/v) sorbitol, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, 4-10 cP at 25 degrees C., such as 140 mg/mL AM-14,formulated with 10 mM acetic acid, 4.5% (w/v) sorbitol, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C. having retention ofphysical and/or chemical stability between about 80-100%, includingretention of stability at least about 99%, 98%, 97%, 96%, 95%, 94%, 93%,92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80%compared to the stability of AM-14 at an initial time point.

A biopharmaceutical formulation of the invention will, in general, beprepared according to pharmaceutical standards and using pharmaceuticalgrade reagents. Similarly, a biopharmaceutical formulation of theinvention will, in general, be prepared using sterile reagents in asterile manufacturing environment or sterilized following preparation.Sterile injectable solutions can be prepared using well known proceduresin the art including, for example, by incorporating AM-14 in aformulation described herein followed by sterilization microfiltration.In the specific embodiment of sterile powders for the preparation ofsterile injectable solutions, particularly useful methods of preparationinclude, for example, vacuum drying and freeze-drying (lyophilization)as described previously. Such drying methods will yield a powder of theone or more biopharmaceuticals together with any additional desiredcomponents from a previously sterile-filtered solution thereof.

Embodiments include pharmaceutical containers comprising a vessel and/orvessel means and a pharmaceutical formulation of AM-14 as disclosedherein. A vessel and/or vessel means is something that holds thepharmaceutical formulation of AM-14 and can be any suitable vessel knownin the art, including, but not limited to a vial, bottle, syringe, orany of a variety of formats well known in the art for packagingpharmaceutical formulations, including subcutaneous and transdermaldelivery devices. The syringe may be filled with a pharmaceuticalformulation of AM-14 as disclosed herein prior to distribution to endusers (i.e. “prefilled syringe”).

Embodiments of the invention include a prefilled syringe containing apharmaceutical formulation of AM-14 as disclosed herein, wherein theprefilled syringe is in the form of an “autoinjector,” such as but notlimited to SureClick®, EverGentle®, Avanti®, DosePro®, and Leva®, or aversion thereof. Embodiments of the invention include a prefilledsyringe containing AM-14 at about 140 mg/mL formulated with 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 in the form of an “autoinjector,” such as but not limited toSureClick®, EverGentle®, Avanti®, DosePro®, and Leva®, or a versionthereof. Embodiments of the invention include a prefilled syringecontaining a pharmaceutical formulation of AM-14 as disclosed herein,wherein the prefilled syringe is in the form of any suitablemicro-infusion pump known in the art. Embodiments of the inventioninclude a prefilled syringe in the form of a micro-infusion pumpcontaining AM-14 at about 140 mg/mL, formulated with 10 mM glutamicacid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2. A“microinfuser” is any micro-infusion pump for subcutaneous drugdelivery. Embodiments of the invention include transdermal delivery of apharmaceutical formulation of AM-14 as disclosed herein. Embodiments ofthe invention include any transdermal delivery system containing AM-14at about 140 mg/mL, formulated with 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2.

Kits are also embodiments of the invention and comprise one or morepharmaceutical containers of AM-14 described in the preceding paragraphstogether with instructions on the use of AM-14. It is understood the kitmay contain other components.

II. Formulations, Dosage and Treatment Regimens

AM-14 in a pharmaceutical composition comprising AM-14 at about 100-150mg/mL formulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2, and in particular AM-14 in apharmaceutical composition comprising AM-14 at about 140 mg/mLformulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 may be used to treat adult, juvenile, and/orpediatric patient populations having diseases including, but are notlimited to, IL-17-related inflammation, IL-17-related autoimmunedisease, IL-17-related cartilage inflammation and/or bone degradation,arthritis, rheumatoid arthritis, SEA Syndrome (Seronegativity,Enthesopathy, Arthropathy Syndrome), pauciarticular rheumatoidarthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoidarthritis, ankylosing spondylitis, enteropathic arthritis, reactivearthritis, Reiter's Syndrome, dermatomyositis, psoriatic arthritis,scleroderma, systemic lupus erythematosus, vasculitis, myolitis,polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodossa,Wegener's granulomatosis, arteritis, polymyalgia rheumatica,sarcoidosis, scleroderma, sclerosis, primary biliary sclerosis,sclerosing cholangitis, Sjogren's syndrome, psoriasis, plaque psoriasis,guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermicpsoriasis, dermatitis, atopic dermatitis, atherosclerosis, lupus,Still's disease, Systemic Lupus Erythematosus (SLE), myasthenia gravis,inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis,celiac disease, multiple sclerosis (MS), asthma, COPD, Guillain-Barredisease, Type I diabetes mellitus, Graves' disease, Addison's disease,Raynaud's phenomenon, autoimmune hepatitis, GVHD, pernicious anemia,vitiligo, Kawasaki's Disease, ANCA-associated vasculitides, pemphigusbullous pemphigoid, autoimmune ovarian failure, Hashimoto's thyroiditis,uveitis, thrombotic thrombocytopenic, purpura, hemolytic uremicsyndrome, periodic fever syndromes, familial mediterranean fever, TNFreceptor-1 associated periodic syndrome, hyper-IgD syndrome, Marshall'ssyndrome, cryopyrin-associated periodic syndromes, PAPA (Pyogenicarthritis, pyoderma gangrenosum, and acne) syndrome, Blau syndrome,interstitial pneumonias (such as usual interstitial pneumonia,desquamative interstitial pneumonia, respiratory bronchiolitisassociated interstitial lung disease, acute interstitial pneumonia,nonspecific interstitial pneumonia, lymphocytic interstitial pneumonia,cryptogenic organizing pneumonitis), pulmonary fibrosis, fibrosingsyndromes (such as scleredema, scleromyxedema, overlap syndromes,nephrogenic systemic fibrosis, amyloidosis, eosinophilic fasciitis,chronic graft-versus-host disease, drug-induced scleroderma, andenvironmental exposure fibrosis), neutrophilic dermatoses (such as,pyoderma gangrenosum, SAPHO (synovitis, acne, pustulosis, hyperostosis,and osteitis) syndrome, palmoplantar pustulosis, subcorneal pustulardermatosis, bowel-associated dermatosis-arthritis syndrome, Behcet'sdisease, neutrophilic dermatoses associated with rheumatoid arthritis,rheumatoid neutrophilic dermatosis, neutrophilic eccrine hidradenitis,and neutrophilic dermatosis of the dorsal hands), sepsis/SIRS,post-cardiac injury syndrome, and Dressler's Syndrome, idiopathicarthritis, and the like.

AM-14 in a pharmaceutical composition comprising AM-14 at about 140mg/mL formulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2 may be used to treat adult, juvenile,and/or pediatric patient populations having diseases including, but arenot limited to, IL-17-related inflammation, IL-17-related autoimmunedisease, IL-17-related cartilage inflammation and/or bone degradation,arthritis, rheumatoid arthritis, ankylosing spondylitis, psoriaticarthritis, scleroderma, psoriasis, plaque psoriasis, guttate psoriasis,dermatitis, atopic dermatitis, inflammatory bowel disease (IBD), Crohn'sdisease, ulcerative colitis, celiac disease, multiple sclerosis (MS),asthma, and COPD.

AM-14 in a pharmaceutical composition comprising AM-14 at about 140mg/mL formulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2 may be used to treat adult, juvenile,and/or pediatric patient populations having diseases including, but arenot limited to, rheumatoid arthritis, ankylosing spondylitis, psoriaticarthritis, psoriasis, plaque psoriasis, Crohn's disease, multiplesclerosis (MS), and asthma.

As described in Examples 2 and 6, AM-14 shows efficacy in treatingpsoriasis in human patients. Examples 2 and 6 provide clinical evidenceof AM-14's efficacy in treating psoriasis in human patients havingpsoriasis, and in particular, plaque psoriasis. Subcutaneous andintravenous administration of AM-14 significantly reduced the symptomsof psoriasis. Example 2 describes the reduction in psoriatic symptoms,as measured by the art-accepted PASI scoring system. Tables 2.9, 2.9,2.10, and 2.11 show PASI scores and % PASI (i.e., % reduction in PASIscore).

Furthermore, sophisticated PK-PD modeling was performed based on thedata from the Phase 1 psoriasis study (see Example 2). The predictivemodel correlated very closely to the actual PASI response data (see FIG.11), which substantiates the validity of predicting efficacy for variousdoses. In addition, FIG. 12 shows the predicted time course of mean PASIresponse for four multiple dose scenarios (over 12 weeks) includingplacebo effect based on the model developed from single dose data. Themodeled placebo response was assumed to act after only the first dose.The mean response for the 140 mg SC dose (at WK 0, 1, 2, 4, 6, 8, 10)was expected to exceed 50% PASI improvement for much of the study periodincluding the 12 week (day 84) primary efficacy endpoint. The meanresponse for the 210 and 280 mg SC doses (at WK 0, 1, 2, 4, 6, 8, 10)was expected to exceed 75% PASI improvement for much of the study periodincluding the 12 week (day 84) primary efficacy endpoint. And finally,FIG. 13 depicts the predicted week 12 median percent PASI improvement(dose-response curve) for AM-14, with 90% confidence interval shaded;for various dose levels each administered SC at week 0, 1, 2, 4, 6, 8,and 10.

Example 6 describes a Phase 2 study wherein AM-14 showed remarkableefficacy in treating psoriasis. Subjects received 70, 140, or 210 mgAM-14 at day 1 and weeks 1, 2, 4, 6, 8, and 10 or 280 mg at day 1 andweeks 4 and 8. AM-14 showed the following PASI responses at week 12: 70mg dosing achieved a 33.3% PASI 75 response; 70 mg dosing achieved a17.9% PASI 90 response; 70 mg dosing achieved a 10.3% PASI 100 response;140 mg dosing achieved a 76.9% PASI 75 response; 140 mg dosing achieveda 71.8% PASI 90 response; 140 mg dosing achieved a 38.5% PASI 100response; 210 mg dosing achieved a 82.5% PASI 75 response; 210 mg dosingachieved a 75.0% PASI 90 response; 210 mg dosing achieved a 62.5% PASI100 response; 280 mg dosing achieved a 66.7% PASI 75 response; 280 mgdosing achieved a 57.1% PASI 90 response; and 280 mg dosing achieved a28.6% PASI 100 response. Therefore, administration of AM-14 at thedosages and administration schedules described herein may be used toreduce the PASI score in a patient having psoriasis by at least 10, 15,20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100%.

Based on all these findings, AM-14 can be used to treat the variousforms of psoriasis disclosed above, and in particular plaque psoriasis,in adult and/or juvenile patients at a dose range of 70 to 1,000 mg perdose, and in particular a dose range of 70 to 700 mg per dose. AM-14 canbe used to treat psoriasis, and in particular plaque psoriasis, in adultand/or juvenile patients having psoriasis at a dose range of about 140to about 300 mg per dose. AM-14 can be used to treat psoriasis, and inparticular plaque psoriasis, in adult and/or juvenile patients havingpsoriasis at a dose of 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120,125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190,195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260,265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330,335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400,405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470,475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540,545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610,615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680,685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750,755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820,825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890,895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960,965, 970, 975, 980, 985, 990, 995, and or 1,000 mg per dose.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with multipledosing at a dose of 70 mg per dose. AM-14 can be used to treat psoriasisin adult and/or juvenile patients having psoriasis, and in particularplaque psoriasis, with multiple dosing at a dose of 140 mg per dose.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with multipledosing at a dose of 210 mg per dose. AM-14 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, with multiple dosing at a dose of 280 mgper dose.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with multipledosing at a dose of 70 mg per dose delivered by subcutaneous injection.AM-14 can be used to psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, with multiple dosing at adose of 140 mg per dose delivered by subcutaneous injection. AM-14 canbe used to treat psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, with multiple dosing at adose of 210 mg per dose delivered by subcutaneous injection. AM-14 canbe used to treat psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, with multiple dosing at adose of 280 mg per dose delivered by subcutaneous injection.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 70 mgper dose delivered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 140mg per dose delivered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 210mg per dose delivered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 280mg per dose delivered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 70 mgper dose delivered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, at a dose of 140 mg perdose delivered by subcutaneous injection administered at time “0” (thefirst administration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, at a dose of 210 mg per dose deliveredby subcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, at a dose of 280 mg per dose deliveredby subcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with multipledosing at a dose of 70 mg per dose delivered by subcutaneous injectionby syringe. AM-14 can be used to treat psoriasis in adult and/orjuvenile patients having psoriasis, and in particular plaque psoriasis,with multiple dosing at a dose of 140 mg per dose delivered bysubcutaneous injection by syringe. AM-14 can be used to treat psoriasisin adult and/or juvenile patients having psoriasis, and in particularplaque psoriasis, with multiple dosing at a dose of 210 mg per dosedelivered by subcutaneous injection by syringe. AM-14 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, with multiple dosing at a dose of 280 mgper dose delivered by subcutaneous injection by syringe.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 70 mgper dose delivered by subcutaneous injection by syringe administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 140mg per dose delivered by subcutaneous injection by syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 210mg per dose delivered by subcutaneous injection by syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 280mg per dose delivered by subcutaneous injection by syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 70 mgper dose delivered by subcutaneous injection by syringe administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, at a dose of 140 mg perdose delivered by subcutaneous injection by syringe administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, at a dose of 210 mg perdose delivered by subcutaneous injection by syringe administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, at a dose of 280 mg perdose delivered by subcutaneous injection by syringe administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with multipledosing at a dose of 70 mg per dose delivered by subcutaneous injectionby autoinjector syringe. AM-14 can be used to treat psoriasis in adultand/or juvenile patients having psoriasis, and in particular plaquepsoriasis, with multiple dosing at a dose of 140 mg per dose deliveredby subcutaneous injection by autoinjector syringe. AM-14 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, with multiple dosing at a dose of 210 mgper dose delivered by subcutaneous injection by autoinjector syringe.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with multipledosing at a dose of 280 mg per dose delivered by subcutaneous injectionby autoinjector syringe.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 70 mgper dose delivered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration. AM-14 can be used to treat psoriasis in adult and/orjuvenile patients having psoriasis, and in particular plaque psoriasis,at a dose of 140 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, at a dose of 210 mg per dose deliveredby subcutaneous injection by autoinjector syringe administered at time“0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 280mg per dose delivered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 70 mgper dose delivered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat psoriasis in adult and/orjuvenile patients having psoriasis, and in particular plaque psoriasis,at a dose of 140 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, at a dose of 210 mg per dose deliveredby subcutaneous injection by autoinjector syringe administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, at a dose of 280 mg perdose delivered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with at least onedose at a dose of 70 mg per dose delivered by subcutaneous injection bymicroinfuser. AM-14 can be used to treat psoriasis in adult and/orjuvenile patients having psoriasis, and in particular plaque psoriasis,with at least one dose at a dose of 140 mg per dose delivered bysubcutaneous injection by microinfuser. AM-14 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, with at least one dose at a dose of 210 mgper dose delivered by subcutaneous injection by microinfuser. AM-14 canbe used to treat psoriasis in adult and/or juvenile patients havingpsoriasis, and in particular plaque psoriasis, with at least one dose ata dose of 280 mg per dose delivered by subcutaneous injection bymicroinfuser.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 70 mgper dose delivered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration. AM-14 can be used to treat psoriasis in adult and/orjuvenile patients having psoriasis, and in particular plaque psoriasis,at a dose of 140 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration. AM-14 can be used to treat psoriasis in adultand/or juvenile patients having psoriasis, and in particular plaquepsoriasis, at a dose of 210 mg per dose delivered by subcutaneousinjection by microinfuser administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, at a dose of 280 mg per dose deliveredby subcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 70 mgper dose delivered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat psoriasis in adult and/orjuvenile patients having psoriasis, and in particular plaque psoriasis,at a dose of 140 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat psoriasis in adult and/orjuvenile patients having psoriasis, and in particular plaque psoriasis,at a dose of 210 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat psoriasis in adult and/orjuvenile patients having psoriasis, and in particular plaque psoriasis,at a dose of 280 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with multiple dosing at a dose of 70 mg perdose. AM-14 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who are candidates forsystemic therapy or phototherapy with multiple dosing at a dose of 140mg per dose. AM-14 can be used to treat adult and/or juvenile patientswith chronic moderate to severe plaque psoriasis who are candidates forsystemic therapy or phototherapy with multiple dosing at a dose of 210mg per dose. AM-14 can be used to treat adult and/or juvenile patientswith chronic moderate to severe plaque psoriasis who are candidates forsystemic therapy or phototherapy with multiple dosing at a dose of 280mg per dose. AM-14 can be used to treat adult and/or juvenile patientswith chronic moderate to severe plaque psoriasis who are candidates forsystemic therapy or phototherapy with multiple dosing at a dose of 70 mgper dose delivered by subcutaneous injection. AM-14 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy withmultiple dosing at a dose of 140 mg per dose delivered by subcutaneousinjection. AM-14 can be used to treat adult and/or juvenile patientswith chronic moderate to severe plaque psoriasis who are candidates forsystemic therapy or phototherapy with multiple dosing at a dose of 210mg per dose delivered by subcutaneous injection. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 280 mg per dose delivered bysubcutaneous injection.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 70 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 140 mg per dose delivered by subcutaneous injectionadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy at a dose of 210 mg perdose delivered by subcutaneous injection administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration. AM-14 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 280 mg per dose delivered by subcutaneous injectionadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 70 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 140 mg per dose delivered by subcutaneous injectionadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy at a dose of 210 mg perdose delivered by subcutaneous injection administered at time “0” (thefirst administration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 280 mg per dose delivered by subcutaneous injectionadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with multiple dosing at a dose of 70 mg per dosedelivered by subcutaneous injection by syringe. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 140 mg per dose delivered bysubcutaneous injection by syringe. AM-14 can be used to treat adultand/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy withmultiple dosing at a dose of 210 mg per dose delivered by subcutaneousinjection by syringe. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy with multiple dosing ata dose of 280 mg per dose delivered by subcutaneous injection bysyringe.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 70 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 140 mg per dose delivered by subcutaneous injection bysyringe administered at time “0” (the first administration), at one weekpost time “0”, and then administered every two weeks following the weekone administration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy at a dose of 210 mg perdose delivered by subcutaneous injection by syringe administered at time“0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 280 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 70 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 140 mg per dose delivered by subcutaneous injection bysyringe administered at time “0” (the first administration), at one weekpost time “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy at a dose of 210 mg perdose delivered by subcutaneous injection by syringe administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who are candidates for systemic therapy orphototherapy at a dose of 280 mg per dose delivered by subcutaneousinjection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with multiple dosing at a dose of 70 mg per dosedelivered by subcutaneous injection by autoinjector syringe. AM-14 canbe used to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who are candidates for systemic therapy orphototherapy with multiple dosing at a dose of 140 mg per dose deliveredby subcutaneous injection by autoinjector syringe. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 210 mg per dose delivered bysubcutaneous injection by autoinjector syringe. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 280 mg per dose delivered bysubcutaneous injection by autoinjector syringe.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 70 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 140 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 210 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 280 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 70 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who are candidates for systemic therapy orphototherapy at a dose of 140 mg per dose delivered by subcutaneousinjection by autoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 210 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 280 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with multiple dosing at a dose of 70 mg per dosedelivered by subcutaneous injection by microinfuser. AM-14 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 140 mg per dose delivered bysubcutaneous injection by microinfuser. AM-14 can be used to treat adultand/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy withmultiple dosing at a dose of 210 mg per dose delivered by subcutaneousinjection by microinfuser. AM-14 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy with multiple dosingat a dose of 280 mg per dose delivered by subcutaneous injection bymicroinfuser.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 70 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration. AM-14 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 140 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration. AM-14 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy at a dose of 210 mgper dose delivered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy at a dose of 280 mg perdose delivered by subcutaneous injection by microinfuser administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 70 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 140 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy at a dose of 210 mg perdose delivered by subcutaneous injection by microinfuser administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who are candidates for systemic therapy orphototherapy at a dose of 280 mg per dose delivered by subcutaneousinjection by microinfuser administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 70 mg perdose. AM-14 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who fail to respond to, havea contraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 140 mg perdose. AM-14 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who fail to respond to, havea contraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 210 mg perdose. AM-14 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who fail to respond to, havea contraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 280 mg perdose.

AM-14 can be used to adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 70 mg perdose delivered by subcutaneous injection. AM-14 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who fail to respond to, have a contraindication to, or areintolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 140 mg per dose delivered by subcutaneousinjection. AM-14 can be used to treat adult and/or juvenile patientswith chronic moderate to severe plaque psoriasis who fail to respond to,have a contraindication to, or are intolerant to other systemictherapies including cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 210 mg perdose delivered by subcutaneous injection. AM-14 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who fail to respond to, have a contraindication to, or areintolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 280 mg per dose delivered by subcutaneousinjection.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 70 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 210 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 70 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration. AM-14can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 210 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 70 mg perdose delivered by subcutaneous injection by syringe. AM-14 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 140 mg per dose delivered by subcutaneousinjection by syringe. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who fail torespond to, have a contraindication to, or are intolerant to othersystemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) with multiple dosing at adose of 210 mg per dose delivered by subcutaneous injection by syringe.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 280 mg perdose delivered by subcutaneous injection by syringe.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 70 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who fail torespond to, have a contraindication to, or are intolerant to othersystemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 210 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 280 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 70 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who fail torespond to, have a contraindication to, or are intolerant to othersystemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 210 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who fail to respond to, have a contraindicationto, or are intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 70 mg perdose delivered by subcutaneous injection by autoinjector syringe. AM-14can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 140 mg perdose delivered by subcutaneous injection by autoinjector syringe. AM-14can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 210 mg perdose delivered by subcutaneous injection by autoinjector syringe. AM-14can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 280 mg perdose delivered by subcutaneous injection by autoinjector syringe.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 70 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 140 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 210 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 280 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 70 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who fail to respond to, have a contraindicationto, or are intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 210 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 70 mg perdose delivered by subcutaneous injection by microinfuser. AM-14 can beused to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who fail to respond to, have a contraindicationto, or are intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 140 mg per dose delivered by subcutaneousinjection by microinfuser. AM-14 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) with multiple dosing at adose of 210 mg per dose delivered by subcutaneous injection bymicroinfuser. AM-14 can be used to treat adult and/or juvenile patientswith chronic moderate to severe plaque psoriasis who fail to respond to,have a contraindication to, or are intolerant to other systemictherapies including cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 280 mg perdose delivered by subcutaneous injection by microinfuser.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 70 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration. AM-14 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration. AM-14 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 210 mg per dosedelivered by subcutaneous injection by microinfuser administered at time“0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 280 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 70 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration. AM-14 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who fail torespond to, have a contraindication to, or are intolerant to othersystemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 210 mg per dosedelivered by subcutaneous injection by microinfuser administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 can beused to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who fail to respond to, have a contraindicationto, or are intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, with multiple dosing at a dose of 70mg per dose. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with multipledosing at a dose of 140 mg per dose. AM-14 in a formulation comprising140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis in adultand/or juvenile patients having psoriasis, and in particular plaquepsoriasis, with multiple dosing at a dose of 210 mg per dose. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, with multiple dosing at a dose of 280 mgper dose.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, with multiple dosing at a dose of 70mg per dose delivered by subcutaneous injection. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis inadult and/or juvenile patients having psoriasis, and in particularplaque psoriasis, with multiple dosing at a dose of 140 mg per dosedelivered by subcutaneous injection. AM-14 in a formulation comprising140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis in adultand/or juvenile patients having psoriasis, and in particular plaquepsoriasis, with multiple dosing at a dose of 210 mg per dose deliveredby subcutaneous injection. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat psoriasis in adult and/or juvenilepatients having psoriasis, and in particular plaque psoriasis, withmultiple dosing at a dose of 280 mg per dose delivered by subcutaneousinjection.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile psoriasis in patients having psoriasis,and in particular plaque psoriasis, at a dose of 70 mg per dosedelivered by subcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis inadult and/or juvenile patients having psoriasis, and in particularplaque psoriasis, at a dose of 140 mg per dose delivered by subcutaneousinjection administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat psoriasis in adult and/or juvenilepatients having psoriasis, and in particular plaque psoriasis, at a doseof 210 mg per dose delivered by subcutaneous injection administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 280 mg per dosedelivered by subcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 70 mg per dosedelivered by subcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis inadult and/or juvenile patients having psoriasis, and in particularplaque psoriasis, at a dose of 140 mg per dose delivered by subcutaneousinjection administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 210mg per dose delivered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, at a dose of 280 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, with multiple dosing at a dose of 70mg per dose delivered by subcutaneous injection by syringe. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, with multiple dosing at a dose of 140 mgper dose delivered by subcutaneous injection by syringe. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, with multiple dosing at a dose of 210 mgper dose delivered by subcutaneous injection by syringe. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, with multiple dosing at a dose of 280 mgper dose delivered by subcutaneous injection by syringe.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 70 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 140 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 210 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 280 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 70 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, at a dose of 140 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis inpatients having psoriasis, and in particular plaque psoriasis, at a doseof 210 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, at a dose of 280mg per dose delivered by subcutaneous injection by syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, with multiple dosing at a dose of 70mg per dose delivered by subcutaneous injection by autoinjector syringe.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, with multiple dosing at a dose of140 mg per dose delivered by subcutaneous injection by autoinjectorsyringe. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat psoriasis in adult and/or juvenile patientshaving psoriasis, and in particular plaque psoriasis, with multipledosing at a dose of 210 mg per dose delivered by subcutaneous injectionby autoinjector syringe. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat psoriasis in adult and/or juvenilepatients having psoriasis, and in particular plaque psoriasis, withmultiple dosing at a dose of 280 mg per dose delivered by subcutaneousinjection by autoinjector syringe.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 70 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 140 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 210 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 280 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 70 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, at a dose of 140 mg per dose deliveredby subcutaneous injection by autoinjector syringe administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, at a dose of 210 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, at a dose of 280 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, with multiple dosing at a dose of 70mg per dose delivered by subcutaneous injection by microinfuser. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat psoriasis in adult and/or juvenile patients having psoriasis, andin particular plaque psoriasis, with multiple dosing at a dose of 140 mgper dose delivered by subcutaneous injection by microinfuser. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, with multiple dosing at a dose of 210 mgper dose delivered by subcutaneous injection by microinfuser. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, with multiple dosing at a dose of 280 mgper dose delivered by subcutaneous injection by microinfuser.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 70 mg per dosedelivered by subcutaneous injection by microinfuser administered at time“0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 140 mg per dosedelivered by subcutaneous injection by microinfuser administered at time“0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 210 mg per dosedelivered by subcutaneous injection by microinfuser administered at time“0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 280 mg per dosedelivered by subcutaneous injection by microinfuser administered at time“0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, at a dose of 70 mg per dosedelivered by subcutaneous injection by microinfuser administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatpsoriasis in adult and/or juvenile patients having psoriasis, and inparticular plaque psoriasis, at a dose of 140 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis inadult and/or juvenile patients having psoriasis, and in particularplaque psoriasis, at a dose of 210 mg per dose delivered by subcutaneousinjection by microinfuser administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis inadult and/or juvenile patients having psoriasis, and in particularplaque psoriasis, at a dose of 280 mg per dose delivered by subcutaneousinjection by microinfuser administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 70 mg per dose. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy with multiple dosingat a dose of 140 mg per dose. AM-14 in a formulation comprising 140mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy with multiple dosing ata dose of 210 mg per dose. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who are candidates forsystemic therapy or phototherapy with multiple dosing at a dose of 280mg per dose. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with multiple dosing at a dose of 70 mg per dosedelivered by subcutaneous injection. AM-14 in a formulation comprising140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy with multiple dosing ata dose of 140 mg per dose delivered by subcutaneous injection. AM-14 ina formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy withmultiple dosing at a dose of 210 mg per dose delivered by subcutaneousinjection. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with multiple dosing at a dose of 280 mg perdose delivered by subcutaneous injection.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 70 mg per dose delivered by subcutaneous injectionadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 140 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy at a dose of 210 mgper dose delivered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 280 mg per dose delivered by subcutaneous injectionadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 70 mg per dose delivered by subcutaneous injectionadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 140 mg per dose delivered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy at a dose of 210 mgper dose delivered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy at adose of 280 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 70 mg per dose delivered bysubcutaneous injection by syringe. AM-14 in a formulation comprising 140mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who arecandidates for systemic therapy or phototherapy with multiple dosing ata dose of 140 mg per dose delivered by subcutaneous injection bysyringe. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with multiple dosing at a dose of 210 mg perdose delivered by subcutaneous injection by syringe. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy withmultiple dosing at a dose of 280 mg per dose delivered by subcutaneousinjection by syringe.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 70 mg per dose delivered by subcutaneous injection bysyringe administered at time “0” (the first administration), at one weekpost time “0”, and then administered every two weeks following the weekone administration. AM-14 in a formulation comprising 140 mg/mL AM-14,10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 140 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy at a dose of 210 mgper dose delivered by subcutaneous injection by syringe administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 280 mg per dose delivered by subcutaneous injection bysyringe administered at time “0” (the first administration), at one weekpost time “0”, and then administered every two weeks following the weekone administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 70 mg per dose delivered by subcutaneous injection bysyringe administered at time “0” (the first administration), at one weekpost time “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 140 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy at a dose of 210 mgper dose delivered by subcutaneous injection by syringe administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy at adose of 280 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 70 mg per dose delivered bysubcutaneous injection by autoinjector syringe. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy with multiple dosingat a dose of 140 mg per dose delivered by subcutaneous injection byautoinjector syringe. AM-14 in a formulation comprising 140 mg/mL AM-14,10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with multiple dosing at a dose of 210 mg perdose delivered by subcutaneous injection by autoinjector syringe. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith multiple dosing at a dose of 280 mg per dose delivered bysubcutaneous injection by autoinjector syringe.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 70 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy at a dose of 140 mgper dose delivered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 210 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 280 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 70 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy at a dose of 140 mgper dose delivered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 210 mg per dose delivered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy at adose of 280 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapywith at least one dose at a dose of 70 mg per dose delivered bysubcutaneous injection by microinfuser. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy with at least onedose at a dose of 140 mg per dose delivered by subcutaneous injection bymicroinfuser. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy with at least one dose at a dose of 210 mg perdose delivered by subcutaneous injection by microinfuser. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy withat least one dose at a dose of 280 mg per dose delivered by subcutaneousinjection by microinfuser.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 70 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who are candidates forsystemic therapy or phototherapy at a dose of 140 mg per dose deliveredby subcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who are candidates for systemic therapy or phototherapy at adose of 210 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who are candidates forsystemic therapy or phototherapy at a dose of 280 mg per dose deliveredby subcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy or phototherapyat a dose of 70 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 140 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whoare candidates for systemic therapy or phototherapy at a dose of 210 mgper dose delivered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who are candidates for systemictherapy or phototherapy at a dose of 280 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredmonthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 70 mg per dose. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) with multiple dosing at adose of 140 mg per dose. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who fail to respond to, havea contraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 210 mg perdose. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamicacid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can beused to treat adult and/or juvenile patients with chronic moderate tosevere plaque psoriasis who fail to respond to, have a contraindicationto, or are intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 280 mg per dose. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) with multiple dosing at adose of 70 mg per dose delivered by subcutaneous injection. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who fail to respond to, have a contraindication to, or areintolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 140 mg per dose delivered by subcutaneousinjection. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 210 mg perdose delivered by subcutaneous injection. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) with multiple dosing at adose of 280 mg per dose delivered by subcutaneous injection.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 70 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 210 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 70 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 140 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 210 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 70 mg per dose delivered by subcutaneousinjection by syringe. AM-14 in a formulation comprising 140 mg/mL AM-14,10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 140 mg perdose delivered by subcutaneous injection by syringe. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who fail to respond to, have a contraindication to, or areintolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 210 mg per dose delivered by subcutaneousinjection by syringe. AM-14 in a formulation comprising 140 mg/mL AM-14,10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 280 mg perdose delivered by subcutaneous injection by syringe.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 70 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 140 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 210 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 70 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 140 mg per dose delivered bysubcutaneous injection by syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 210 mg per dosedelivered by subcutaneous injection by syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who fail to respond to, have a contraindication to, or areintolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection by syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 70 mg per dose delivered by subcutaneousinjection by autoinjector syringe. AM-14 in a formulation comprising 140mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 can be used to treat adult and/or juvenilepatients with chronic moderate to severe plaque psoriasis who fail torespond to, have a contraindication to, or are intolerant to othersystemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) with multiple dosing at adose of 140 mg per dose delivered by subcutaneous injection byautoinjector syringe. AM-14 in a formulation comprising 140 mg/mL AM-14,10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with multiple dosing at a dose of 210 mg perdose delivered by subcutaneous injection by autoinjector syringe. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withmultiple dosing at a dose of 280 mg per dose delivered by subcutaneousinjection by autoinjector syringe.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 70 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 140 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 210 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 280 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 70 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 140 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 210 mg per dose delivered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 280 mg per dosedelivered by subcutaneous injection by autoinjector syringe administeredat time “0” (the first administration), at one week post time “0”, andthen administered monthly following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withat least one dose at a dose of 70 mg per dose delivered by subcutaneousinjection by microinfuser. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who fail to respond to, havea contraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with at least one dose at a dose of 140 mgper dose delivered by subcutaneous injection by microinfuser. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who fail to respond to, have a contraindication to, or areintolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) withat least one dose at a dose of 210 mg per dose delivered by subcutaneousinjection by microinfuser. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who fail to respond to, havea contraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) with at least one dose at a dose of 280 mgper dose delivered by subcutaneous injection by microinfuser.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 70 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who fail to respond to, havea contraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 140 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who fail to respond to, have a contraindication to, or areintolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 210 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration. AM-14 in a formulation comprising 140 mg/mLAM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate20, pH 4.8±0.2 can be used to treat adult and/or juvenile patients withchronic moderate to severe plaque psoriasis who fail to respond to, havea contraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 280 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 70 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration. AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mMglutamic acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH4.8±0.2 can be used to treat adult and/or juvenile patients with chronicmoderate to severe plaque psoriasis who fail to respond to, have acontraindication to, or are intolerant to other systemic therapiesincluding cyclosporin, methotrexate, and PUVA (psoralen plusultraviolet-A phototherapy) at a dose of 140 mg per dose delivered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredmonthly following the week one administration. AM-14 in a formulationcomprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treat adult and/orjuvenile patients with chronic moderate to severe plaque psoriasis whofail to respond to, have a contraindication to, or are intolerant toother systemic therapies including cyclosporin, methotrexate, and PUVA(psoralen plus ultraviolet-A phototherapy) at a dose of 210 mg per dosedelivered by subcutaneous injection by microinfuser administered at time“0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration. AM-14 in aformulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used to treatadult and/or juvenile patients with chronic moderate to severe plaquepsoriasis who fail to respond to, have a contraindication to, or areintolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy) at adose of 280 mg per dose delivered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered monthly following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 90 kg every two weeks and patients weighinggreater than 90 kg are administered a 210 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose every two weeks to patients weighing lessthan or approximately equal to 100 kg and patients weighing greater than100 kg are administered a 210 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose every two weeks to patients weighing lessthan or approximately equal to 110 kg and patients weighing greater than110 kg are administered a 210 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose every two weeks to patients weighing lessthan or approximately equal to 90 kg and patients weighing greater than90 kg are administered a 280 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose every two weeks to patients weighing lessthan or approximately equal to 100 kg and patients weighing greater than100 kg are administered a 280 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose every two weeks to patients weighing lessthan or approximately equal to 110 kg and patients weighing greater than110 kg are administered a 280 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose every four weeks to patients weighing lessthan or approximately equal to 90 kg and patients weighing greater than90 kg are administered a 210 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose every four weeks to patients weighing lessthan or approximately equal to 100 kg and patients weighing greater than100 kg are administered a 210 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose every four weeks to patients weighing lessthan or approximately equal to 110 kg and patients weighing greater than110 kg are administered a 210 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose every four weeks to patients weighing lessthan or approximately equal to 90 kg and patients weighing greater than90 kg are administered a 280 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose every four weeks to patients weighing lessthan or approximately equal to 100 kg and patients weighing greater than100 kg are administered a 280 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose every four weeks to patients weighing lessthan or approximately equal to 110 kg and patients weighing greater than110 kg are administered a 280 mg dose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose by subcutaneous injection to patientsweighing less than or approximately equal to 90 kg every two weeks andpatients weighing greater than 90 kg are administered a 210 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose by subcutaneous injection every two weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose by subcutaneous injection every two weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose by subcutaneous injection every two weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose by subcutaneous injection every two weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose by subcutaneous injection every two weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose by subcutaneous injection every four weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose by subcutaneous injection every four weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose by subcutaneous injection every four weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose by subcutaneous injection every four weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose by subcutaneous injection every four weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose by subcutaneous injection every four weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dose bysubcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection byautoinjector syringe to patients weighing less than or approximatelyequal to 90 kg every two weeks and patients weighing greater than 90 kgare administered a 210 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-praline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every four weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every four weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every four weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every four weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every four weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every four weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose delivered by subcutaneous injection byautoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection bymicroinfuser to patients weighing less than or approximately equal to 90kg every two weeks and patients weighing greater than 90 kg areadministered a 210 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every four weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every four weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every four weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every four weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every four weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every four weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose delivered by subcutaneous injection bymicroinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose, wherein the AM-14 is administered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in patients having psoriasis, and in particularplaque psoriasis, wherein said patients are administered a 140 mg doseto patients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dose,wherein the AM-14 is administered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose, wherein the AM-14 is administered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 100 kg, and patients weighing greaterthan 100 kg are administered a 210 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 110 kg, and patients weighing greaterthan 110 kg are administered a 210 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 90 kg, and patients weighing greater than90 kg are administered a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 100 kg, and patients weighing greaterthan 100 kg are administered a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-praline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 110 kg, and patients weighing greaterthan 110 kg are administered a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-praline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose, wherein the AM-14 is administered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose, wherein the AM-14 is administered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose, wherein the AM-14 is administered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection by autoinjector syringe administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by autoinjector syringe a 280 mgdose at time “0” (the first administration), at one week post time “0”,and every four weeks to patients weighing less than or approximatelyequal to 100 kg, and patients weighing greater than 100 kg areadministered a 210 mg dose at time “0” (the first administration), atone week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by autoinjector syringe a 280 mgdose at time “0” (the first administration), at one week post time “0”,and every four weeks to patients weighing less than or approximatelyequal to 110 kg, and patients weighing greater than 110 kg areadministered a 210 mg dose at time “0” (the first administration), atone week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by autoinjector syringe a 280 mgdose at time “0” (the first administration), at one week post time “0”,and every four weeks to patients weighing less than or approximatelyequal to 90 kg, and patients weighing greater than 90 kg areadministered a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by autoinjector syringe a 280 mgdose at time “0” (the first administration), at one week post time “0”,and every four weeks to patients weighing less than or approximatelyequal to 100 kg, and patients weighing greater than 100 kg areadministered a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by autoinjector syringe a 280 mgdose at time “0” (the first administration), at one week post time “0”,and every four weeks to patients weighing less than or approximatelyequal to 110 kg, and patients weighing greater than 110 kg areadministered a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose, wherein the AM-14 is administered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose, wherein the AM-14 is administered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 140 mg dose to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose, wherein the AM-14 is administered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered a 280 mg dose to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose, wherein the AM-14 is administered bysubcutaneous injection by microinfuser administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by microinfuser a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 100 kg, and patients weighing greater than 100 kg are administered a210 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by microinfuser a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 110 kg, and patients weighing greater than 110 kg are administered a210 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by microinfuser a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 90 kg, and patients weighing greater than 90 kg are administered a280 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat psoriasis in adult and/or juvenile patients having psoriasis,and in particular plaque psoriasis, wherein said patients areadministered by subcutaneous injection by microinfuser a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 100 kg, and patients weighing greater than 100 kg are administered a280 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks. AM-14 in a formulation comprising 140mg/mL AM-14, 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 can be used to treat psoriasis in adultand/or juvenile patients having psoriasis, and in particular plaquepsoriasis, wherein said patients are administered by subcutaneousinjection by microinfuser a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 90 kg every twoweeks and patients weighing greater than 90 kg are administered a 210 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose everytwo weeks to patients weighing less than or approximately equal to 100kg and patients weighing greater than 100 kg are administered a 210 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose everytwo weeks to patients weighing less than or approximately equal to 110kg and patients weighing greater than 110 kg are administered a 210 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose everytwo weeks to patients weighing less than or approximately equal to 90 kgand patients weighing greater than 90 kg are administered a 280 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose everytwo weeks to patients weighing less than or approximately equal to 100kg and patients weighing greater than 100 kg are administered a 280 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose everytwo weeks to patients weighing less than or approximately equal to 110kg and patients weighing greater than 110 kg are administered a 280 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose everyfour weeks to patients weighing less than or approximately equal to 90kg and patients weighing greater than 90 kg are administered a 210 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose everyfour weeks to patients weighing less than or approximately equal to 100kg and patients weighing greater than 100 kg are administered a 210 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose everyfour weeks to patients weighing less than or approximately equal to 110kg and patients weighing greater than 110 kg are administered a 210 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose everyfour weeks to patients weighing less than or approximately equal to 90kg and patients weighing greater than 90 kg are administered a 280 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose everyfour weeks to patients weighing less than or approximately equal to 100kg and patients weighing greater than 100 kg are administered a 280 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose everyfour weeks to patients weighing less than or approximately equal to 110kg and patients weighing greater than 110 kg are administered a 280 mgdose every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose bysubcutaneous injection to patients weighing less than or approximatelyequal to 90 kg every two weeks and patients weighing greater than 90 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose bysubcutaneous injection every two weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose bysubcutaneous injection every two weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose bysubcutaneous injection every two weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose bysubcutaneous injection every two weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose bysubcutaneous injection every two weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose bysubcutaneous injection every four weeks to patients weighing less thanor approximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose bysubcutaneous injection every four weeks to patients weighing less thanor approximately equal to 100 kg and patients weighing greater than 100kg are administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose bysubcutaneous injection every four weeks to patients weighing less thanor approximately equal to 110 kg and patients weighing greater than 110kg are administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose bysubcutaneous injection every four weeks to patients weighing less thanor approximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose bysubcutaneous injection every four weeks to patients weighing less thanor approximately equal to 100 kg and patients weighing greater than 100kg are administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose bysubcutaneous injection every four weeks to patients weighing less thanor approximately equal to 110 kg and patients weighing greater than 110kg are administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by autoinjector syringe to patientsweighing less than or approximately equal to 90 kg every two weeks andpatients weighing greater than 90 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks to patients weighing less than or approximately equal to 100 kgand patients weighing greater than 100 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks to patients weighing less than or approximately equal to 110 kgand patients weighing greater than 110 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks to patients weighing less than or approximately equal to 90 kg andpatients weighing greater than 90 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks to patients weighing less than or approximately equal to 100 kgand patients weighing greater than 100 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks to patients weighing less than or approximately equal to 110 kgand patients weighing greater than 110 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every fourweeks to patients weighing less than or approximately equal to 90 kg andpatients weighing greater than 90 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every fourweeks to patients weighing less than or approximately equal to 100 kgand patients weighing greater than 100 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every fourweeks to patients weighing less than or approximately equal to 110 kgand patients weighing greater than 110 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every fourweeks to patients weighing less than or approximately equal to 90 kg andpatients weighing greater than 90 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every fourweeks to patients weighing less than or approximately equal to 100 kgand patients weighing greater than 100 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every fourweeks to patients weighing less than or approximately equal to 110 kgand patients weighing greater than 110 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by microinfuser to patients weighingless than or approximately equal to 90 kg every two weeks and patientsweighing greater than 90 kg are administered a 210 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by microinfuser every two weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dosedelivered by subcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by microinfuser every two weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dosedelivered by subcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by microinfuser every two weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by microinfuser every two weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dosedelivered by subcutaneous injection by microinfuser every two weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every four weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every four weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dosedelivered by subcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every four weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dosedelivered by subcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every four weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every four weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every four weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dosedelivered by subcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dose,wherein the AM-14 is administered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dose,wherein the AM-14 is administered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dose,wherein the AM-14 is administered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dose,wherein the AM-14 is administered by subcutaneous injection administeredat time “0” (the first administration), at one week post time “0”, andthen administered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 100 kg, and patients weighing greater than 100 kg are administered a210 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 110 kg, and patients weighing greater than 110 kg are administered a210 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 90 kg, and patients weighing greater than 90 kg are administered a280 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 100 kg, and patients weighing greater than 100 kg are administered a280 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery four weeks to patients weighing less than or approximately equalto 110 kg, and patients weighing greater than 110 kg are administered a280 mg dose at time “0” (the first administration), at one week posttime “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dose,wherein the AM-14 is administered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dose,wherein the AM-14 is administered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dose,wherein the AM-14 is administered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dose,wherein the AM-14 is administered by subcutaneous injection byautoinjector syringe administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by autoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 100 kg, andpatients weighing greater than 100 kg are administered a 210 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by autoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 210 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by autoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 90 kg, andpatients weighing greater than 90 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by autoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 100 kg, andpatients weighing greater than 100 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by autoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dose,wherein the AM-14 is administered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dose,wherein the AM-14 is administered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dose,wherein the AM-14 is administered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 140 mg dose topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dose,wherein the AM-14 is administered by subcutaneous injection bymicroinfuser administered at time “0” (the first administration), at oneweek post time “0”, and then administered every two weeks following theweek one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered a 280 mg dose topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by microinfuser a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 100 kg, andpatients weighing greater than 100 kg are administered a 210 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by microinfuser a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 210 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by microinfuser a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 90 kg, andpatients weighing greater than 90 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by microinfuser a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 100 kg, andpatients weighing greater than 100 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who are candidates for systemic therapy orphototherapy, wherein said patients are administered by subcutaneousinjection by microinfuser a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 90 kg every two weeks andpatients weighing greater than 90 kg are administered a 210 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose every two weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose every two weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose every two weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose every two weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose every two weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose every four weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose every four weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose every four weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose every four weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose every four weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose every four weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg doseevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose by subcutaneousinjection to patients weighing less than or approximately equal to 90 kgevery two weeks and patients weighing greater than 90 kg areadministered a 210 mg dose by subcutaneous injection every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose by subcutaneousinjection every two weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose by subcutaneousinjection every two weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose by subcutaneousinjection every two weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose by subcutaneousinjection every two weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose by subcutaneousinjection every two weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose by subcutaneousinjection every four weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose by subcutaneousinjection every four weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose by subcutaneousinjection every four weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 210 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose by subcutaneousinjection every four weeks to patients weighing less than orapproximately equal to 90 kg and patients weighing greater than 90 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose by subcutaneousinjection every four weeks to patients weighing less than orapproximately equal to 100 kg and patients weighing greater than 100 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose by subcutaneousinjection every four weeks to patients weighing less than orapproximately equal to 110 kg and patients weighing greater than 110 kgare administered a 280 mg dose by subcutaneous injection every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by autoinjector syringe to patients weighing lessthan or approximately equal to 90 kg every two weeks and patientsweighing greater than 90 kg are administered a 210 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by autoinjector syringe every four weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 210 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by autoinjector syringe every four weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by autoinjector syringe every four weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 210 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by autoinjector syringe every four weeks topatients weighing less than or approximately equal to 90 kg and patientsweighing greater than 90 kg are administered a 280 mg dose delivered bysubcutaneous injection by autoinjector syringe every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by autoinjector syringe every four weeks topatients weighing less than or approximately equal to 100 kg andpatients weighing greater than 100 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by autoinjector syringe every four weeks topatients weighing less than or approximately equal to 110 kg andpatients weighing greater than 110 kg are administered a 280 mg dosedelivered by subcutaneous injection by autoinjector syringe every twoweeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by microinfuser to patients weighing less than orapproximately equal to 90 kg every two weeks and patients weighinggreater than 90 kg are administered a 210 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by microinfuser every two weeks to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 210 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by microinfuser every two weeks to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 210 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by microinfuser every two weeks to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by microinfuser every two weeks to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose delivered bysubcutaneous injection by microinfuser every two weeks to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every four weeks to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 210 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every four weeks to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 210 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every four weeks to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 210 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every four weeks to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every four weeks to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every four weeks to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 280 mg dose delivered bysubcutaneous injection by microinfuser every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 210 mg dose, wherein the AM-14 isadministered by subcutaneous injection administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 280 mg dose, wherein the AM-14 isadministered by subcutaneous injection administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection administered at time “0”(the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 210 mg dose, wherein the AM-14 isadministered by subcutaneous injection administered at time “0” (thefirst administration), at one week post time “0”, and then administeredevery two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose at time “0” (thefirst administration), at one week post time “0”, and every four weeksto patients weighing less than or approximately equal to 100 kg, andpatients weighing greater than 100 kg are administered a 210 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose at time “0” (thefirst administration), at one week post time “0”, and every four weeksto patients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 210 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose at time “0” (thefirst administration), at one week post time “0”, and every four weeksto patients weighing less than or approximately equal to 90 kg, andpatients weighing greater than 90 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose at time “0” (thefirst administration), at one week post time “0”, and every four weeksto patients weighing less than or approximately equal to 100 kg, andpatients weighing greater than 100 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose at time “0” (thefirst administration), at one week post time “0”, and every four weeksto patients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 210 mg dose, wherein the AM-14 isadministered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 280 mg dose, wherein the AM-14 isadministered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 210 mg dose, wherein the AM-14 isadministered by subcutaneous injection by autoinjector syringeadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection byautoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 100 kg, andpatients weighing greater than 100 kg are administered a 210 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection byautoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 210 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection byautoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 90 kg, andpatients weighing greater than 90 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection byautoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 100 kg, andpatients weighing greater than 100 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection byautoinjector syringe a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every four weeks topatients weighing less than or approximately equal to 110 kg, andpatients weighing greater than 110 kg are administered a 280 mg dose attime “0” (the first administration), at one week post time “0”, andevery two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 210 mg dose, wherein the AM-14 isadministered by subcutaneous injection by microinfuser administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 210 mg dose, wherein theAM-14 is administered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 280 mg dose, wherein the AM-14 isadministered by subcutaneous injection by microinfuser administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 100 kg and patientsweighing greater than 100 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 140 mg dose to patientsweighing less than or approximately equal to 110 kg and patientsweighing greater than 110 kg are administered a 280 mg dose, wherein theAM-14 is administered by subcutaneous injection by microinfuseradministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered a 280 mg dose to patientsweighing less than or approximately equal to 90 kg and patients weighinggreater than 90 kg are administered a 210 mg dose, wherein the AM-14 isadministered by subcutaneous injection by microinfuser administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection bymicroinfuser a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 100 kg, and patients weighing greaterthan 100 kg are administered a 210 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection bymicroinfuser a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 110 kg, and patients weighing greaterthan 110 kg are administered a 210 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection bymicroinfuser a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 90 kg, and patients weighing greater than90 kg are administered a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

AM-14 in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid,3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be usedto treat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection bymicroinfuser a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 100 kg, and patients weighing greaterthan 100 kg are administered a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks. AM-14in a formulation comprising 140 mg/mL AM-14, 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 can be used totreat adult and/or juvenile patients with chronic moderate to severeplaque psoriasis who fail to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and PUVA (psoralen plus ultraviolet-A phototherapy),wherein said patients are administered by subcutaneous injection bymicroinfuser a 280 mg dose at time “0” (the first administration), atone week post time “0”, and every four weeks to patients weighing lessthan or approximately equal to 110 kg, and patients weighing greaterthan 110 kg are administered a 280 mg dose at time “0” (the firstadministration), at one week post time “0”, and every two weeks.

Administration and dosage regimens of AM-14 formulations can be adjustedto provide an effective amount for an optimum therapeutic response. Forexample, a single bolus can be administered, several divided doses canbe administered over time or the dose can be proportionally reduced orincreased as indicated by the exigencies of the therapeutic situation.AM-14 may be formulated for subcutaneous, intravenous, parenteral,intradermal, intramuscular, and/or intraperitoneal administration in aunit dosage form for ease of administration and uniformity of dosage.AM-14 formulated in 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 may be formulated for subcutaneous,intravenous, parenteral, intradermal, intramuscular, and/orintraperitoneal administration in a unit dosage form for ease ofadministration and uniformity of dosage. Unit dosing refers to aphysically discrete amount of AM-14 suited as unitary dosages for thesubjects to be treated; each unit contains a predetermined quantity ofactive biopharmaceutical calculated to produce a desired therapeuticeffect.

AM-14 formulations may be administered subcutaneously, intravenously,parenterally, intradermally, intramuscularly, and/or intraperitoneallyusing standard techniques. AM-14 may be administered subcutaneously,intravenously, parenterally, intradermally, intramuscularly, and/orintraperitoneally at the dosages described above and in the formulationsdescribed herein for the treatment of the diseases listed above. AM-14formulated in 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2 may be administered subcutaneously,intravenously, parenterally, intradermally, intramuscularly, and/orintraperitoneally using standard techniques at the dosages and dosingregimens described above for the treatment of the psoriasis listedabove. AM-14 formulated in 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2 may be administeredsubcutaneously, intravenously, intradermally, and/or intramuscularlyusing standard techniques at the dosages and dosing regimens describedabove for the treatment of the psoriasis listed above. AM-14 may beformulated at about 140 mg/ml formulated in 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 may beadministered subcutaneously, intravenously, intradermally, and/orintramuscularly using standard techniques at the dosages and dosingregimens described above for the treatment of the psoriasis listedabove. AM-14 formulations, such as AM-14 formulated in 10 mM glutamicacid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, may beadministered more than once at scheduled intervals over a period oftime. In certain embodiments, AM-14 formulations, such as AM-14formulated in 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, are administered over a period of at least amonth or more. Embodiments include long-term treatment of the chronicconditions described above. Shorter periods of administration can besufficient when treating acute conditions including, for example, fromone to twenty four weeks. In general, AM-14 formulations areadministered until the patient manifests a medically relevant degree ofimprovement over baseline for the chosen indicator or indicators asadjudged by a medical professional. Specifically, AM-14 formulations,such as AM-14 formulated in 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2, may be administered once everyweek or 6 to 8 days, or every two weeks or 12 to 16 days, or every threeweeks or 19 to 23 days, or every month or 26 to 30 days, or every fiveweeks or 33 to 34 days, or every six weeks or 40 to 44 days, or everyseven weeks or 47 to 51 days, or every two months or 54 to 58 dayssubcutaneously, intravenously, parenterally, intradermally,intramuscularly, and/or intraperitoneally at the dosages described aboveand in the formulations described herein for an indefinite period oftime for the treatment of the diseases and conditions described above,and in particular psoriasis.

Aspects of the invention include dosing regimens that further comprise aloading step. A “loading dose” refers to the step of initiallyadministering at least one dose of an AM-14 formulation to the patientby any of the routes described above and prior to the administration ofthe same or lower dose at any of the intervals and routes describedabove. The initial dose or doses rapidly increase the serum drugconcentration to an efficacious target serum concentration. The loadingdose or series of loading doses is/are administered 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 13, and/or 14 days prior to the normal course ofdosing. It is understood that a “day” also includes any time intervalbetween 1 and 24 hours. For example, as described above in more detail,AM-14 formulated in 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, is administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration.

It is understood that the methods of treating the diseases describedherein would administer an effective amount of an AM-14 formulation,such as AM-14 formulated in 10 mM glutamic acid, 3% (w/v) L-proline,0.01% (w/v) polysorbate 20, pH 4.8±0.2. Depending on the indication tobe treated, a therapeutically effective amount is sufficient to cause areduction in at least one symptom of the targeted pathological conditionby at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more, relative to untreatedsubjects.

Aspects of the invention also include methods of regulating geneexpression in psoriasis patients using AM-14. Example 3 describes indetail the genes that are regulated by AM-14. Thus, aspects of theinvention include methods of regulating the genes in tables 3.1, 3.2,and/or 3.3 in psoriasis patients by administering AM-14. Aspects of theinvention include the use of AM-14 for the preparation of a medicamentfor regulating the genes in tables 3.1, 3.2, and/or 3.3 in psoriasispatients. Further aspects described in Example 3 are also envisioned inmethods of use, such as the temporal relationship between administrationof AM-14 and gene regulation as well as the extent (e.g., fold change)of gene regulation and administration of AM-14.

Aspects of the invention also include methods of regulating geneexpression in psoriasis patients using AM-14 and concomitantly reducingthe PASI score in a patient having psoriasis by at least 10, 15, 20, 25,30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100%. Example3 describes in detail the genes that are regulated by AM-14. Thus,aspects of the invention include methods of regulating the genes intables 3.1, 3.2, and/or 3.3 and concomitantly reducing the PASI score ina patient having psoriasis by at least 10, 15, 20, 25, 30, 35, 40, 45,50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% in psoriasis patients byadministering AM-14. Aspects of the invention include the use of AM-14for the preparation of a medicament for regulating the genes in tables3.1, 3.2, and/or 3.3 and concomitantly reducing the PASI score in apatient having psoriasis by at least 10, 15, 20, 25, 30, 35, 40, 45, 50,55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% in psoriasis patients.Further aspects described in Example 3 are also envisioned in methods ofuse, such as the temporal relationship between administration of AM-14and gene regulation as well as the extent (e.g., fold change) of generegulation and administration of AM-14.

Aspects of the invention also include methods of regulating geneexpression in 15 days or less in psoriasis patients using AM-14 andconcomitantly reducing the PASI score in a patient having psoriasis byat least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,90, 95, or 100%. Example 3 describes in detail the genes that areregulated by AM-14. Thus, aspects of the invention include methods ofregulating the genes in tables 3.1, 3.2, and/or 3.3 in 15 days or lessand concomitantly reducing the PASI score in a patient having psoriasisby at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,85, 90, 95, or 100% in psoriasis patients by administering AM-14.Aspects of the invention include the use of AM-14 for the preparation ofa medicament for regulating the genes in tables 3.1, 3.2, and/or 3.3 in15 days or less and concomitantly reducing the PASI score in a patienthaving psoriasis by at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60,65, 70, 75, 80, 85, 90, 95, or 100% in psoriasis patients. Furtheraspects described in Example 3 are also envisioned in methods of use,such as the temporal relationship between administration of AM-14 andgene regulation as well as the extent (e.g., fold change) of generegulation and administration of AM-14.

Aspects of the invention also include methods of regulating geneexpression in psoriasis patients using IL-17 antagonistic antibodies. An“IL-17 antagonistic antibody” is an antibody that inhibits IL-17A orIL-17A/F from activating its cognate receptor(s) including IL-17RA,IL-17RC, and IL-17RA/RC. IL-17 antagonistic antibodies includesantibodies against IL-17RA or antibodies against IL-17A and/or IL-17A/F.Example 3 describes in detail the genes that are regulated by anexemplary antibody, AM-14. Thus, aspects of the invention includemethods of regulating the genes in tables 3.1, 3.2, and/or 3.3 inpsoriasis patients by administering an IL-17 antagonistic antibody.Aspects of the invention include the use of an IL-17 antagonisticantibody for the preparation of a medicament for regulating the genes intables 3.1, 3.2, and/or 3.3 in psoriasis patients. Further aspectsdescribed in Example 3 are also envisioned in methods of use, such asthe temporal relationship between administration of an IL-17antagonistic antibody and gene regulation as well as the extent (e.g.,fold change) of gene regulation and administration of an IL-17antagonistic antibody.

Aspects of the invention also include methods of regulating geneexpression and concomitantly reducing the PASI score in a patient havingpsoriasis by at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,70, 75, 80, 85, 90, 95, or 100% in psoriasis patients using IL-17antagonistic antibodies. An “IL-17 antagonistic antibody” is an antibodythat inhibits IL-17A or IL-17A/F from activating its cognate receptor(s)including IL-17RA, IL-17RC, and IL-17RA/RC. IL-17 antagonisticantibodies includes antibodies against IL-17RA or antibodies againstIL-17A and/or IL-17A/F. Example 3 describes in detail the genes that areregulated by an exemplary antibody, AM-14. Thus, aspects of theinvention include methods of regulating the genes in tables 3.1, 3.2,and/or 3.3 and concomitantly reducing the PASI score in a patient havingpsoriasis by at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,70, 75, 80, 85, 90, 95, or 100% in psoriasis patients by administeringan IL-17 antagonistic antibody. Aspects of the invention include the useof an IL-17 antagonistic antibody for the preparation of a medicamentfor regulating the genes in tables 3.1, 3.2, and/or 3.3 andconcomitantly reducing the PASI score in a patient having psoriasis byat least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,90, 95, or 100% in psoriasis patients. Further aspects described inExample 3 are also envisioned in methods of use, such as the temporalrelationship between administration of an IL-17 antagonistic antibodyand gene regulation as well as the extent (e.g., fold change) of generegulation and administration of an IL-17 antagonistic antibody.

Aspects of the invention also include methods of regulating geneexpression in 15 days or less and concomitantly reducing the PASI scorein a patient having psoriasis by at least 10, 15, 20, 25, 30, 35, 40,45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% in psoriasispatients using IL-17 antagonistic antibodies. An “IL-17 antagonisticantibody” is an antibody that inhibits IL-17A or IL-17A/F fromactivating its cognate receptor(s) including IL-17RA, IL-17RC, andIL-17RA/RC. IL-17 antagonistic antibodies includes antibodies againstIL-17RA or antibodies against IL-17A and/or IL-17A/F. Example 3describes in detail the genes that are regulated by an exemplaryantibody, AM-14. Thus, aspects of the invention include methods ofregulating the genes in tables 3.1, 3.2, and/or 3.3 in 15 days or lessand concomitantly reducing the PASI score in a patient having psoriasisby at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,85, 90, 95, or 100% in psoriasis patients by administering an IL-17antagonistic antibody. Aspects of the invention include the use of anIL-17 antagonistic antibody for the preparation of a medicament forregulating the genes in tables 3.1, 3.2, and/or 3.3 in 15 days or lessand concomitantly reducing the PASI score in a patient having psoriasisby at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,85, 90, 95, or 100% in psoriasis patients. Further aspects described inExample 3 are also envisioned in methods of use, such as the temporalrelationship between administration of an IL-17 antagonistic antibodyand gene regulation as well as the extent (e.g., fold change) of generegulation and administration of an IL-17 antagonistic antibody.

Embodiments of the invention include those described above andthroughout the specification, including:

1. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per dose, whereinsaid antibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, aheavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprisingSEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chainCDR2 comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ IDNO:11, and wherein said antibody specifically binds human IL-17 receptorA.2. The method of embodiment 1, wherein the psoriasis is plaquepsoriasis.3. The method of embodiment 2, wherein the plaque psoriasis is moderateto severe plaque psoriasis.4. The method of embodiment 3, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.5. The method of embodiment 3, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.6. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 mg antibody per dose, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.7. The method of embodiment 6, wherein the psoriasis is plaquepsoriasis.8. The method of embodiment 6, wherein the plaque psoriasis is moderateto severe plaque psoriasis.9. The method of embodiment 8, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.10. The method of embodiment 8, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.11. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 140 mg antibody per dose, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.12. The method of embodiment 11, wherein the psoriasis is plaquepsoriasis.13. The method of embodiment 12, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.14. The method of embodiment 13, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.15. The method of embodiment 13, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.16. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 210 mg antibody per dose, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.17. The method of embodiment 16, wherein the psoriasis is plaquepsoriasis.18. The method of embodiment 17, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.19. The method of embodiment 18, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.20. The method of embodiment 18, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.21. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 280 mg antibody per dose, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.22. The method of embodiment 21, wherein the psoriasis is plaquepsoriasis.23. The method of embodiment 22, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.24. The method of embodiment 23, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.25. The method of embodiment 23, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.26. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per dose, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain variable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.27. The method of embodiment 26, wherein the psoriasis is plaquepsoriasis.28. The method of embodiment 27, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.29. The method of embodiment 28, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.30. The method of embodiment 28, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.31. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 mg antibody per dose, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.32. The method of embodiment 31, wherein the psoriasis is plaquepsoriasis.33. The method of embodiment 32, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.34. The method of embodiment 33, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.35. The method of embodiment 33, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.36. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 140 mg antibody per dose, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.37. The method of embodiment 36, wherein the psoriasis is plaquepsoriasis.38. The method of embodiment 36, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.39. The method of embodiment 38, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.40. The method of embodiment 38, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.41. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 210 mg antibody per dose, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.42. The method of embodiment 41, wherein the psoriasis is plaquepsoriasis.43. The method of embodiment 42, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.44. The method of embodiment 43, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.45. The method of embodiment 43, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.46. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 280 mg antibody per dose, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.47. The method of embodiment 46, wherein the psoriasis is plaquepsoriasis.48. The method of embodiment 47, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.49. The method of embodiment 48, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.50. The method of embodiment 48, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.51. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per dose, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.52. The method of embodiment 51, wherein the psoriasis is plaquepsoriasis.53. The method of embodiment 52, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.54. The method of embodiment 53, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.55. The method of embodiment 53, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.56. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 mg antibody per dose, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.57. The method of embodiment 56, wherein the psoriasis is plaquepsoriasis.58. The method of embodiment 57, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.59. The method of embodiment 58, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.60. The method of embodiment 58, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.61. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 140 mg antibody per dose, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.62. The method of embodiment 61, wherein the psoriasis is plaquepsoriasis.63. The method of embodiment 62, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.64. The method of embodiment 63, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.65. The method of embodiment 63, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.66. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 210 mg antibody per dose, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.67. The method of embodiment 66, wherein the psoriasis is plaquepsoriasis.68. The method of embodiment 67, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.69. The method of embodiment 68, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.70. The method of embodiment 68, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.71. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 280 mg antibody per dose, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.72. The method of embodiment 71, wherein the psoriasis is plaquepsoriasis.73. The method of embodiment 72, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.74. The method of embodiment 73, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.75. The method of embodiment 73, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.76. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 70 to about 300mg antibody per dose, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.77. The method of embodiment 76, wherein the psoriasis is plaquepsoriasis.78. The method of embodiment 77, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.79. The method of embodiment 78, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.80. The method of embodiment 78, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.81. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 70 mg antibodyper dose, wherein said antibody comprises a heavy chain CDR1 comprisingSEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chainCDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9,a light chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3comprising SEQ ID NO:11, and wherein said antibody specifically bindshuman IL-17 receptor A.82. The method of embodiment 81, wherein the psoriasis is plaquepsoriasis.83. The method of embodiment 82, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.84. The method of embodiment 83, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.85. The method of embodiment 83, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.86. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 140 mg antibodyper dose, wherein said antibody comprises a heavy chain CDR1 comprisingSEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chainCDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9,a light chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3comprising SEQ ID NO:11, and wherein said antibody specifically bindshuman IL-17 receptor A.87. The method of embodiment 86, wherein the psoriasis is plaquepsoriasis.88. The method of embodiment 87, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.89. The method of embodiment 88, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.90. The method of embodiment 88, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.91. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 210 mg antibodyper dose, wherein said antibody comprises a heavy chain CDR1 comprisingSEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chainCDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9,a light chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3comprising SEQ ID NO:11, and wherein said antibody specifically bindshuman IL-17 receptor A.92. The method of embodiment 91, wherein the psoriasis is plaquepsoriasis.93. The method of embodiment 92, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.94. The method of embodiment 93, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.95. The method of embodiment 93, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.96. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 280 mg antibodyper dose, wherein said antibody comprises a heavy chain CDR1 comprisingSEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chainCDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9,a light chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3comprising SEQ ID NO:11, and wherein said antibody specifically bindshuman IL-17 receptor A.97. The method of embodiment 96, wherein the psoriasis is plaquepsoriasis.98. The method of embodiment 97, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.99. The method of embodiment 98, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.100. The method of embodiment 99, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.101. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 70 to about 300mg antibody per dose, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.102. The method of embodiment 101, wherein the psoriasis is plaquepsoriasis.103. The method of embodiment 102, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.104. The method of embodiment 103, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.105. The method of embodiment 103, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.106. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 70 mg antibodyper dose, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain variable domain sequence comprising SEQ ID NO:3and a light chain variable domain sequence comprising SEQ ID NO:4, andwherein said antibody specifically binds human IL-17 receptor A.107. The method of embodiment 106, wherein the psoriasis is plaquepsoriasis.108. The method of embodiment 107, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.109. The method of embodiment 108, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.110. The method of embodiment 108, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.111. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 140 mg antibodyper dose, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain variable domain sequence comprising SEQ ID NO:3and a light chain variable domain sequence comprising SEQ ID NO:4, andwherein said antibody specifically binds human IL-17 receptor A.112. The method of embodiment 111, wherein the psoriasis is plaquepsoriasis.113. The method of embodiment 112, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.114. The method of embodiment 113, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.115. The method of embodiment 113, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.116. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 210 mg antibodyper dose, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain variable domain sequence comprising SEQ ID NO:3and a light chain variable domain sequence comprising SEQ ID NO:4, andwherein said antibody specifically binds human IL-17 receptor A.117. The method of embodiment 116, wherein the psoriasis is plaquepsoriasis.118. The method of embodiment 117, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.119. The method of embodiment 118, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.120. The method of embodiment 118, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.121. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 280 mg antibodyper dose, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain variable domain sequence comprising SEQ ID NO:3and a light chain variable domain sequence comprising SEQ ID NO:4, andwherein said antibody specifically binds human IL-17 receptor A.122. The method of embodiment 121, wherein the psoriasis is plaquepsoriasis.123. The method of embodiment 122, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.124. The method of embodiment 123, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.125. The method of embodiment 123, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.126. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 70 to about 300mg antibody per dose, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.127. The method of embodiment 126, wherein the psoriasis is plaquepsoriasis.128. The method of embodiment 127, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.129. The method of embodiment 128, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.130. The method of embodiment 128, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.131. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 70 mg antibodyper dose, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain sequence comprising SEQ ID NO:1 and a lightchain sequence comprising SEQ ID NO:2.132. The method of embodiment 131, wherein the psoriasis is plaquepsoriasis.133. The method of embodiment 132, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.134. The method of embodiment 133, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.135. The method of embodiment 133, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.136. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 140 mg antibodyper dose, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain sequence comprising SEQ ID NO:1 and a lightchain sequence comprising SEQ ID NO:2.137. The method of embodiment 136, wherein the psoriasis is plaquepsoriasis.138. The method of embodiment 137, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.139. The method of embodiment 138, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.140. The method of embodiment 138, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.141. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 210 mg antibodyper dose, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain sequence comprising SEQ ID NO:1 and a lightchain sequence comprising SEQ ID NO:2.142. The method of embodiment 141, wherein the psoriasis is plaquepsoriasis.143. The method of embodiment 142, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.144. The method of embodiment 143, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.145. The method of embodiment 143, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.146. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anisolated antibody in a single or divided dose of about 280 mg antibodyper dose, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain sequence comprising SEQ ID NO:1 and a lightchain sequence comprising SEQ ID NO:2.147. The method of embodiment 146, wherein the psoriasis is plaquepsoriasis.148. The method of embodiment 147, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.149. The method of embodiment 148, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.150. The method of embodiment 148, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.151. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per doseadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.152. The method of embodiment 151, wherein the psoriasis is plaquepsoriasis.153. The method of embodiment 152, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.154. The method of embodiment 153, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.155. The method of embodiment 153, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.156. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 70 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.157. The method of embodiment 156, wherein the psoriasis is plaquepsoriasis.158. The method of embodiment 157, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.159. The method of embodiment 158, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.160. The method of embodiment 158, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.161. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.162. The method of embodiment 161, wherein the psoriasis is plaquepsoriasis.163. The method of embodiment 162, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.164. The method of embodiment 163, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.165. The method of embodiment 163, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.166. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 210 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.167. The method of embodiment 166, wherein the psoriasis is plaquepsoriasis.168. The method of embodiment 167, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.169. The method of embodiment 168, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.170. The method of embodiment 168, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.171. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.172. The method of embodiment 171, wherein the psoriasis is plaquepsoriasis.173. The method of embodiment 172, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.174. The method of embodiment 173, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.175. The method of embodiment 173, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.176. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per doseadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.177. The method of embodiment 176, wherein the psoriasis is plaquepsoriasis.178. The method of embodiment 177, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.179. The method of embodiment 178, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.180. The method of embodiment 178, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.181. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 70 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.182. The method of embodiment 181, wherein the psoriasis is plaquepsoriasis.183. The method of embodiment 182, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.184. The method of embodiment 183, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.185. The method of embodiment 183, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.186. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.187. The method of embodiment 186, wherein the psoriasis is plaquepsoriasis.188. The method of embodiment 187, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.189. The method of embodiment 188, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.190. The method of embodiment 188, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.191. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 210 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.192. The method of embodiment 191, wherein the psoriasis is plaquepsoriasis.193. The method of embodiment 192, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.194. The method of embodiment 193, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.195. The method of embodiment 193, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.196. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.197. The method of embodiment 196, wherein the psoriasis is plaquepsoriasis.198. The method of embodiment 197, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.199. The method of embodiment 198, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.200. The method of embodiment 198, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.201. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per doseadministered at time “0” (the first administration), at one week posttime “0”, and then administered every two weeks following the week oneadministration, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.202. The method of embodiment 201, wherein the psoriasis is plaquepsoriasis.203. The method of embodiment 202, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.204. The method of embodiment 203, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.205. The method of embodiment 203, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.206. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 70 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.207. The method of embodiment 206, wherein the psoriasis is plaquepsoriasis.208. The method of embodiment 207, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.209. The method of embodiment 208, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.210. The method of embodiment 208, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.211. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.212. The method of embodiment 211, wherein the psoriasis is plaquepsoriasis.213. The method of embodiment 212, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.214. The method of embodiment 213, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.215. The method of embodiment 213, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.216. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 210 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.217. The method of embodiment 216, wherein the psoriasis is plaquepsoriasis.218. The method of embodiment 217, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.219. The method of embodiment 218, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.220. The method of embodiment 218, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.221. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administered everytwo weeks following the week one administration, wherein said antibody,or IL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.222. The method of embodiment 221, wherein the psoriasis is plaquepsoriasis.223. The method of embodiment 222, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.224. The method of embodiment 223, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.225. The method of embodiment 223, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.226. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per doseadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.227. The method of embodiment 226, wherein the psoriasis is plaquepsoriasis.228. The method of embodiment 227, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.229. The method of embodiment 228, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.230. The method of embodiment 228, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.231. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 70 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.232. The method of embodiment 231, wherein the psoriasis is plaquepsoriasis.233. The method of embodiment 232, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.234. The method of embodiment 233, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.235. The method of embodiment 233, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.236. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.237. The method of embodiment 236, wherein the psoriasis is plaquepsoriasis.238. The method of embodiment 237, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.239. The method of embodiment 238, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.240. The method of embodiment 238, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.241. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 210 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.242. The method of embodiment 241, wherein the psoriasis is plaquepsoriasis.243. The method of embodiment 242, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.244. The method of embodiment 243, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.245. The method of embodiment 243, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.246. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibodycomprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, alight chain CDR1 comprising SEQ ID NO:9, a light chain CDR2 comprisingSEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11, andwherein said antibody specifically binds human IL-17 receptor A.247. The method of embodiment 246, wherein the psoriasis is plaquepsoriasis.248. The method of embodiment 247, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.249. The method of embodiment 248, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.250. The method of embodiment 248, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.251. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per doseadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.252. The method of embodiment 251, wherein the psoriasis is plaquepsoriasis.253. The method of embodiment 252, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.254. The method of embodiment 253, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.255. The method of embodiment 253, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.256. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 70 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.257. The method of embodiment 256, wherein the psoriasis is plaquepsoriasis.258. The method of embodiment 257, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.259. The method of embodiment 258, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.260. The method of embodiment 258, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.261. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.262. The method of embodiment 261, wherein the psoriasis is plaquepsoriasis.263. The method of embodiment 262, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.264. The method of embodiment 263, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.265. The method of embodiment 263, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.266. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 210 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.267. The method of embodiment 266, wherein the psoriasis is plaquepsoriasis.268. The method of embodiment 267, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.269. The method of embodiment 268, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.270. The method of embodiment 268, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.271. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.272. The method of embodiment 271, wherein the psoriasis is plaquepsoriasis.273. The method of embodiment 272, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.274. The method of embodiment 273, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.275. The method of embodiment 273, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.276. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of about 70 to about 300 mg antibody per doseadministered at time “0” (the first administration), at one week posttime “0”, and then administered monthly following the week oneadministration, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.277. The method of embodiment 276, wherein the psoriasis is plaquepsoriasis.278. The method of embodiment 277, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.279. The method of embodiment 278, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.280. The method of embodiment 278, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.281. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 70 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.282. The method of embodiment 281, wherein the psoriasis is plaquepsoriasis.283. The method of embodiment 282, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.284. The method of embodiment 283, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.285. The method of embodiment 283, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.286. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.287. The method of embodiment 286, wherein the psoriasis is plaquepsoriasis.288. The method of embodiment 287, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.289. The method of embodiment 288, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.290. The method of embodiment 288, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.291. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 210 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.292. The method of embodiment 291, wherein the psoriasis is plaquepsoriasis.293. The method of embodiment 292, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.294. The method of embodiment 293, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.295. The method of embodiment 293, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.296. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg per dose administered at time “0” (the firstadministration), at one week post time “0”, and then administeredmonthly following the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.297. The method of embodiment 296, wherein the psoriasis is plaquepsoriasis.298. The method of embodiment 297, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.299. The method of embodiment 298, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.300. The method of embodiment 298, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.301. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 90 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 90 kg, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.302. The method of embodiment 301, wherein the psoriasis is plaquepsoriasis.303. The method of embodiment 302, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.304. The method of embodiment 303, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.305. The method of embodiment 303, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.306. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 100 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 100 kg, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.307. The method of embodiment 306, wherein the psoriasis is plaquepsoriasis.308. The method of embodiment 307, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.309. The method of embodiment 308, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.310. The method of embodiment 308, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.311. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 110 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 110 kg, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.312. The method of embodiment 311, wherein the psoriasis is plaquepsoriasis.313. The method of embodiment 312, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.314. The method of embodiment 313, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.315. The method of embodiment 313, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.316. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 90 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 90 kg, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.317. The method of embodiment 316, wherein the psoriasis is plaquepsoriasis.318. The method of embodiment 317, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.319. The method of embodiment 318, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.320. The method of embodiment 318, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.321. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 100 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 100 kg, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.322. The method of embodiment 321, wherein the psoriasis is plaquepsoriasis.323. The method of embodiment 322, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.324. The method of embodiment 323, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.325. The method of embodiment 323, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.326. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 110 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 110 kg, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.327. The method of embodiment 326, wherein the psoriasis is plaquepsoriasis.328. The method of embodiment 327, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.329. The method of embodiment 328, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.330. The method of embodiment 328, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.331. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 90 kg and a single or divided dose of 210mg every two weeks to patients weighing greater than 90 kg, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.332. The method of embodiment 331, wherein the psoriasis is plaquepsoriasis.333. The method of embodiment 332, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.334. The method of embodiment 333, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.335. The method of embodiment 333, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.336. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 100 kg and a single or divided dose of210 mg every two weeks to patients weighing greater than 100 kg, whereinsaid antibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, aheavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprisingSEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chainCDR2 comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ IDNO:11, and wherein said antibody specifically binds human IL-17 receptorA.337. The method of embodiment 336, wherein the psoriasis is plaquepsoriasis.338. The method of embodiment 337, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.339. The method of embodiment 338, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.340. The method of embodiment 338, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.341. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 110 kg and a single or divided dose of210 mg every two weeks to patients weighing greater than 110 kg, whereinsaid antibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, aheavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprisingSEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chainCDR2 comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ IDNO:11, and wherein said antibody specifically binds human IL-17 receptorA.342. The method of embodiment 341, wherein the psoriasis is plaquepsoriasis.343. The method of embodiment 342, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.344. The method of embodiment 343, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.345. The method of embodiment 343, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.346. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 90 kg and a single or divided dose of 280mg every two weeks to patients weighing greater than 90 kg, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.347. The method of embodiment 346, wherein the psoriasis is plaquepsoriasis.348. The method of embodiment 347, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.349. The method of embodiment 348, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.350. The method of embodiment 348, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.351. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 100 kg and a single or divided dose of280 mg every two weeks to patients weighing greater than 100 kg, whereinsaid antibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, aheavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprisingSEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chainCDR2 comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ IDNO:11, and wherein said antibody specifically binds human IL-17 receptorA.352. The method of embodiment 351, wherein the psoriasis is plaquepsoriasis.353. The method of embodiment 352, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.354. The method of embodiment 353, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.355. The method of embodiment 323, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.356. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 110 kg and a single or divided dose of280 mg every two weeks to patients weighing greater than 110 kg, whereinsaid antibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, aheavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprisingSEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chainCDR2 comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ IDNO:11, and wherein said antibody specifically binds human IL-17 receptorA.357. The method of embodiment 356, wherein the psoriasis is plaquepsoriasis.358. The method of embodiment 357, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.359. The method of embodiment 358, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.360. The method of embodiment 358, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.361. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 90 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 90 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.362. The method of embodiment 361, wherein the psoriasis is plaquepsoriasis.363. The method of embodiment 362, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.364. The method of embodiment 363, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.365. The method of embodiment 363, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.366. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 100 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 100 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.367. The method of embodiment 366, wherein the psoriasis is plaquepsoriasis.368. The method of embodiment 367, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.369. The method of embodiment 368, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.370. The method of embodiment 368, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.371. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 110 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 110 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.372. The method of embodiment 371, wherein the psoriasis is plaquepsoriasis.373. The method of embodiment 372, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.374. The method of embodiment 373, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.375. The method of embodiment 373, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.376. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 90 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 90 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.377. The method of embodiment 376, wherein the psoriasis is plaquepsoriasis.378. The method of embodiment 377, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.379. The method of embodiment 378, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.380. The method of embodiment 378, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.381. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 100 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 100 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.382. The method of embodiment 381, wherein the psoriasis is plaquepsoriasis.383. The method of embodiment 382, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.384. The method of embodiment 383, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.385. The method of embodiment 383, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.386. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 110 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 110 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.387. The method of embodiment 386, wherein the psoriasis is plaquepsoriasis.388. The method of embodiment 387, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.389. The method of embodiment 388, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.390. The method of embodiment 388, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.391. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 90 kg and a single or divided dose of 210mg every two weeks to patients weighing greater than 90 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.392. The method of embodiment 391, wherein the psoriasis is plaquepsoriasis.393. The method of embodiment 392, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.394. The method of embodiment 393, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.395. The method of embodiment 393, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.396. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 100 kg and a single or divided dose of210 mg every two weeks to patients weighing greater than 100 kg, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain variable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.397. The method of embodiment 396, wherein the psoriasis is plaquepsoriasis.398. The method of embodiment 397, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.399. The method of embodiment 398, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.400. The method of embodiment 398, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.401. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 110 kg and a single or divided dose of210 mg every two weeks to patients weighing greater than 110 kg, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain variable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.402. The method of embodiment 401, wherein the psoriasis is plaquepsoriasis.403. The method of embodiment 402, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.404. The method of embodiment 403, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.405. The method of embodiment 403, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.406. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 90 kg and a single or divided dose of 280mg every two weeks to patients weighing greater than 90 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.407. The method of embodiment 406, wherein the psoriasis is plaquepsoriasis.408. The method of embodiment 407, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.409. The method of embodiment 408, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.410. The method of embodiment 408, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.411. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 100 kg and a single or divided dose of280 mg every two weeks to patients weighing greater than 100 kg, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain variable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.412. The method of embodiment 411, wherein the psoriasis is plaquepsoriasis.413. The method of embodiment 412, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.414. The method of embodiment 413, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.415. The method of embodiment 413, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.416. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 110 kg and a single or divided dose of280 mg every two weeks to patients weighing greater than 110 kg, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain variable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.417. The method of embodiment 416, wherein the psoriasis is plaquepsoriasis.418. The method of embodiment 417, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.419. The method of embodiment 418, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.420. The method of embodiment 418, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.421. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 90 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 90 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.422. The method of embodiment 421, wherein the psoriasis is plaquepsoriasis.423. The method of embodiment 422, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.424. The method of embodiment 423, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.425. The method of embodiment 423, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.426. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 100 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 100 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.427. The method of embodiment 426, wherein the psoriasis is plaquepsoriasis.428. The method of embodiment 427, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.429. The method of embodiment 428, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.430. The method of embodiment 428, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.431. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 110 kg and a single or divided dose of 210 mgevery two weeks to patients weighing greater than 110 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.432. The method of embodiment 431, wherein the psoriasis is plaquepsoriasis.433. The method of embodiment 432, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.434. The method of embodiment 433, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.435. The method of embodiment 433, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.436. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 90 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 90 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.437. The method of embodiment 436, wherein the psoriasis is plaquepsoriasis.438. The method of embodiment 437, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.439. The method of embodiment 438, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.440. The method of embodiment 438, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.441. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 100 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 100 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.442. The method of embodiment 441, wherein the psoriasis is plaquepsoriasis.443. The method of embodiment 442, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.444. The method of embodiment 443, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.445. The method of embodiment 443, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.446. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 140 mg every two weeks to patients weighing less thanor approximately equal to 110 kg and a single or divided dose of 280 mgevery two weeks to patients weighing greater than 110 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.447. The method of embodiment 446, wherein the psoriasis is plaquepsoriasis.448. The method of embodiment 447, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.449. The method of embodiment 448, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.450. The method of embodiment 448, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.451. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 90 kg and a single or divided dose of 210mg every two weeks to patients weighing greater than 90 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.452. The method of embodiment 451, wherein the psoriasis is plaquepsoriasis.453. The method of embodiment 452, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.454. The method of embodiment 453, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.455. The method of embodiment 453, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.456. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 100 kg and a single or divided dose of210 mg every two weeks to patients weighing greater than 100 kg, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.457. The method of embodiment 456, wherein the psoriasis is plaquepsoriasis.458. The method of embodiment 457, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.459. The method of embodiment 458, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.460. The method of embodiment 458, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.461. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 110 kg and a single or divided dose of210 mg every two weeks to patients weighing greater than 110 kg, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.462. The method of embodiment 461, wherein the psoriasis is plaquepsoriasis.463. The method of embodiment 462, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.464. The method of embodiment 463, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.465. The method of embodiment 463, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.466. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 90 kg and a single or divided dose of 280mg every two weeks to patients weighing greater than 90 kg, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.467. The method of embodiment 466, wherein the psoriasis is plaquepsoriasis.468. The method of embodiment 467, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.469. The method of embodiment 468, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.470. The method of embodiment 468, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.471. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 100 kg and a single or divided dose of280 mg every two weeks to patients weighing greater than 100 kg, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.472. The method of embodiment 471, wherein the psoriasis is plaquepsoriasis.473. The method of embodiment 472, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.474. The method of embodiment 473, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.475. The method of embodiment 473, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.476. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising an isolated antibody in a singleor divided dose of 280 mg every four weeks to patients weighing lessthan or approximately equal to 110 kg and a single or divided dose of280 mg every two weeks to patients weighing greater than 110 kg, whereinsaid antibody, or IL-17RA-binding fragment thereof, comprises a heavychain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.477. The method of embodiment 476, wherein the psoriasis is plaquepsoriasis.478. The method of embodiment 477, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.479. The method of embodiment 478, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.480. The method of embodiment 478, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.481. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of about 70 to about 300 mgantibody per dose administered at time “0” (the first administration),at one week post time “0”, and then administered every two weeksfollowing the week one administration, wherein said antibody comprises aheavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2 comprisingSEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID NO:8, a light chainCDR1 comprising SEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10,and a light chain CDR3 comprising SEQ ID NO:11, and wherein saidantibody specifically binds human IL-17 receptor A.482. The method of embodiment 481, wherein the psoriasis is plaquepsoriasis.483. The method of embodiment 482, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.484. The method of embodiment 483, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.485. The method of embodiment 483, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.486. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 70 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody comprises a heavy chain CDR1 comprising SEQ IDNO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, alight chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3comprising SEQ ID NO:11, and wherein said antibody specifically bindshuman IL-17 receptor A.487. The method of embodiment 486, wherein the psoriasis is plaquepsoriasis.488. The method of embodiment 487, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.489. The method of embodiment 488, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.490. The method of embodiment 488, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.491. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody comprises a heavy chain CDR1 comprising SEQ IDNO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, alight chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3comprising SEQ ID NO:11, and wherein said antibody specifically bindshuman IL-17 receptor A.492. The method of embodiment 491, wherein the psoriasis is plaquepsoriasis.493. The method of embodiment 492, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.494. The method of embodiment 493, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.495. The method of embodiment 493, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.496. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 210 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody comprises a heavy chain CDR1 comprising SEQ IDNO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, alight chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3comprising SEQ ID NO:11, and wherein said antibody specifically bindshuman IL-17 receptor A.497. The method of embodiment 496, wherein the psoriasis is plaquepsoriasis.498. The method of embodiment 497, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.499. The method of embodiment 498, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.500. The method of embodiment 498, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.501. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody comprises a heavy chain CDR1 comprising SEQ IDNO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, alight chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3comprising SEQ ID NO:11, and wherein said antibody specifically bindshuman IL-17 receptor A.502. The method of embodiment 501, wherein the psoriasis is plaquepsoriasis.503. The method of embodiment 502, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.504. The method of embodiment 503, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.505. The method of embodiment 503, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.506. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of about 70 to about 300 mgantibody per dose administered at time “0” (the first administration),at one week post time “0”, and then administered every two weeksfollowing the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain variabledomain sequence comprising SEQ ID NO:3 and a light chain variable domainsequence comprising SEQ ID NO:4, and wherein said antibody specificallybinds human IL-17 receptor A.507. The method of embodiment 506, wherein the psoriasis is plaquepsoriasis.508. The method of embodiment 507, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.509. The method of embodiment 508, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.510. The method of embodiment 508, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.511. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 70 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody, or IL-17RA-binding fragment thereof, comprises aheavy chain variable domain sequence comprising SEQ ID NO:3 and a lightchain variable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.512. The method of embodiment 511, wherein the psoriasis is plaquepsoriasis.513. The method of embodiment 512, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.514. The method of embodiment 513, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.515. The method of embodiment 513, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.516. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody, or IL-17RA-binding fragment thereof, comprises aheavy chain variable domain sequence comprising SEQ ID NO:3 and a lightchain variable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.517. The method of embodiment 516, wherein the psoriasis is plaquepsoriasis.518. The method of embodiment 517, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.519. The method of embodiment 518, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.520. The method of embodiment 518, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.521. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 210 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody, or IL-17RA-binding fragment thereof, comprises aheavy chain variable domain sequence comprising SEQ ID NO:3 and a lightchain variable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.522. The method of embodiment 521, wherein the psoriasis is plaquepsoriasis.523. The method of embodiment 522, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.524. The method of embodiment 523, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.525. The method of embodiment 523, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.526. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody, or IL-17RA-binding fragment thereof, comprises aheavy chain variable domain sequence comprising SEQ ID NO:3 and a lightchain variable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.527. The method of embodiment 526, wherein the psoriasis is plaquepsoriasis.528. The method of embodiment 527, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.529. The method of embodiment 528, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.530. The method of embodiment 528, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.531. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of about 70 to about 300 mgantibody per dose administered at time “0” (the first administration),at one week post time “0”, and then administered every two weeksfollowing the week one administration, wherein said antibody, orIL-17RA-binding fragment thereof, comprises a heavy chain sequencecomprising SEQ ID NO:1 and a light chain sequence comprising SEQ IDNO:2.532. The method of embodiment 531, wherein the psoriasis is plaquepsoriasis.533. The method of embodiment 532, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.534. The method of embodiment 533, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.535. The method of embodiment 533, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.536. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 70 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody, or IL-17RA-binding fragment thereof, comprises aheavy chain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.537. The method of embodiment 536, wherein the psoriasis is plaquepsoriasis.538. The method of embodiment 537, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.539. The method of embodiment 538, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.540. The method of embodiment 538, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.541. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody, or IL-17RA-binding fragment thereof, comprises aheavy chain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.542. The method of embodiment 541, wherein the psoriasis is plaquepsoriasis.543. The method of embodiment 542, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.544. The method of embodiment 543, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.545. The method of embodiment 543, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.546. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 210 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody, or IL-17RA-binding fragment thereof, comprises aheavy chain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.547. The method of embodiment 546, wherein the psoriasis is plaquepsoriasis.548. The method of embodiment 547, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.549. The method of embodiment 548, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.550. The method of embodiment 548, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.551. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered every two weeks following the week one administration,wherein said antibody, or IL-17RA-binding fragment thereof, comprises aheavy chain sequence comprising SEQ ID NO:1 and a light chain sequencecomprising SEQ ID NO:2.552. The method of embodiment 551, wherein the psoriasis is plaquepsoriasis.553. The method of embodiment 552, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.554. The method of embodiment 553, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.555. The method of embodiment 553, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.556. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of about 70 to about 300 mgantibody per dose administered at time “0” (the first administration),at one week post time “0”, and then administered monthly following theweek one administration, wherein said antibody comprises a heavy chainCDR1 comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7,a heavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.557. The method of embodiment 556, wherein the psoriasis is plaquepsoriasis.558. The method of embodiment 557, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.559. The method of embodiment 558, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.560. The method of embodiment 558, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.561. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 70 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.562. The method of embodiment 561, wherein the psoriasis is plaquepsoriasis.563. The method of embodiment 562, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.564. The method of embodiment 563, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.565. The method of embodiment 563, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.566. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.567. The method of embodiment 566, wherein the psoriasis is plaquepsoriasis.568. The method of embodiment 567, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.569. The method of embodiment 568, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.570. The method of embodiment 568, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.571. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 210 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.572. The method of embodiment 571, wherein the psoriasis is plaquepsoriasis.573. The method of embodiment 572, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.574. The method of embodiment 573, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.575. The method of embodiment 573, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.576. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavychain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ IDNO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain CDR2comprising SEQ ID NO:10, and a light chain CDR3 comprising SEQ ID NO:11,and wherein said antibody specifically binds human IL-17 receptor A.577. The method of embodiment 576, wherein the psoriasis is plaquepsoriasis.578. The method of embodiment 577, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.579. The method of embodiment 578, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.580. The method of embodiment 578, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.581. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of about 70 to about 300 mgantibody per dose administered at time “0” (the first administration),at one week post time “0”, and then administered monthly following theweek one administration, wherein said antibody, or IL-17RA-bindingfragment thereof, comprises a heavy chain variable domain sequencecomprising SEQ ID NO:3 and a light chain variable domain sequencecomprising SEQ ID NO:4, and wherein said antibody specifically bindshuman IL-17 receptor A.582. The method of embodiment 581, wherein the psoriasis is plaquepsoriasis.583. The method of embodiment 582, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.584. The method of embodiment 583, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.585. The method of embodiment 583, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.586. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 70 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.587. The method of embodiment 586, wherein the psoriasis is plaquepsoriasis.588. The method of embodiment 587, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.589. The method of embodiment 588, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.590. The method of embodiment 588, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.591. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.592. The method of embodiment 591, wherein the psoriasis is plaquepsoriasis.593. The method of embodiment 592, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.594. The method of embodiment 593, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.595. The method of embodiment 593, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.596. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 210 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.597. The method of embodiment 596, wherein the psoriasis is plaquepsoriasis.598. The method of embodiment 597, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.599. The method of embodiment 598, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.600. The method of embodiment 598, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.601. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainvariable domain sequence comprising SEQ ID NO:3 and a light chainvariable domain sequence comprising SEQ ID NO:4, and wherein saidantibody specifically binds human IL-17 receptor A.602. The method of embodiment 601, wherein the psoriasis is plaquepsoriasis.603. The method of embodiment 602, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.604. The method of embodiment 603, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.605. The method of embodiment 603, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.606. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of about 70 to about 300 mgantibody per dose administered at time “0” (the first administration),at one week post time “0”, and then administered monthly following theweek one administration, wherein said antibody, or IL-17RA-bindingfragment thereof, comprises a heavy chain sequence comprising SEQ IDNO:1 and a light chain sequence comprising SEQ ID NO:2.607. The method of embodiment 606, wherein the psoriasis is plaquepsoriasis.608. The method of embodiment 607, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.609. The method of embodiment 608, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.610. The method of embodiment 608, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.611. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 70 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.612. The method of embodiment 611, wherein the psoriasis is plaquepsoriasis.613. The method of embodiment 612, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.614. The method of embodiment 613, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.615. The method of embodiment 613, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.616. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.617. The method of embodiment 616, wherein the psoriasis is plaquepsoriasis.618. The method of embodiment 617, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.619. The method of embodiment 618, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.620. The method of embodiment 618, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.621. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 210 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.622. The method of embodiment 621, wherein the psoriasis is plaquepsoriasis.623. The method of embodiment 622, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.624. The method of embodiment 623, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.625. The method of embodiment 623, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.626. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg per dose administered attime “0” (the first administration), at one week post time “0”, and thenadministered monthly following the week one administration, wherein saidantibody, or IL-17RA-binding fragment thereof, comprises a heavy chainsequence comprising SEQ ID NO:1 and a light chain sequence comprisingSEQ ID NO:2.627. The method of embodiment 626, wherein the psoriasis is plaquepsoriasis.628. The method of embodiment 627, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.629. The method of embodiment 628, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.630. The method of embodiment 628, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.631. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 210 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.632. The method of embodiment 631, wherein the psoriasis is plaquepsoriasis.633. The method of embodiment 632, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.634. The method of embodiment 633, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.635. The method of embodiment 633, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.636. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.637. The method of embodiment 636, wherein the psoriasis is plaquepsoriasis.638. The method of embodiment 637, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.639. The method of embodiment 638, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.640. The method of embodiment 638, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.641. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.642. The method of embodiment 641, wherein the psoriasis is plaquepsoriasis.643. The method of embodiment 642, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.644. The method of embodiment 643, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.645. The method of embodiment 643, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.646. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 280 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.647. The method of embodiment 646, wherein the psoriasis is plaquepsoriasis.648. The method of embodiment 647, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.649. The method of embodiment 648, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.650. The method of embodiment 648, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.651. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.652. The method of embodiment 651, wherein the psoriasis is plaquepsoriasis.653. The method of embodiment 652, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.654. The method of embodiment 653, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.655. The method of embodiment 653, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.656. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.657. The method of embodiment 656, wherein the psoriasis is plaquepsoriasis.658. The method of embodiment 657, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.659. The method of embodiment 658, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.660. The method of embodiment 658, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.661. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 210 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.662. The method of embodiment 661, wherein the psoriasis is plaquepsoriasis.663. The method of embodiment 662, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.664. The method of embodiment 663, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.665. The method of embodiment 663, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.666. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.667. The method of embodiment 666, wherein the psoriasis is plaquepsoriasis.668. The method of embodiment 667, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.669. The method of embodiment 668, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.670. The method of embodiment 668, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.671. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.672. The method of embodiment 671, wherein the psoriasis is plaquepsoriasis.673. The method of embodiment 672, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.674. The method of embodiment 673, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.675. The method of embodiment 673, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.676. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 280 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.677. The method of embodiment 676, wherein the psoriasis is plaquepsoriasis.678. The method of embodiment 677, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.679. The method of embodiment 678, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.680. The method of embodiment 678, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.681. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.682. The method of embodiment 681, wherein the psoriasis is plaquepsoriasis.683. The method of embodiment 682, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.684. The method of embodiment 683, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.685. The method of embodiment 683, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.686. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody comprises a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, and wherein said antibodyspecifically binds human IL-17 receptor A.687. The method of embodiment 686, wherein the psoriasis is plaquepsoriasis.688. The method of embodiment 687, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.689. The method of embodiment 688, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.690. The method of embodiment 688, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.691. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 210 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain variable domain sequence comprising SEQ ID NO:3and a light chain variable domain sequence comprising SEQ ID NO:4, andwherein said antibody specifically binds human IL-17 receptor A.692. The method of embodiment 691, wherein the psoriasis is plaquepsoriasis.693. The method of embodiment 692, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.694. The method of embodiment 693, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.695. The method of embodiment 693, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.696. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.697. The method of embodiment 696, wherein the psoriasis is plaquepsoriasis.698. The method of embodiment 697, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.699. The method of embodiment 698, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.700. The method of embodiment 698, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.701. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.702. The method of embodiment 701, wherein the psoriasis is plaquepsoriasis.703. The method of embodiment 702, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.704. The method of embodiment 703, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.705. The method of embodiment 703, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.706. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 280 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain variable domain sequence comprising SEQ ID NO:3and a light chain variable domain sequence comprising SEQ ID NO:4, andwherein said antibody specifically binds human IL-17 receptor A.707. The method of embodiment 706, wherein the psoriasis is plaquepsoriasis.708. The method of embodiment 707, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.709. The method of embodiment 708, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.710. The method of embodiment 708, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.711. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.712. The method of embodiment 711, wherein the psoriasis is plaquepsoriasis.713. The method of embodiment 712, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.714. The method of embodiment 713, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.715. The method of embodiment 713, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.716. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.717. The method of embodiment 716, wherein the psoriasis is plaquepsoriasis.718. The method of embodiment 717, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.719. The method of embodiment 718, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.720. The method of embodiment 718, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.721. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 210 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain variable domain sequence comprising SEQ ID NO:3and a light chain variable domain sequence comprising SEQ ID NO:4, andwherein said antibody specifically binds human IL-17 receptor A.722. The method of embodiment 721, wherein the psoriasis is plaquepsoriasis.723. The method of embodiment 722, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.724. The method of embodiment 723, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.725. The method of embodiment 723, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.726. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.727. The method of embodiment 726, wherein the psoriasis is plaquepsoriasis.728. The method of embodiment 727, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.729. The method of embodiment 728, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.730. The method of embodiment 728, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.731. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.732. The method of embodiment 731, wherein the psoriasis is plaquepsoriasis.733. The method of embodiment 732, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.734. The method of embodiment 733, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.735. The method of embodiment 733, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.736. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 280 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain variable domain sequence comprising SEQ ID NO:3and a light chain variable domain sequence comprising SEQ ID NO:4, andwherein said antibody specifically binds human IL-17 receptor A.737. The method of embodiment 736, wherein the psoriasis is plaquepsoriasis.738. The method of embodiment 737, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.739. The method of embodiment 738, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.740. The method of embodiment 738, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.741. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.742. The method of embodiment 741, wherein the psoriasis is plaquepsoriasis.743. The method of embodiment 742, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.744. The method of embodiment 743, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.745. The method of embodiment 743, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.746. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain variable domain sequence comprising SEQID NO:3 and a light chain variable domain sequence comprising SEQ IDNO:4, and wherein said antibody specifically binds human IL-17 receptorA.747. The method of embodiment 746, wherein the psoriasis is plaquepsoriasis.748. The method of embodiment 747, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.749. The method of embodiment 748, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.750. The method of embodiment 748, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.751. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 210 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain sequence comprising SEQ ID NO:1 and a lightchain sequence comprising SEQ ID NO:2.752. The method of embodiment 751, wherein the psoriasis is plaquepsoriasis.753. The method of embodiment 752, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.754. The method of embodiment 753, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.755. The method of embodiment 753, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.756. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.757. The method of embodiment 756, wherein the psoriasis is plaquepsoriasis.758. The method of embodiment 757, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.759. The method of embodiment 758, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.760. The method of embodiment 758, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.761. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.762. The method of embodiment 761, wherein the psoriasis is plaquepsoriasis.763. The method of embodiment 762, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.764. The method of embodiment 763, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.765. The method of embodiment 763, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.766. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 280 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain sequence comprising SEQ ID NO:1 and a lightchain sequence comprising SEQ ID NO:2.767. The method of embodiment 766, wherein the psoriasis is plaquepsoriasis.768. The method of embodiment 767, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.769. The method of embodiment 768, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.770. The method of embodiment 768, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.771. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.772. The method of embodiment 771, wherein the psoriasis is plaquepsoriasis.773. The method of embodiment 772, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.774. The method of embodiment 773, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.775. The method of embodiment 773, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.776. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 140 mg every two weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.777. The method of embodiment 776, wherein the psoriasis is plaquepsoriasis.778. The method of embodiment 777, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.779. The method of embodiment 778, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.780. The method of embodiment 778, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.781. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 210 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain sequence comprising SEQ ID NO:1 and a lightchain sequence comprising SEQ ID NO:2.782. The method of embodiment 781, wherein the psoriasis is plaquepsoriasis.783. The method of embodiment 782, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.784. The method of embodiment 783, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.785. The method of embodiment 783, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.786. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.787. The method of embodiment 786, wherein the psoriasis is plaquepsoriasis.788. The method of embodiment 787, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.789. The method of embodiment 788, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.790. The method of embodiment 788, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.791. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 210 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.792. The method of embodiment 791, wherein the psoriasis is plaquepsoriasis.793. The method of embodiment 792, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.794. The method of embodiment 793, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.795. The method of embodiment 793, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.796. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 90 kg and a singleor divided dose of 280 mg every two weeks to patients weighing greaterthan 90 kg, wherein said antibody, or IL-17RA-binding fragment thereof,comprises a heavy chain sequence comprising SEQ ID NO:1 and a lightchain sequence comprising SEQ ID NO:2.797. The method of embodiment 796, wherein the psoriasis is plaquepsoriasis.798. The method of embodiment 797, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.799. The method of embodiment 798, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.800. The method of embodiment 798, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.801. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 100 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 100 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.802. The method of embodiment 801, wherein the psoriasis is plaquepsoriasis.803. The method of embodiment 802, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.804. The method of embodiment 803, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.805. The method of embodiment 803, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.806. A method of treating psoriasis in adult and/or juvenile patientshaving psoriasis, comprising administering to said patient apharmaceutical composition comprising 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of anantibody in a single or divided dose of 280 mg every four weeks topatients weighing less than or approximately equal to 110 kg and asingle or divided dose of 280 mg every two weeks to patients weighinggreater than 110 kg, wherein said antibody, or IL-17RA-binding fragmentthereof, comprises a heavy chain sequence comprising SEQ ID NO:1 and alight chain sequence comprising SEQ ID NO:2.807. The method of embodiment 806, wherein the psoriasis is plaquepsoriasis.808. The method of embodiment 807, wherein the plaque psoriasis ismoderate to severe plaque psoriasis.809. The method of embodiment 808, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and saidpatients are candidates for systemic therapy or phototherapy.810. The method of embodiment 808, wherein the moderate to severe plaquepsoriasis is chronic moderate to severe plaque psoriasis and whereinsaid patients have failed to respond to, have a contraindication to, orare intolerant to other systemic therapies including cyclosporin,methotrexate, and psoralen plus ultraviolet-A phototherapy.811. A pharmaceutical formulation, comprising an aqueous solution of aglutamic acid buffer and an antibody comprising a heavy chain CDR1comprising SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, aheavy chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprisingSEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a lightchain CDR3 comprising SEQ ID NO:11, wherein said antibody, or fragmentthereof, specifically binds human IL-17 receptor A, and wherein:

-   -   a) said glutamic acid buffer comprises a glutamic acid        concentration of 5-30 mM±0.2 mM;    -   b) said glutamic acid buffer comprises a pH of 4.5-5.2±0.2;    -   c) said formulation further comprises 2-4% proline (w/v) and        0.005-0.02% (w/v) polysorbate 20; and    -   d) said antibody is at a concentration of 100 to 150 mg/ml.        812. The pharmaceutical formulation of claim 1, wherein the        antibody or fragment thereof comprises a heavy chain variable        domain sequence comprising SEQ ID NO:3 and a light chain        variable domain sequence comprising SEQ ID NO:4.        813. The pharmaceutical formulation of claim 1, wherein the        antibody comprises a heavy chain sequence comprising SEQ ID NO:1        and a light chain sequence comprising SEQ ID NO:2, or        alternatively, a heavy chain sequence comprising SEQ ID NO:12        and the light chain sequence comprising SEQ ID NO:2.        814. The pharmaceutical formulation of embodiment 811, wherein        the glutamic acid buffer or acetic acid buffer concentration is        10 mM±0.2 mM.        815. The pharmaceutical formulation of embodiment 811, wherein        the formulation has a pH of 4.8±0.2.        816 The pharmaceutical formulation of embodiment 811, having an        isotonic or near-isotonic osmolarity of 250 to 400 osm.        817. The pharmaceutical formulation of embodiment 811, having an        isotonic or near-isotonic osmolarity of 275 to 325 osm.        818. The pharmaceutical formulation of embodiment 811,        comprising an osmolarity of about 300 osm/L.        819 The pharmaceutical formulation of embodiment 811, comprising        100-200 mg/mL AM-14, formulated with 5-15 mM glutamic acid, 7-9%        (w/v) sucrose, 0.005-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2.        820. The pharmaceutical formulation of embodiment 811,        comprising about 140 mg/mL AM-14, formulated with 10±0.2 mM        glutamic acid, 8±0.2% (w/v) sucrose, 0.01±0.002% (w/v)        polysorbate 20, pH 4.8±0.2.        821. The pharmaceutical formulation of embodiment 811,        comprising 100-200 mg/mL AM-14, formulated with 5-15 mM glutamic        acid, 1-3% (w/v) glycine, 0.005-0.02% (w/v) polysorbate 20, pH        4.5-5.5±0.2.        822. The pharmaceutical formulation of embodiment 811,        comprising about 140 mg/mL AM-14, formulated with 10±0.2 mM        glutamic acid, 2±0.2% (w/v) glycine, 0.01±0.002% (w/v)        polysorbate 20, pH 4.8±0.2.        823. The pharmaceutical formulation of embodiment 811,        comprising 100-200 mg/mL AM-14, formulated with 5-15 mM glutamic        acid, 2-4% (w/v) proline, 0.005-0.02% (w/v) polysorbate 20, pH        4.5-5.5±0.2.        824. The pharmaceutical formulation of embodiment 811,        comprising about 140 mg/mL AM-14, formulated with 10±0.2 mM        glutamic acid, 3±0.2% (w/v) L-proline, 0.01±0.002% (w/v)        polysorbate 20, pH 4.8±0.2.        825. The pharmaceutical formulation of embodiment 811,        comprising 100-200 mg/mL AM-14, formulated with 5-15 mM acetic        acid, 1-3% (w/v) glycine, 0.005-0.02% (w/v) polysorbate 20, pH        4.5-5.5±0.2.        826. The pharmaceutical formulation of embodiment 81, comprising        about 140 mg/mL AM-14, formulated with 10±0.2 mM acetic acid,        2±0.2% (w/v) glycine, 0.01±0.002% (w/v) polysorbate 20, pH        4.8±0.2.        827. The pharmaceutical formulation of embodiment 811,        comprising 100-200 mg/mL AM-14, formulated with 5-15 mM acetic        acid, 2-4% (w/v) proline, 0.005-0.02% (w/v) polysorbate 20, pH        4.5-5.5±0.2.        828. The pharmaceutical formulation of embodiment 811,        comprising about 140 mg/mL AM-14, formulated with 10±0.2 mM        acetic acid, 3±0.2% (w/v) L-proline, 0.01±0.002% (w/v)        polysorbate 20, pH 4.8±0.2.        829. The pharmaceutical formulation of embodiment 811,        comprising 100-200 mg/mL AM-14, formulated with 5-15 mM acetic        acid, 7-9% (w/v) sucrose, 0.005-0.02% (w/v) polysorbate 20, pH        4.5-5.5±0.2.        830. The pharmaceutical formulation of embodiment 811,        comprising about 140 mg/mL AM-14, formulated with 10±0.2 mM        acetic acid, 8±0.2% (w/v) sucrose, 0.01±0.002% (w/v) polysorbate        20, pH 4.8±0.2.        831. The pharmaceutical formulation of embodiment 811,        comprising 100-200 mg/mL AM-14, formulated with 5-15 mM acetic        acid, 2-4% (w/v) glycerol, 0.005-0.02% (w/v) polysorbate 20, pH        4.5-5.5±0.2.        832. The pharmaceutical formulation of embodiment 811,        comprising about 140 mg/mL AM-14, formulated with 10±0.2 mM        acetic acid, 3±0.2% (w/v) glycerol, 0.01±0.002% (w/v)        polysorbate 20, pH 4.8±0.2.        833. The pharmaceutical formulation of embodiment 811,        comprising 100-200 mg/mL AM-14, formulated with 5-15 mM acetic        acid, 3.5-5.5% (w/v) sorbitol, 0.005-0.02% (w/v) polysorbate 20,        pH 4.5-5.5±0.2.        834. The pharmaceutical formulation of embodiment 811,        comprising about 140 mg/mL AM-14, formulated with 10±0.2 mM        acetic acid, 4.5±0.2% (w/v) sorbitol, 0.01±0.002% (w/v)        polysorbate 20, pH 4.8±0.2.        835. The pharmaceutical formulation according to any of        embodiments 811 to 834, wherein said formulation has a viscosity        of 4 to 10 cP at 25 degrees C.        836. The pharmaceutical formulation according to any of        embodiments 811 to 834, wherein said formulation has a viscosity        of 5 to 7 cP at 25 degrees C.        837. A method of preparing a pharmaceutical formulation,        comprising combining an aqueous solution of a glutamic acid or        acetic acid buffer and an isolated antibody, or IL-17RA-binding        fragment thereof, comprising a heavy chain CDR1 comprising SEQ        ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy        chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising        SEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a        light chain CDR3 comprising SEQ ID NO:11, wherein said antibody        specifically binds human IL-17 receptor A, and wherein:    -   a) said aqueous solution of a glutamic acid or acetic acid        buffer comprises a pH of 4.5 to 5.2±0.2;    -   b) said glutamic acid or acetic acid buffer comprises a glutamic        acid or acetic concentration of 5 to 30 mM±0.2 mM;    -   c) said formulation comprises an excipient selected from the        group consisting of sucrose, glycine, proline, glycerol and/or        sorbitol at a concentration of 1 to 20%±0.2% (w/v); and    -   d) said antibody comprises a concentration of 100 to 200 mg/ml.        838. A pharmaceutical container, comprising a vessel and an        aqueous solution of the pharmaceutical formulation of any of        embodiments 811 to 836.        839. The pharmaceutical container of embodiment 838, wherein the        vessel is a vial, bottle, or a pre-filled syringe.        840. A kit, comprising one or more pharmaceutical containers        according to embodiment 838 and instructions regarding the use        thereof.        841. A method of treating IL-17-related inflammation in a human        patient in need thereof, comprising administering to the patient        a single or divided 70 to 1,000 mg dose of the pharmaceutical        formulation of any of embodiments 811 to 836.        842. The method of embodiment 841, wherein the single or divided        dose of the pharmaceutical formulation of any of embodiments 811        to 836 is administered subcutaneously, intravenously,        parenterally, intradermally, intramuscularly, and/or        intraperitoneally.        843. The method of embodiment 841, wherein the single or divided        dose of the pharmaceutical formulation of any of embodiments 811        to 836 is approximately 140 to 800 mg and is administered by        subcutaneous injection, intradermal administration, and/or        intravenously.        844. A method of treating IL-17-related autoimmune disease in a        human patient in need thereof, comprising administering to the        patient a single or divided 70 to 1,000 mg dose of the        pharmaceutical formulation of any of embodiments 811 to 836 at        least once every one to six weeks.        845. The method of embodiment 844, wherein the single or divided        dose of the pharmaceutical formulation of any of embodiments 811        to 836 is administered subcutaneously, intravenously,        parenterally, intradermally, intramuscularly, and/or        intraperitoneally.        846. The method of embodiment 844, wherein the single or divided        dose of the pharmaceutical formulation of any of embodiments 811        to 836 is approximately 140 to 800 mg and is administered by        subcutaneous injection, intradermal administration, and/or        intravenously.        847. A method of treating psoriasis in a human patient in need        thereof, comprising administering to the patient a single or        divided 70 to 1,000 mg dose of the pharmaceutical formulation of        any of embodiments 811 to 836 at least once every one to six        weeks.        848. The method of embodiment 847, wherein the single or divided        dose of the pharmaceutical formulation of any of embodiments 811        to 836 is administered subcutaneously, intravenously,        parenterally, intradermally, intramuscularly, and/or        intraperitoneally.        849. The method of embodiment 847, wherein the single or divided        dose of the pharmaceutical formulation of any of embodiments 811        to 836 is approximately 140 to 300 mg and is administered by        subcutaneous injection, intradermally, and/or intravenously.        850. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient        comprising administering an effective amount of AM-14 to the        patient.        851. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient and        concomitantly reducing the PASI score in the patient by at least        10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,        90, 95, or 100% comprising administering an effective amount of        AM-14 to the patient.        852. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in 15 days or less in a        psoriasis patient and concomitantly reducing the PASI score in        the patient by at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55,        60, 65, 70, 75, 80, 85, 90, 95, or 100% comprising administering        an effective amount of AM-14 to the patient.        853. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient        comprising administering an effective amount of an antibody that        binds IL-17RA and prevents the activation of IL-17RA by one or        more IL-17 ligands.        854. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient and        concomitantly reducing the PASI score in the patient by at least        10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,        90, 95, or 100% comprising administering an effective amount of        an antibody that binds IL-17RA and prevents the activation of        IL-17RA by one or more IL-17 ligands.        855. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in 15 days or less in a        psoriasis patient and concomitantly reducing the PASI score in        the patient by at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55,        60, 65, 70, 75, 80, 85, 90, 95, or 100% comprising administering        an effective amount of an antibody that binds IL-17RA and        prevents the activation of IL-17RA by one or more IL-17 ligands.        856. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient        comprising administering an effective amount of a monoclonal        antibody that specifically binds human IL-17A.        857. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient and        concomitantly reducing the PASI score in the patient by at least        10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,        90, 95, or 100% comprising administering an effective amount of        a monoclonal antibody that specifically binds human IL-17A.        858. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient and        concomitantly reducing the PASI score in the patient by at least        50% comprising administering an effective amount of a monoclonal        antibody that specifically binds human IL-17A.        859. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient and        concomitantly reducing the PASI score in the patient by at least        75% comprising administering an effective amount of a monoclonal        antibody that specifically binds human IL-17A.        860. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient        comprising administering an effective amount of AM-14 to the        patient.        861. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient        comprising administering to said patient a pharmaceutical        composition comprising 10 mM glutamic acid, 3% (w/v) L-proline,        0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of an        antibody in a single or divided dose, wherein said antibody        comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy        chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising        SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light        chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3        comprising SEQ ID NO:11, and wherein said antibody specifically        binds human IL-17 receptor A.        862. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient        comprising administering to said patient a pharmaceutical        composition comprising 10 mM glutamic acid, 3% (w/v) L-proline,        0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of an        antibody in a single or divided dose, wherein said antibody, or        IL-17RA-binding fragment thereof, comprises a heavy chain        variable domain sequence comprising SEQ ID NO:3 and a light        chain variable domain sequence comprising SEQ ID NO:4, and        wherein said antibody specifically binds human IL-17 receptor A.        863. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient        comprising administering to said patient a pharmaceutical        composition comprising 10 mM glutamic acid, 3% (w/v) L-proline,        0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of an        antibody in a single or divided dose, wherein said antibody, or        IL-17RA-binding fragment thereof, comprises a heavy chain        sequence comprising SEQ ID NO:1 and a light chain sequence        comprising SEQ ID NO:2.        864. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient and        concomitantly reducing the PASI score in the patient by at least        75% comprising administering to said patient a pharmaceutical        composition comprising 10 mM glutamic acid, 3% (w/v) L-proline,        0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of an        antibody in a single or divided dose, wherein said antibody        comprises a heavy chain CDR1 comprising SEQ ID NO:5, a heavy        chain CDR2 comprising SEQ ID NO:7, a heavy chain CDR3 comprising        SEQ ID NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light        chain CDR2 comprising SEQ ID NO:10, and a light chain CDR3        comprising SEQ ID NO:11, and wherein said antibody specifically        binds human IL-17 receptor A.        865. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient and        concomitantly reducing the PASI score in the patient by at least        75% comprising administering to said patient a pharmaceutical        composition comprising 10 mM glutamic acid, 3% (w/v) L-proline,        0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of an        antibody in a single or divided dose, wherein said antibody, or        IL-17RA-binding fragment thereof, comprises a heavy chain        variable domain sequence comprising SEQ ID NO:3 and a light        chain variable domain sequence comprising SEQ ID NO:4, and        wherein said antibody specifically binds human IL-17 receptor A.        866. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in a psoriasis patient and        concomitantly reducing the PASI score in the patient by at least        75% comprising administering to said patient a pharmaceutical        composition comprising 10 mM glutamic acid, 3% (w/v) L-proline,        0.01% (w/v) polysorbate 20, pH 4.8±0.2 and 140 mg/mL of an        antibody in a single or divided dose, wherein said antibody, or        IL-17RA-binding fragment thereof, comprises a heavy chain        sequence comprising SEQ ID NO:1 and a light chain sequence        comprising SEQ ID NO:2.        867. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in 15 days or less in a        psoriasis patient and concomitantly reducing the PASI score in        the patient by at least 75% comprising administering to said        patient a pharmaceutical composition comprising 10 mM glutamic        acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2        and 140 mg/mL of an antibody in a single or divided dose,        wherein said antibody comprises a heavy chain CDR1 comprising        SEQ ID NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy        chain CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising        SEQ ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a        light chain CDR3 comprising SEQ ID NO:11, and wherein said        antibody specifically binds human IL-17 receptor A.        868. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in 15 days or less in a        psoriasis patient and concomitantly reducing the PASI score in        the patient by at least 75% comprising administering to said        patient a pharmaceutical composition comprising 10 mM glutamic        acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2        and 140 mg/mL of an antibody in a single or divided dose,        wherein said antibody, or IL-17RA-binding fragment thereof,        comprises a heavy chain variable domain sequence comprising SEQ        ID NO:3 and a light chain variable domain sequence comprising        SEQ ID NO:4, and wherein said antibody specifically binds human        IL-17 receptor A.        869. A method of regulating the expression of one or more of the        genes in tables 3.1, 3.2, and/or 3.3 in 15 days or less in a        psoriasis patient and concomitantly reducing the PASI score in        the patient by at least 75% comprising administering to said        patient a pharmaceutical composition comprising 10 mM glutamic        acid, 3% (w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2        and 140 mg/mL of an antibody in a single or divided dose,        wherein said antibody, or IL-17RA-binding fragment thereof,        comprises a heavy chain sequence comprising SEQ ID NO:1 and a        light chain sequence comprising SEQ ID NO:2.        870. A pharmaceutical formulation, comprising an aqueous        solution of a glutamic acid buffer and an antibody comprising a        heavy chain CDR1 comprising SEQ ID NO:5, a heavy chain CDR2        comprising SEQ ID NO:7, a heavy chain CDR3 comprising SEQ ID        NO:8, a light chain CDR1 comprising SEQ ID NO:9, a light chain        CDR2 comprising SEQ ID NO:10, and a light chain CDR3 comprising        SEQ ID NO:11, wherein said antibody, or fragment thereof,        specifically binds human IL-17 receptor A, and wherein:    -   a) said glutamic acid buffer comprises a glutamic acid        concentration of 5-30 mM±0.2 mM;    -   b) said glutamic acid buffer comprises a pH of 4.5-5.2±0.2;    -   c) said formulation further comprises 2-4% proline (w/v) and        0.005-0.02% (w/v) polysorbate 20; and    -   d) said antibody is at a concentration of 100 to 150 mg/ml.        871. The pharmaceutical formulation of embodiment 870, wherein        the antibody or fragment thereof comprises a heavy chain        variable domain sequence comprising SEQ ID NO:3 and a light        chain variable domain sequence comprising SEQ ID NO:4.        872. The pharmaceutical formulation of embodiment 870, wherein        the antibody comprises a heavy chain sequence comprising SEQ ID        NO:1 and a light chain sequence comprising SEQ ID NO:2, or        alternatively, a heavy chain sequence comprising SEQ ID NO:12        and the light chain sequence comprising SEQ ID NO:2.        873. The pharmaceutical formulation of embodiment 870, further        comprising an osmolarity of 275 to 325 osm.        874. The pharmaceutical formulation of embodiment 870, further        comprising a viscosity of 5 to 7 cP at 25 degrees C.        875. The pharmaceutical formulation of embodiment 870,        comprising about 140 mg/mL of said antibody, formulated with        10±0.2 mM glutamic acid, 3±0.2% (w/v) L-proline, 0.01±0.002%        (w/v) polysorbate 20, pH 4.8±0.2.        876. The pharmaceutical formulation of embodiment 871,        comprising about 140 mg/mL of said antibody, formulated with        10±0.2 mM glutamic acid, 3±0.2% (w/v) L-proline, 0.01±0.002%        (w/v) polysorbate 20, pH 4.8±0.2.        877. The pharmaceutical formulation of embodiment 872,        comprising about 140 mg/mL of said antibody, formulated with        10±0.2 mM glutamic acid, 3±0.2% (w/v) L-proline, 0.01±0.002%        (w/v) polysorbate 20, pH 4.8±0.2.        878. A pharmaceutical container, comprising a vessel and the        pharmaceutical formulation of any of embodiments 880 to 877,        wherein the vessel is a vial, bottle, pre-filled syringe, or        pre-filled autoinjector syringe.        879. A kit, comprising one or more pharmaceutical containers        according to embodiment 878 and instructions regarding the use        thereof.        880. A method of treating psoriasis in a human patient in need        thereof, comprising administering to the patient a single or        divided 70 to 1,000 mg dose of an antibody, wherein said        antibody is selected from the group consisting of:    -   a) an antibody comprising a heavy chain CDR1 comprising SEQ ID        NO:5, a heavy chain CDR2 comprising SEQ ID NO:7, a heavy chain        CDR3 comprising SEQ ID NO:8, a light chain CDR1 comprising SEQ        ID NO:9, a light chain CDR2 comprising SEQ ID NO:10, and a light        chain CDR3 comprising SEQ ID NO:11, wherein said antibody, or        fragment thereof, specifically binds human IL-17 receptor A;    -   b) an antibody comprising a heavy chain variable domain sequence        comprising SEQ ID NO:3 and a light chain variable domain        sequence comprising SEQ ID NO:4, wherein said antibody, or        fragment thereof, specifically binds human IL-17 receptor A; and    -   c) an antibody comprising a heavy chain sequence comprising SEQ        ID NO:1 and a light chain sequence comprising SEQ ID NO:2, or        alternatively, a heavy chain sequence comprising SEQ ID NO:12        and the light chain sequence comprising SEQ ID NO:2.        881. The method of embodiment 880, wherein said patient is        administered a single or divided 70 to 280 mg dose of said        antibody administered at time “0” (the first administration), at        one week post time “0” (week one), and then administered every        two to four weeks following the week one administration.        882. The method of embodiment 881, wherein a single or divided        dose of 140 mg of said antibody is administered at time “0” (the        first administration), at one week post time “0” (week one), and        then administered every two weeks to patients weighing less than        or approximately equal to 100 kg, and wherein a single or        divided dose of 280 mg of said antibody is administered at time        “0” (the first administration), at one week post time “0” (week        one), and then administered every two weeks to patients weighing        greater than 100 kg.        883. The method of any of embodiments 880 to 882, wherein the        psoriasis is selected from the group consisting of:    -   a) plaque psoriasis;    -   b) moderate to severe plaque psoriasis;    -   c) chronic moderate to severe plaque psoriasis and said patients        are candidates for systemic therapy or phototherapy; and    -   d) chronic moderate to severe plaque psoriasis and wherein said        patients have failed to respond to, have a contraindication to,        or are intolerant to other systemic therapies including        cyclosporin, methotrexate, and psoralen plus ultraviolet-A        phototherapy.        884. The method of any of embodiments 880 to 883, wherein said        antibody is in a pharmaceutical formulation comprising about 140        mg/mL of said antibody, formulated with 10±0.2 mM glutamic acid,        3±0.2% (w/v) L-proline, 0.01±0.002% (w/v) polysorbate 20, pH        4.8±0.2.        885. The method of embodiment 884, wherein the pharmaceutical        formulation is administered subcutaneously, intradermally,        intramuscularly, and/or intravenously.

TABLE A AM-14 sequences AM-14 full- SEQ ID NO: 1QVQLVQSGAEVKKPGASVKVSCKASGYTFTR length YGISWVRQAPGQGLEWMGWISTYSGNTNYAheavy QKLQGRVTMTTDTSTSTAYMELRSLRSDDTA chainVYYCARRQLYFDYWGQGTLVTVSSASTKGPS VFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVT VPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMIS RTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLN GKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKS LSLSPGK

EXAMPLES Example 1 AM-14 Formulations

Numerous formulations were prepared using lab scale UF/DF(ultrafiltration/diafiltration) system at room temperature for thepurpose of identifying excipients and formulations that are uniquelysuited for AM-14. The UF/DF buffers were prepared at lower pH (3.5, 3.8or 4.0) with glutamic acid or acetic acid as buffering agents andvarious excipients including sucrose, L-proline, glycine, sorbitol, andothers.

Sample preparation from lyophilized vials for reconstitution of AM-14 ata higher concentration (180 mg/mL) was performed as follows: UF/DF ofAM-14 final purified bulk (FPB) was performed from 70 mg/mL A52Su (10 mMacetic acid, 9% sucrose, pH 5.2)[ ] formulation to approximately 90mg/mL with a 5-fold increase in diafiltration volume (ml) of a) 10 mMglutamate, 0.5% sucrose, pH 4.2, and b) 10 mM glutamate, 0.5% sucrose,pH 5.2, respectively. After UF/DF, the resulting concentrations for theabove two conditions were 90.8 mg/mL at pH 5.33 for a), and 89.6 mg/mLat pH 5.63 for b) buffers, respectively. The AM-14 formulations werefiltered through 0.45 micron filters and 1.25 mL were filled into 3 ccglass vials. The formulations were lyophilized. The samples preparedfrom buffer a) are denoted with E4.5_ (i.e., 10 mM glutamate, pH 4.5),and samples from buffer b) are denoted with E5.5_ (i.e., 10 mMglutamate, pH 5.5). At room temperature, E4.5 vials were reconstitutedwith 0.685 mL of one of the diluents listed in Table 1.0) and E5.5 vialswere reconstituted with 0.596 mL of one of the diluents listed in Table1.0), which is approximately half of its initial fill volume, resultingin the reconstituted formulations having a final concentration of 20 mMglutamate. After the lyophilized cakes were dissolved, the samples wereready for viscosity measurement.

The viscosity of the protein liquid formulations was measured by arheometer with the cone/plate geometry (RV 111+ model, BrookfieldEngineering Labs, Inc., Middleboro, Mass.). Sample temperature wasmaintained at 25° C. during measurement with a water bath. The spindlespeed ranged from 15 to 125 rpm with 10 rpm per increment. Datacollection was carried out with Rheocalc™ software, version 2.7. At eachshear condition, 4 readings were collected with 10 second interval, andeach data point was the average of the 4 readings. After a new shearcondition was established, the first reading was made after 30 secondwaiting time. See Tables 1.0 and 1.1. The viscosity results for theformulations listed in Table 1.0 were graphed as a function of shearstress and are shown in FIGS. 1 and 2.

With reference to Table 1.1, Formulation 1, having a final pH of 5.11,and Formulation 2, having a final pH of 3.33, showed significantlyhigher viscosity, while those formulations having a pH of 4.55 to 4.93had much lower viscosity, demonstrating a clear optimal range of pH in ahighly concentrated formulation of AM-14 that yielded lower viscosity.

TABLE 1.0 AM-14 concentrations at approximately 180 mg/ml ReconstitutionViscosity AM-14 Final Buffer/pH Excipient (cP) pH Clarity 10 mMglutamate, 4% sorbitol 19.64 5.24 clear pH 4.5 10 mM glutamate, 200 mM32.31 5.29 clear pH 4.5 PEG200 10 mM glutamate, 2.5% 18.29 5.24 clear pH4.5 glycerol (271.5 mM) 10 mM glutamate, 3% proline 19.99 5.28 clear pH4.5 (260 mM) 10 mM glutamate, 160 mM 12.50 4.98 clear pH 4.5 glutamicacid 10 mM glutamate, 200 mM 11.89 4.6 clear pH 4.5 creatinine 10 mMglutamate, 200 mM L- 12.85 4.8 clear pH 4.5 carnitine 10 mM glutamate,50 mM 17.15 5.2 clear pH 4.5 creatinine + 70 mM NaCl 10 mM glutamate, 50mM 12.77 4.9 clear pH 4.5 creatinine + 110 mM glutamic acid 10 mMglutamate, 80 mM 14.85 5.05 clear pH 4.5 arginine + 80 mM glutamic acid10 mM glutamate, 130 mM 17.25 5.39 clear pH 4.5 proline + 70 mM NaCl 10mM glutamate, 160 mM 15.42 5.12 clear pH 4.5 glycine 10 mM glutamate,160 mM 20.75 5.13 clear pH 4.5 betaine 10 mM glutamate, 4% sorbitol44.20 5.6 clear pH 5.5 10 mM glutamate, 200 mM 39.45 5.6 clear pH 5.5PEG200 10 mM glutamate, 2.5% 34.5 5.6 clear pH 5.5 glycerol (271.5 mM)10 mM glutamate, 3% proline 27.3 5.65 clear pH 5.5 (260 mM) 10 mMglutamate, 160 mM 19.02 5.7 clear pH 5.5 glutamic acid 10 mM glutamate,160 mM 15.74 5.7 clear pH 5.5 arginine- HCl, pH 5.5 10 mM glutamate, 200mM 15.22 5.6 clear pH 5.5 creatinine 10 mM glutamate, 200 mM L- 18.075.6 clear pH 5.5 carnitine 10 mM glutamate, 50 mM 24.62 6.08 clear pH5.5 creatinine + 70 mM NaCl 10 mM glutamate, 50 mM 17.97 5.7 clear pH5.5 creatinine + 110 mM glutamic acid 10 mM glutamate, 80 mM 17.42 5.69clear pH 5.5 arginine + 80 mM glutamic acid 10 mM glutamate, 130 mM15.88 5.76 hazy pH 5.5 proline + 70 mM NaCl

TABLE 1.1 Effect of pH on viscosity for highly concentrated AM-14formulations AM-14 Formulation Buffer Final Concentration ViscosityFormulation components Excipient Buffer pH pH on (mg/mL) (cP) 1. A48SuTacetic acid; Sucrose Acetate 3.8 5.11 148.95 12.61 sucrose, andpolysorbate 20 2. E44GT Glutamic Glycine L-glutamic 3.2 3.33 148 19.60acid, glycine, acid and polysorbate 20 3. A48GT acetic acid, GlycineAcetate 3.8 4.64 150.3 7.64 glycine, and polysorbate 20 4. E40/48GTglutamic Glycine L-glutamic 4 4.72 153.84 6.95 acid, glycine, acidpolysorbate 20 5. E52GT glutamic Glycine L-glutamic 4.2 4.85 147.99 6.51acid, glycine, acid polysorbate 20 6. E48PT glutamic Proline L-glutamic3.8 4.55 147.3 5.99 acid, proline, acid and polysorbate 20 7. E52PTglutamic Proline L-glutamic 4.2 4.93 147.88 6.69 acid, proline, acid andpolysorbate 20 8. E48ST glutamic Sorbitol L-glutamic 3.8 4.79 148.7 7.55acid, sorbitol, acid and polysorbate 20 9. E44SuT glutamic SucroseL-glutamic 3.2 4.66 148.55 7.61 acid, acid sucrose, and polysorbate 2010. E48SuT glutamic Sucrose L-glutamic 3.8 4.85 147.36 8.42 acid, acidsucrose, and polysorbate 20 11. A48PT acetic acid, Proline Acetate 4.8153.57 6.89 proline, and polysorbate 20

A separate study was performed to investigate the relationship betweenviscosity and varying concentrations of AM-14 in the A52S formulation(10 mM sodium acetate, pH 5.2, 5% sorbitol). Table 1.3 shows AM-14 wasformulated at concentrations ranging from approximately 48 mg/ml toapproximately 163 mg/ml. The effect on viscosity is depicted in FIG. 3.

TABLE 1.3 Viscosity of AM-14 at different concentrations (see FIG. 3)AM-14 A52S Concentration (mg/ml) Density mPa*s 47.725 1.027807 1.584272.086 1.034805 2.2012 91.429 1.042012 3.4675 127.04 1.052502 9.3879130.37 1.054458 12.1759 163.22 1.061677 27.9541

In a separate study, the effect of pH on a highly concentratedformulation of AM-14 was conducted. AM-14 concentrations wereapproximately 200 mg/mL. The samples were prepared similarly usinglyophilization process. The starting material was 70 mg/mL AM-14 in abuffer of 10 mM glutamate, pH 4.8 and 1% sucrose. The 1.5 mL of startingmaterial was filled in 3 cc vials and then lyophilized. Each vialcontained approximately 100 mg of AM-14. A series of solutions of 30 mMglutamate and 30 mM histidine at pH 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0and 6.5 were prepared. 0.5 mL of these buffers was added to thelyophilized vials to generate the material for viscosity measurement,which was about 200 mg/mL with different pH values. The effect of pH onthe viscosity of AM-14 was determined and shown in FIG. 4, which depictsa subset of this data. This data demonstrates that the viscositymeasured at 25° C. at higher pH, such as pH higher than 5.7 (viscosityis >40 cP) has a much higher viscosity than that seen at lower pHformulations (viscosity is greater or equal to 20 cP).

Stability studies for AM-14 were performed using either a 3 cc glassvial or a 1 mL pre-filled glass syringe. Samples were stored at 4, 25,29, 37, 40, and 45 degrees C. Standard stability indicating assays wereused to monitor the stability of the AM-14 formulations includingSE-HPLC, CEX-HPLC, HIAC (sub-visible particle) and visual inspection.

1.4 4° C. stability (SE-HPLC assay), in pre-filled syringe Decrease inSample time 0 1 month 3 month SEC % MP 1 A48SuT 99.65 99.66 99.63 0.02 2E44GT 45.63 40.96 41.65 3.98 3 A48GT 99.7 99.67 99.67 0.03 4 E4048GT99.76 99.72 99.68 0.08 5 E52GT 99.7 99.7 99.68 0.02 6 E48PT 99.75 99.7399.7 0.05 7 E52PT 99.71 99.71 99.7 0.01 8 E48ST 99.67 99.69 99.46 0.21 9E44SuT 99.73 99.69 99.72 0.01 10 E48SuT 99.57 99.61 99.62 −0.05

TABLE 1.5 25° C. stability; in pre-filled syringe Sample 0 1 m 3 mDecrease in SE % MP 1 A48SuT 99.65 99.44 99.23 0.42 2 E44GT 45.63 2.61.76 43.87 3 A48GT 99.7 99.5 99.09 0.61 4 E4048GT 99.76 99.53 99.13 0.635 E52GT 99.7 99.58 99.23 0.47 6 E48PT 99.75 99.64 99.42 0.33 7 E52PT99.71 99.63 99.45 0.26 8 E48ST 99.67 99.56 99.33 0.34 9 E44SuT 99.7399.56 99.33 0.4 10 E48SuT 99.57 99.44 99.15 0.42

TABLE 1.6 Freeze-thaw stability from scale down study (1L scale) withcontrol rate freezer After 2 Intial final Protein Viscosity freezeFormulation Excipient buffer pH pH conc (25C) T = 0 thaw 110 mg/ml AM-Sucrose L- 3.8 4.8 110 3.56 99.77 99.79 14 formulated glutamic with 10mM acid glutamate, 8.5% sucrose and 0.01% polysorbate 20 150 mg/ml AM-Sucrose L- 3.8 4.8 140 6.7 99.73 99.71 14 formulated glutamic with 10 mMacid glutamate, 8.0% sucrose and 0.01% polysorbate 20 150 mg/ml AM-Proline L- 4 4.8 140 4.74 99.73 99.7 14 formulated glutamic with 10 mMacid glutamate, 3% proline and 0.01% polysorbate 20Based on this data, embodiments of AM-14 formulations include: 100-150mg/mL AM-14, formulated with 5-15 mM glutamic acid, 7-9% (w/v) sucrose,0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2; such as 140 mg/mLAM-14, formulated with 10 mM glutamic acid, 8% (w/v) sucrose, 0.01%(w/v) polysorbate 20, pH 4.8±0.2; 100-150 mg/mL AM-14, formulated with5-15 mM glutamic acid, 1-3% (w/v) glycine, 0.003-0.02% (w/v) polysorbate20, pH 4.5-5.5±0.2, such as 140 mg/mL AM-14, formulated with 10 mMglutamic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2;100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid, 2-4% (w/v)proline, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, such as about140 mg/mL AM-14, formulated with 10 mM glutamic acid, 3% (w/v)L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, and 140 mg/mL AM-14,formulated with 10 mM glutamic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2; 100-150 mg/mL AM-14, formulated with 5-15 mMacetic acid, 1-3% (w/v) glycine, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, such as 140 mg/mL AM-14, formulated with 10 mM acetic acid,2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2; 100-150 mg/mLAM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v) proline,0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, such as 140 mg/mLAM-14, formulated with 10 mM acetic acid, 3% (w/v) L-proline, 0.01%(w/v) polysorbate 20, pH 4.8±0.2; 100-150 mg/mL AM-14, formulated with5-15 mM acetic acid, 7-9% (w/v) sucrose, 0.003-0.02% (w/v) polysorbate20, pH 4.5-5.5±0.2, such as 140 mg/mL AM-14, formulated with 10 mMacetic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2;100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v)glycerol, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, such as 140mg/mL AM-14, formulated with 10 mM acetic acid, 3% (w/v) glycerol, 0.01%(w/v) polysorbate 20, pH 4.8±0.2; 100-150 mg/mL AM-14, formulated with5-15 mM acetic acid, 3.5-5.5% (w/v) sorbitol, 0.003-0.02% (w/v)polysorbate 20, pH 4.5-5.5±0.2, such as 140 mg/mL AM-14, formulated with10 mM acetic acid, 4.5% (w/v) sorbitol, 0.01% (w/v) polysorbate 20, pH4.8±0.2; 100-150 mg/mL AM-14, formulated with 5-15 mM glutamic acid,7-9% (w/v) sucrose, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2,4-10 cP at 25 degrees C., such as 140 mg/mL AM-14, formulated with 10 mMglutamic acid, 8% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C.; 100-150 mg/mL AM-14, formulated with 5-15 mMglutamic acid, 1-3% (w/v) glycine, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, 4-10 cP at 25 degrees C., such as 140 mg/mL AM-14,formulated with 10 mM glutamic acid, 2% (w/v) glycine, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.; 100-150 mg/mLAM-14, formulated with 5-15 mM glutamic acid, 2-4% (w/v) proline,0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25 degreesC., such as 140 mg/mL AM-14, formulated with 10 mM glutamic acid, 3%(w/v) L-proline, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25degrees C.; 100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid,1-3% (w/v) glycine, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2,4-10 cP at 25 degrees C., such as 140 mg/mL AM-14, formulated with 10 mMacetic acid, 2% (w/v) glycine, 0.01% (w/v) polysorbate 20, pH 4.8±0.2,5-7 cP at 25 degrees C.; 100-150 mg/mL AM-14, formulated with 5-15 mMacetic acid, 2-4% (w/v) proline, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, 4-10 cP at 25 degrees C., such as 140 mg/mL AM-14,formulated with 10 mM acetic acid, 3% (w/v) L-proline, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.; 100-150 mg/mLAM-14, formulated with 5-15 mM acetic acid, 7-9% (w/v) sucrose,0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at 25 degreesC., such as 140 mg/mL AM-14, formulated with 10 mM acetic acid, 8% (w/v)sucrose, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degreesC.; 100-150 mg/mL AM-14, formulated with 5-15 mM acetic acid, 2-4% (w/v)glycerol, 0.003-0.02% (w/v) polysorbate 20, pH 4.5-5.5±0.2, 4-10 cP at25 degrees C., such as 140 mg/mL AM-14, formulated with 10 mM aceticacid, 3% (w/v) glycerol, 0.01% (w/v) polysorbate 20, pH 4.8±0.2, 5-7 cPat 25 degrees C.; 100-150 mg/mL AM-14, formulated with 5-15 mM aceticacid, 3.5-5.5% (w/v) sorbitol, 0.003-0.02% (w/v) polysorbate 20, pH4.5-5.5±0.2, 4-10 cP at 25 degrees C., such as 140 mg/mL AM-14,formulated with 10 mM acetic acid, 4.5% (w/v) sorbitol, 0.01% (w/v)polysorbate 20, pH 4.8±0.2, 5-7 cP at 25 degrees C.

Example 2 Dosages and Treatment Regimens for Treating InflammatoryDiseases in Humans with Anti-IL-17 Receptor “A” Monoclonal AntibodiesPre-Clinical Pharmacokinetics and Drug Metabolism Studies

Pharmacokinetic studies included an one-month and a three-monthtoxicology studies. AM-14 was quantified in cynomolgus monkey serumusing a validated enzyme-linked immunosorbent assay (ELISA). Briefly,microplate wells were coated with a mouse anti-AM-14 monoclonalantibody. Standards and quality controls were prepared by spiking AM-14into a 100% cynomolgus monkey serum pool. The AM-14 in the standards,quality controls, and study samples was captured by immobilized mouseanti-AM-14 monoclonal antibody and then a second mouse anti-AM-14monoclonal antibody conjugated to horseradish peroxidase (HRP) was addedto bind the captured AM-14. A tetramethylbenzidine (TMB) substratesolution reacted with peroxide, and in the presence of HRP, created acolorimetric signal that was proportional to the amount of AM-14 boundby the capture antibody. The optical density was measured at 450 nmminus 650 nm. Data were reduced using a Logistic (auto-estimate)regression model with a weighting factor of 1/Y². The nominal dynamicrange of the assay for the 3 studies was 50 to 2500 ng/mL.

Single-Dose Pharmacokinetic Study

The pharmacokinetics of a single-dose pharmacokinetic study of AM-14given to male cynomolgus monkeys following IV (intravenous) or SC(sub-cutaneous) administration objective was performed. 15 malecynomolgus monkeys were randomly assigned to 5 groups (n=3 per group)and received a 0.5 or 50 mg/kg IV dose of AM-14 or a 0.5, 5, or 50 mg/kgSC dose of AM-14.

AM-14 serum concentration was shown to increase with increased dosing.After a single IV bolus, a 339-fold increase in AUC_(0-int) was observedfor a 100-fold dose increase. After SC doses ranging from 0.5 to 5mg/kg, AM-14 exposure (both AUC_(0-inf) and C_(max)) increased greaterthan dose proportionally. However, after SC doses ranging from 5 to 50mg/kg, the exposure increased approximately dose proportionally (Table2.1).

Because the pharmacokinetic profile of AM-14 was non-linear, it wasnecessary to further analyze the data using a compartmental approach,and therefore, the data were fitted to a 2-compartment model withMichaelis-Menten elimination and an additional first order component ofelimination.

The compartmental analysis performed (Table 2.2) estimated a first orderclearance component of elimination of 1.78 mL/hr, a maximum eliminationrate (V_(max)) of 34.4 ug/hr, and a K_(m) of 0.984 ug/mL. When the dosesof AM-14 led to serum concentrations below 0.1 ug/mL (approximately0.1-fold the K_(m) value), the saturable elimination pathway was totallyfree and the kinetics could be considered linear. Similarly, when thedose of AM-14 led to serum concentrations above 10 ug/mL (approximately10-fold the K_(m) value) during at least 3 to 4 half-lives, thesaturable elimination component was negligible and the kinetics couldalso be considered linear. However, when the dose of AM-14 led to serumconcentrations between 0.1 and 10 ug/mL, the non-linear component becamerelevant and the elimination kinetics varied depending on the dose anddose frequency; this translated into different effective half-lifevalues.

AM-14 exhibited nonlinear pharmacokinetics after single dose IV or SCadministration in cynomolgus monkeys that was consistent withtarget-mediated disposition, and was most pronounced following single SCadministration up to 5 mg/kg. After single or multiple SC doses rangingfrom 5 to 350 mg/kg, the exposure increased approximately doseproportionally. No marked difference between sexes in AM-14 exposure andmoderate accumulation were observed after multiple weekly dosing incynomolgus monkeys for 1 or 3 months.

TABLE 2.1 Mean (SD) Noncompartmental Pharmacokinetic Parameter EstimatesAfter Single-Dose Subcutaneous Administration of AM-14 to CynomolgusMonkeys Dose t_(max) C₀ or C_(max) AUC_(0-t) AUC_(0-inf) Cl or Cl/FV_(z) or V_(z)/F MRT_(0-inf) (mg/kg) (hr) (μg/mL) (hr · μg/mL) (hr ·μg/mL) (mL/hr) (mL) (hr) (n = 3 per group) 0.5 IV — 9.79   160   1688.33  142  18 (0.964)  (44.2)   (46) (2.64) (14.0) (3.5) 0.5 SC 27 1.28 69.7  74.2 22.2  681  45 (0.808)  (43.4)   (41) (11.2)  (522) (9.5)   5SC 72 20.7   3110   3120 4.70 98.7 110 (4.82)   (1160)  (1160) (1.61)(6.99) (8.1)  50 IV — 673  56600  57000 2.33 75.2 140 (66.5)  (18100)(18600) (0.592) (23.6)  (47)  50 SC 72 166  33700  33700 3.98 72.2 150(33.4)  (10400) (10400) (1.18) (9.15)  (28) Parameters are presented asaverage (standard deviation [SD]) to 3 significant figures, except fort_(max) and MRT_(0-inf) t_(max) = time of C_(max) after subcutaneous(SC) administration; C_(max) = maximum observed serum concentration; C₀= estimated initial concentration after intravenous (IV) bolusadministration; AUC_(0-t) = area under the concentration-time curve fromtime 0 to the last quantifiable concentration; AUC_(0-inf) = AUC fromtime 0 to infinity; CL or CL/F = clearance, calculated asDose/AUC_((0-inf)), V_(z) or V_(z)/F = apparent volume of distributionbased on the terminal phase; MRT_(0-inf) = mean residence time from time0 to infinity.

TABLE 2.2 Compartmental Pharmacokinetic Parameter Estimates AfterSingle-dose Subcutaneous Administration of AM-14 to Cynomolgus MonkeysParameter Description Value (SE %) θ₁ F_(SC) bioavailability after SC0.977 (7.2) administration θ₂ (hr⁻¹) K_(aSC), Absorption rate constantfor SC 0.0267 (9.3) administration θ₃ (hr⁻¹) K₁₂, Rate constant ofdistribution from 0.0399 (20.6) central to peripheral θ₄ (hr⁻¹) K₂₁,Rate constant of distribution from 0.0889 (18.5) peripheral to centralθ₅ (mL/hr) CL, First order clearance 1.78 (15.8) θ₆ (ug/mL) K_(m),Maximum rate of Elimination 0.984 (23.6) θ₇ (ug/hr) V_(m),Michaelis-Menten constant 34.4 (10.1) θ₈ (mL) V, Volume of distribution224 (15.1) σ² ₁ Variance of proportional error 0.25² (13.4) σ² ₂Variance of additive error 99.1² (27.5) SC = subcutaneous; SE = standarderror

Clinical Effects of AM-14 in Humans

AM-14 was evaluated in two Phase 1 clinical studies. Study no. 1 was arandomized, double-blind, placebo-controlled, ascending single-dosestudy to evaluate the safety, tolerability, pharmacokinetics, andpharmacodynamics of AM-14 in healthy subjects and subjects with moderateto severe psoriasis. A single dose of AM-14 at 7, 21, 70, 140, 210, 350,or 420 mg SC or 21, 210, or 700 mg IV was administered, as shown inTable 2.3. This was a 2-part study in healthy subjects (Part A) andsubjects with moderate to severe psoriasis (Part B). Healthy subjectswere assigned to 1 of 8 sequential dosing cohorts and randomly assigned(3:1) within each cohort to receive a single SC or IV dose of AM-14 orplacebo (Table 2.3). Subjects with moderate to severe psoriasis wereassigned to 1 of 3 dosing cohorts and randomly assigned within eachcohort to receive a single IV or SC dose of AM-14 or placebo.

AM-14 was formulated in 10 mM sodium acetate, 9% (w/v) sucrose, and0.004% polysorbate 20, pH 5.2 at a final concentration of 70 mg/mL.

TABLE 2.3 Dose Escalation Sequence for Study No. 1 (healthy subjects andsubjects with moderate to severe psoriasis) No. on No. on Subject PartCohort Dose/Route AM-14 Placebo Description A 1 7 mg SC 6 2 Healthyvolunteer A 2 21 mg SC 6 2 Healthy volunteer A 3 21 mg IV 3 1 Healthyvolunteer A 4 70 mg SC 6 2 Healthy volunteer A 5 210 mg SC 6 2 Healthyvolunteer A 6 210 mg IV   4^(a) 1 Healthy volunteer A 7 420 mg SC 6 2Healthy volunteer A 8 700 mg IV 6 2 Healthy volunteer B 9 700 mg IV 8 2Moderate to severe psoriasis B 10 140 mg SC 4 1 Moderate to severepsoriasis B 11 350 mg SC 8 2 Moderate to severe psoriasis IV =intravenous; SC = subcutaneous ^(a)The protocol specified 3 AM-14subjects for this cohort; however, 4 AM-14 subjects were enrolled.

Study No. 2 is a Phase 1 b, randomized, double-blind,placebo-controlled, ascending multiple-dose study to evaluate thesafety, tolerability, pharmacokinetics, pharmacodynamics and efficacy ofAM-14 in subjects with rheumatoid arthritis. Approximately 110 subjectshave received multiple SC or IV doses of AM-14 or matching placebo(Table 2.4). Subjects were randomized 3:1 in cohorts 1 to 3 and 5 and 6.

TABLE 2.4 Cohort and Dosing Schedule for Study No. 2 (rheumatoidarthritis) No. of No. of Cohort Active Placebo Total No. No. Part Dose &Route Subjects Subjects of Subjects 1 A 50 mg SC 6 2 8 q2wks 2 A 140 mgSC 6 2 8 q2wks 3 A 210 mg SC 6 2 8 q2wks 4 B Dose used in 35 35 70 PartA 5 A 420 mg IV on 6 2 8 days 1 & 29 6 A 700 mg IV on 6 2 8 days 1 & 29Total 65 45 110

Pharmacodynamics of AM-14 in Humans

Two assays measuring pharmacodynamic responses to AM-14 were implementedin the clinical trials. A receptor occupancy assay allowed forassessment of target coverage and an ex vivo whole blood stimulationassay was used to evaluate functional IL-17R blockade.

Receptor Occupancy (RO) Assay

Single Dose in Healthy Subjects and Subjects with Psoriasis

A semi-quantitative flow cytometric assay was developed to measure theexpression of IL-17 receptor in subjects, allowing for estimates ofbiochemical coverage by AM-14 on lymphocytes, monocytes, andgranulocytes, with each cell type easily identifiable by standard flowcytometry gating procedures known in the art. Blood specimens fromsubjects were collected on days −1, 1 (predose), 3, 5, 8 or 15, 29, 43,64, and 85. The RO calculation was obtained using IL-17R coverage byAM-14 (with a competitive labeled antibody) in combination with totalIL-17R expression (using a non-competitive IL-17R antibody). The resultsof the mean percent RO in healthy volunteers receiving AM-14 dosesbetween 21 and 700 mg are summarized in FIG. 5 and FIG. 6, respectively.Mean values for AM-14 occupancy of the IL-17 receptor on granulocytes ofhealthy volunteers are shown These data demonstrate biochemical coverageof the IL-17 receptor on whole blood granulocytes at various timespre-dose (0) or post-dose of AM-14 administered either by thesubcutaneous (—) or intravenous (

) route. Receptor occupancy was calculated from a baseline-normalizedratio AM-14-PE (competitive anti-IL17R mAb) to M204-PE (non-competitiveanti-IL-17R mAb) multiplied by 100%. Technical variability in the assayat low levels of occupancy can generate values below zero, which arearbitrarily set to the x-axis. This includes datapoints from the 21 mgIV cohort (Days 1, 8, 29, and 43) and the 210 mg IV and SC groups (Day64).

The results of the mean percent RO in patients with psoriasis receivingAM-14 doses between 21 and 700 mg are summarized in FIG. 6. Mean valuesfor AM-14 occupancy of the IL-17 receptor on granulocytes of patientswith psoriasis are shown. These data demonstrate biochemical coverage ofthe IL-17 receptor on whole blood granulocytes at various times pre-dose(0) or post-dose. Receptor occupancy was calculated from abaseline-normalized ratio of AM-14-PE (competitive anti-IL17R mAb) toM204-PE (non-competitive anti-IL-17R mAb) multiplied by 100%. Technicalvariability in the assay at low levels of occupancy can generate valuesbelow zero, which are arbitrarily set to the x-axis. This includes 2datapoints from the 140 mg SC cohort and 2 data points from the 350 mgSC cohort.

Maximal coverage was observed at the first sampling time in allsubjects, at all dosage levels. Partial RO was observed at days 3 and 5at the 7 and 21 mg SC dose levels. Greater than 90% mean RO was achievedfor the 21 mg IV dose level and all cohorts treated with 70 mg AM-14 andhigher. More prolonged RO was detectable as AM-14 dose levels escalated.Greater than 90% IL-17R RO was observed from 5 to 29 days post-treatmentin individuals receiving 420 or 700 mg AM-14 in a single dose. This datashows that healthy volunteers and psoriasis patients exhibited similarRO profiles when administered equivalent doses of AM-14. There were noapparent changes in the percentage of monocytes, granulocytes,lymphocytes, or lymphocyte subsets, including T cells, B cells, andnatural killer cells.

Multiple Doses in Subjects with RA

Blood specimens from subjects were collected on days −1, 1 (predose), 3,15, 43, and 85 and assayed using a semi-quantitative flow cytometricassay. Results of mean percent RO in rheumatoid arthritis (RA) patientsreceiving ascending doses of AM-14 are summarized in FIG. 7. Notablythere were no differences between RA subjects and healthy volunteers inexpression levels of IL-17R or AM-14 binding to leukocytes based oncomparative in vitro studies in these populations. FIG. 7 shows the meanIL-17 receptor occupancy on granulocytes in RA patients pre-dose (0) orpost-dose AM-14 treatment. Receptor occupancy was calculated from abaseline-normalized ratio AM-14-PE (competitive anti-IL17R mAb) toM204-PE (non-competitive anti-IL-17R mAb). Technical variability in theassay at low levels of occupancy can generate values below zero, whichare arbitrarily set to the x-axis. This includes day −1 of the 50 and140 mg cohorts and day 1 of the 210 mg cohort.

Maximal granulocyte RO by AM-14 was observed 3 days post-treatment atall dose levels. Patients enrolled in cohort 1 (50 mg) exhibited 95% ROat Day 3 and partial RO (32% to 39%) when drug reached trough levels onDays 15, 43, and 85. All patients in cohort 2 (140 mg) exhibited greaterthan 95% RO on Day 3, and greater than 80% RO on Day 15. At Day 43, ROwas greater than 90% in all patients, suggesting some degree ofaccumulation of AM-14. Receptor occupancy remained above 90% in 5 of 6patients at Day 85 and all patients exhibited greater than 80% RO. Datathrough Day 15 for cohort 3 (210 mg) showed that patients exhibitedgreater than 95% RO at Day 3. There were no apparent changes in thepercentage of monocytes, granulocytes, lymphocytes, or lymphocytesubsets including T cells, B cells, and natural killer cells in anycohort of RA patients treated with AM-14.

Whole Blood Stimulation Assay

Assessment of Biological Effects of AM-14 Using an Ex Vivo Whole BloodStimulation Assay

To demonstrate a functional biological effect of AM-14 on IL-17Rsignaling, a pharmacodynamic assay using human whole blood was developedand incorporated into Study no. 1. In this assay, human whole blood wascollected pre- and post-dosing with AM-14 and then stimulated with TNFand a dose-titration of IL-17 for 4 hours. The cells were then lysed andthe lysate was subsequently analyzed for IL-17 responsive genes,including IL-6, using a branched DNA (bDNA) signal amplification assay.In the presence of AM-14, the induction of IL-6 mRNA is competitivelyinhibited, with an observed increase in EC50 for IL-17 dependentincreases in expression. These data can be expressed quantitatively as ashift in the EC50 response to IL-17 relative to the predose baseline foreach patient.

The EC50 curves for IL-17 stimulation of IL-6 mRNA (as measured by thebDNA assay) were significantly shifted compared with predose after asingle dose of AM-14. Some level of functional signaling blockade wasnoted in all AM-14-treated healthy subjects from cohort 4 (70 mg SC) onday 5, and all AM-14-treated healthy subjects in cohorts 5 (210 mg SC)to cohort 8 (700 mg IV) on day 15. In cohort 9 (700 mg IV), all 4 testedAM-14-treated psoriasis subjects showed functional blockade at day 29,and 3 of 4 subjects showed blockade at day 43. The average log 10 EC50shift for each cohort at the tested time points is shown in Table 2.5.

TABLE 2-5 AM-14 Leads to Functional Blockade of IL-17 Signaling in an ExVivo Assay Cohort Dose 30 min^(a) Day 5^(a) Day 8^(a) Day 15^(a) Day29^(a) Day 43^(a) Day 64^(a) 1  7 mg SC −0.04 −0.27 −0.24 2  21 mg SC0.22 0.22 0.35 3  21 mg IV 2.08 0.4 0.19 4  70 mg SC 1.32 0.91 −0.04 5210 mg SC 2.35 1.22 −0.13 6 210 mg IV 2.49 2.09 −0.24 7 420 mg SC 2.12.12 0.15 8 700 mg IV 1.72 1.74 −0.99 9 700 mg IV 1.95 1.46 10 140 mg SC0.45 0.27 11 350 mg SC 2.02 0.45 Placebo^(b) 0.03 −0.08 0.19 0 0.04 0.270.05 ^(a)The log EC50 shift was calculated from the postdose sampleminus the average log EC50 of 2 predose samples per subject. The meanlog EC50 shift is reported for the 3 to 6 tested subjects in each cohort^(b)The mean value of placebo samples across all cohorts collected atthat same time point postdose

Competitive Antagonism Model for Whole Blood Stimulation Data

Preliminary pharmacokinetic/pharmacodynamic analyses using a competitiveantagonist model enabled the modeling of the effects of AM-14 on IL-17Rfunction based on the ex vivo whole blood stimulation (WBS) assay. Thedissociation constant (K_(i)) was estimated to be 51 ng/mL, and theAM-14 IC₅₀ and IC₉₀ levels of IL-17R inhibition were estimated to bewithin the ranges of approximately 130 to 540 and approximately 2860 to15600 ng/mL, respectively, when IL-17 concentration is assumed to rangefrom 0.5 to 50 ng/mL.

Pharmacokinetics of AM-14 in Humans

Serum Pharmacokinetics in Single Dose in Healthy Subjects and Subjectswith Psoriasis

Single-dose IV and SC AM-14 pharmacokinetic data were obtained for thehealthy subjects in cohorts 1 to 8 and the psoriasis subjects in cohorts9 to 11. AM-14 serum concentrations were not detectable in any samplefrom cohort 1 (7 mg SC) or in the majority of samples from cohort 2 (21mg SC). The AM-14 serum concentration vs time profiles from all otherhealthy volunteer cohorts exhibited nonlinear pharmacokinetics and theexposure (as assessed by the maximum observed concentration [C_(max)]and the area under the concentration-time curve from time 0 to the lastquantifiable concentration [AUC_(0-t)]) increased greater than doseproportionally (Table 2.6). After 70, 210, or 420 mg SC administration,the median time to C_(max) (t_(max)) ranged from 48 to 168 hours. Theapparent bioavailability after SC administration was estimated to beapproximately 70% based on simultaneous pharmacokinetic modeling of allSC and IV cohort data. Pharmacokinetic parameters for 700 mg IV dosingin psoriasis subjects appeared to be comparable to those in healthyvolunteers based on direct comparison of 700 mg IV concentration-timecurves in healthy volunteer and psoriasis subjects (cohort 8 and cohort9). Two separate biomarker assays were implemented to determine thebiological activity of AM-14 in whole blood, including receptoroccupancy and functional blockade of the IL-17 receptor, as describedabove. Both assays demonstrated a direct relationship between the serumconcentrations of AM-14 and the functional readouts of these assays,including target (IL-17R) coverage and log EC50 shift measured by thewhole blood stimulation assay. Samples with measurable circulating AM-14consistently showed IL-17 receptor occupancy and an increase in logEC50, with higher shifts at higher concentrations.

TABLE 2.6 Mean (SD) Pharmacokinetic Parameters of AM-14 in HealthyVolunteers (Cohorts 1 to 8) and Psoriasis Subjects (Cohorts 9 to 11)Dose and route T_(max) C_(max) AUC_(0-t) Cohort (mg) (hr) (ug/mL) (ug ·hr/mL)  1 (HV) 7 SC NC NC NC  2 (HV) 21 SC NC NC NC  3 (HV) 21 IV 0.66.67  238 (0.6-4.0) (2.11)    (78.9)  4 (HV) 70 SC 48   2.54  313(48-96) (1.37)  (213)  5 (HV) 210 SC 96   10.6 2790 (72-96) (8.93)(2740)  6 (HV) 210 IV 0.7 63.9 8280 (0.6-0.7) (12.6) (1440)  7 (HV) 420SC 168    23.6 9360  (96-168) (5.37) (2550)  8 (HV) 700 IV 0.7 15936000  (0.7-0.8) (29.5) (8850)  9 (PsO) 700 IV 2.0 198 39800  (0.5-4.0)(39.6) (8610) 10 (PsO) 140 SC 48   5.47  631 (48-48) (3.00)  (347)11^(a) (PsO) 350 SC 168    11.5 3030  (48-168) (5.72)  (1980). ^(a)Onlypartial data available for cohort 11 C_(max) and AUC_(0-t), werereported as mean (SD) values while t_(max) was reported as median(range). All values were rounded to 3 significant figures aftercalculations were performed, except t_(max,) . AUC_(0-t) = area underthe concentration-time curve from time 0 to the last quantifiableconcentration; C_(max) = maximum observed concentration; t_(max) = timeat observed maximum concentration; NC = not calculated due to mostsamples below limit of quantitation; HV = healthy volunteer; PsO =psoriasis subject.Serum Pharmacokinetics in Multiple Doses in Subjects with RA

Preliminary multi-dose SC AM-14 pharmacokinetic data were obtained fromRA subjects in the phase 1 b study. AM-14 serum concentration data wereavailable through the end of study for all cohort 1 subjects (50 mgevery 2 weeks) and up to day 85 for majority of the cohort 2 subjects(140 mg every 2 weeks). AM-14 exhibited nonlinear pharmacokinetics in RAsubjects and the exposure (as assessed by C_(max) and AUC_(0-t)) afterthe first and the last (6^(th)) SC dose increased greater than doseproportionally from the 50 to 140 mg dose (Table 2.7). The mediant_(max) ranged from 36 to 96 hours. Minimal accumulation was observedafter 6 doses of 50 mg SC administered every 2 weeks, whereas theaccumulation was minimal after 140 mg administered every 2 weeks.Pharmacokinetics of AM-14 after the first SC dose of 140 mg in RAsubjects appeared to be comparable to those after single 140 mg SCdosing in psoriasis subjects (cohort 10; C_(max)=5.47±3.00 μg/mL,AUC_(0-t)=631±347 μg-hr/mL).

TABLE 2.7 Mean (SD) Pharmacokinetic Parameters of AM-14 in RA Subjects(Cohorts 1 and 2) Dose and T_(max) C_(max) AUC_(o-t) Cohort route (mg)Phase (hr) (μg/mL) (μg · hr/mL) 1  50 SC q2w 1^(st) dose 36.0 0.742 41.6(4.0-48.0) (0.522) (38.6) 6^(th) dose 48.0 1.35 95.9 (24.0-48.0) (1.07)(73.7) 2 140 SC q2w 1^(st) dose 96.0 5.67 864   (48.0-96.0) (2.98)(668)   6^(th) dose^(a) 96.0 5.93 1200    (48.0-96.0) (5.15) (1240)   C_(max) and AUC_(0-t), were reported as mean (SD) values while t_(max)was reported as median (range). All values were rounded to 3 significantfigures after calculations were performed, except t_(max,) which waspresented to one decimal figure AUC_(0-t) = area under theconcentration-time curve from time 0 to the last quantifiableconcentration; C_(max) = maximum observed concentration; q2w = every 2weeks; t_(max) = time at observed maximum concentration ^(a)Only partialdata available for the last dose of cohort 2.

Psoriasis Study Results

Fifty-seven healthy subjects were enrolled into cohorts 1 to 8; 43subjects received AM-14 and 14 subjects received placebo. Twenty-fivesubjects with moderate to severe psoriasis were enrolled into cohorts 9to 11. In cohort 9, 8 subjects received AM-14 and 2 subjects receivedplacebo; in cohort 10, 4 subjects received AM-14 and 1 subject receivedplacebo, and in cohort 11, 8 subjects received AM-14 and 2 subjectsreceived placebo.

PASI scores for all psoriasis subjects (A-J) in cohort 9 through day 85(end of study) are presented in Table 2.8. PASI scores for all psoriasissubjects (A-E) in cohort 10 through day 85 (end of study) are presentedin Table 2.10. PASI scores for all psoriasis subjects (A-J) in cohort 11through day 85 (end of study) are presented in Table 2.11.

In cohort 9 (700 mg IV) maximal PASI effects were observed at day 43, atwhich time a 75% reduction in PASI score (PASI 75) was observed in 7 of8 (88%) subjects receiving AM-14 (Table 2.8). All subjects receivingAM-14 in cohort 9 reached a PASI 50 (50% reduction) by day 29, while nosubjects receiving placebo attained a PASI 50 response at any timepoint. A PASI 90 response (90% reduction from baseline PASI score) wasobserved in 3 of 8 (38%) subjects by day 43 receiving 700 mg IV AM-14(Tables 2.8 and 2.9). Compared to the high dose group of PsO subjects(700 mg IV), there were lower PASI responses for subjects receiving 140mg and 350 mg of AM-14 given SC. As shown in Table 2.10, only 1 of 4subjects had a significant PASI response (>50%) in the 140 mg SC dosegroup and this response was gone by day 43. In the 350 mg SC cohort, 6of 8 and 5 of 8 subjects achieved PASI 50 and PASI 75, respectively,during the course of the study (Table 2.11).

There was a positive relationship between AM-14 dose and PASI 50/75/90response among the AM-14-treated subjects. No subjects who receivedplacebo achieved a PASI 50 response or greater at any postdose timepoint. The mean percent improvement in PASI score increased withincreasing AM-14 dose through Day 29. The 700 mg IV and 350 mg SC groupshad higher mean percent improvement in PASI scores than the placebogroup at all postdose time points. A total of 7 of 8 (88%) and 5 of 8(63%) subjects in the 700 mg IV and 350 mg SC groups, respectively,achieved a PASI 75 score or greater response. The 140 mg SC group hadhigher mean percent improvement in PASI scores than the placebo group upto Day 29, with 2 of 4 subjects (50%) achieving a PASI 50 response atany postdose time point.

The mean PGA improvement from baseline scores was higher in the 700 mgIV group compared with the placebo group at all time points; thesedifferences were statistically significant (α=0.05) at all time pointsbased on post hoc analyses, an exception was the mean PGA improvementscore on Day 85 (p=0.0510). Based on post hoc analyses, the mean PGAimprovement scores from baseline were significantly (α=0.05) higher inthe 350 mg SC group compared with placebo on Days 15 and 43; similarresults were observed for the 140 mg SC group on Day 15 (α=0.05).

TABLE 2.8 PASI Responses for Cohort 9 Cohort 9 PASI score A B C-PBO D EF G H-PBO I J Pre dose 17.4 15.2 26.2 11.6 11.0 16.0 12.6 11.8 12.5 12.1Day 15 6.6 6.1 17.8 5.2 6.4 7.8 5.0 8.4 2.7 2.9 Day 29 4.9 2.8 17.0 4.15.2 4.8 2.4 9.5 2.1 0.4 Day 43 4.1 0.9 19.5 1.3 2.4 4.5 1.0 8.8 2.8 0.0Day 64 7.0 4.5 21.2 2.2 1.8 9.5 2.4 11.4 2.8 0.0 Day 85 7.6 5.1 18.0 3.74.7 14.3 8.2 12.9 10.8 0.0 %PASI Reduction A B C-PBO D E F G H-PBO I JDay 15 62% 60% 32% 55% 42% 51% 60% 29% 78%  76% Day 29 72% 82% 35% 65%53% 70% 81% 19% 83%  97% Day 43 76% 94% 26% 89% 78% 72% 92% 25% 78% 100%Day 64 60% 70% 19% 81% 84% 41% 81%  3% 78% 100% Day 85 56% 66% 31% 68%57% 11% 35% −9% 14% 100%

TABLE 2.9 PASI Response for Cohort 9 - Percent Improvement over Time byTreatment Group AM-14 at 700 PASI Placebo mg dose (IV) Response TimePoint n/N (%) n/N (%) ≥50% Day 15 0/2(0) 7/8(88) Day 29 0/2(0)  8/8(100)Day 43 0/2(0)  8/8(100) Day 64 0/2(0) 7/8(88) Day 85 0/2(0) 4/8(50) ≥75%Day 15 0/2(0) 2/8(25) Day 29 0/2(0) 5/8(63) Day 43 0/2(0) 7/8(88) Day 640/2(0) 4/8(50) Day 85 0/2(0) 1/8(13) ≥90% Day 15 0/2(0) 0/8(0)  Day 290/2(0) 1/8(13) Day 43 0/2(0) 3/8(38) Day 64 0/2(0) 1/8(13) Day 85 0/2(0)1/8(13) N = Number of subjects who received treatment and had anassessment at each visit n = Number of responders at each visit

TABLE 2.10 PASI Responses for Cohort 10 A B C D E-PBO Cohort 10 PASIscore Pre dose 12.6 15.4 10.5 11.0 16.8 Day 15 12.0 11.6 5.2 8.1 17.2Day 29 11.6 5.4 6.6 9.9 16.2 Day 43 12.1 9.8 8.1 9.8 14.8 Day 64 15.613.6 8.9 10.1 15.9 Day 85 12.5 15.6 8.9 9.6 16.5 % PASI Reduction Day 155% 25% 50% 26% −2%  Day 29 8% 65% 37% 10% 4% Day 43 4% 36% 23% 11% 12% Day 64 −24%  12% 15%  8% 5% Day 85 1% −1% 15% 13% 2%

TABLE 2.11 PASI Responses for Cohort 11 Cohort 11 PASI score A B C D-PBOE F G H I J-PBO Pre dose 13.3 17.8 14.2 12.5 6.4 13.4 19.0 13.3 12.016.3 Day 15 6.9 13.6 12.6 12.5 0.0 3.4 9.2 4.0 4.0 11.7 Day 29 7.8 11.812.8 11.0 2.4 0.4 7.2 2.8 2.1 11.7 Day 43 10.4 7.8 14.4 10.7 1.0 7.5 4.84.8 2.0 12.7 Day 64 11.3 7.4 13.1 12.5 2.4 5.9 4.5 5.6 6.0 11.3 Day 8511.0 12.2 14.0 12.5 2.4 6.2 7.6 5.2 5.8 12.6 %PASI Reduction A B C D-PBOE F G H-PBO I J-PBO Day 15 48% 24% 11%  0% 100% 75% 52% 70% 67% 28% Day29 41% 34% 10% 12%  63% 97% 62% 79% 83% 28% Day 43 22% 56% −1% 14%  84%44% 75% 64% 83% 22% Day 64 15% 58%  8%  0%  63% 56% 76% 58% 50% 31% Day85 17% 31%  1% −2%  63% 54% 60% 61% 52% 23%

Rheumatoid Arthritis Study Results

To date, all subjects in cohorts 1-3 (50 mg SC, 140 mg SC and 210 mg SC)have completed the study. All 24 subjects enrolled in cohorts 1-3 werereceiving concomitant MTX (n=23) or leflunomide (n=1). To date allsubjects in cohort 5 (420 mg IV) have completed dosing, and 6 of 8subjects in cohort 6 (700 mg IV) have been enrolled. AM-14 has been welltolerated at the doses tested (50, 140, and 210 mg SC).

Pharmacokinetic/Pharmacodynamic Modeling

Compartmental pharmacokinetic modeling was conducted on AM-14 serumconcentration time data from the healthy volunteers (cohorts 3 to 8). Atwo-compartment model with parallel linear and nonlinear eliminationpathways and an added compartment for SC absorption was used to describethe AM-14 concentration-time data. The nonlinear elimination pathway wasmodeled via Michaelis-Menten kinetics, with resulting maximumelimination rate (V_(max)) and Michaelis-Menten constant (K_(m)) of 1290μg/day/mL (4% SE) and 14.9 ng/mL (270% SE), respectively. The estimatedhuman pharmacokinetic parameters were used to simulate pharmacokineticconcentration-time profiles and calculate exposures (AUC and C_(max))across a range of single and multiple IV and SC doses for potentialclinical study. The single-dose predictions compared well withsubsequent available data from the psoriasis cohorts (cohorts 9 to 11).The multiple dose predictions also compared well with available datafrom cohorts 1 and 2 of the phase 1 b study, although with lessaccumulation of concentration than expected for the 140 mg every 2 weeksdosing. Additionally, the model also predicted well for AM-14pharmacokinetics in RA subjects in the phase 1 b study, suggestingcomparable pharmacokinetics of AM-14 among healthy and disease (both RAand psoriasis) populations.

Pharmacokinetic/Pharmacodynamic Relationships

There was a monotonically increasing relationship between the pEC50shift measured by the whole blood stimulation assay and theconcentration of circulating AM-14 measured by the pharmacokineticassay, as shown in FIG. 8. The concentration of AM-14 is on the x-axisand the pEC50 shift is on the y-axis. The log EC50 shift is measuredfrom the average of 2 baseline samples. The lower limit of quantitation(LLOQ) for the PK assay was 50 ng/mL, and therefore post-dose samplesbelow the LLOQ are plotted at 25 ng/mL on the x-axis, and have log EC50values predominantly below 2. The mean log EC50 shift for placebosamples is 0.02±0.6. Samples with measurable circulating AM-14consistently show an increase in log EC50, with higher shifts at higherconcentrations. Similar to placebo samples, the log EC50 shift withsamples at low concentrations of AM-14, below the LLOQ of 50 ng/mL, islimited. The overall relationship fits a model of competitive inhibitionbetween AM-14 and IL-17A.

AM-14 proposed doses and dosing regimens are depicted in FIG. 9 based onmodeling described above. The IC₅₀ and IC₉₀ levels for AM-14 are basedon data from the ex vivo whole blood stimulation assay, and uses acompetitive antagonism PK/PD model over an IL-17 concentration range of0.5 to 50 ng/mL. IC_(50/90): AM-14 serum concentration that inhibits theincrease of IL-6 mRNA level by 50/90% in the ex vivo whole blood assay.The 70 mg dose (with week 1 load) is projected to achieve significantexposure above the IC₅₀ level. The 140 and 210 mg doses administeredevery 2 weeks (with an additional dose at week 1) are expected toachieve sustained exposure within and above, respectively, the expectedIC₉₀ range for the duration of the study period. The 280 mg doseadministered every 4 weeks is also expected to achieve exposure withinthe expected IC₉₀ range, but with trough excursions below the IC₅₀range.

The exposure margins were estimated as the ratio of exposure incynomolgus monkeys post-dose on day 78 at 90 mg/kg SC to the predictedhuman exposure at steady state. The mean AUC_(0-168 hr) and C_(max)after dosing on Day 78 in the monkey toxicokinetic study was 159,000ug-hr/mL and 1180 ug/mL, respectively. The predicted steady stateAUC_(0-336 hr) after the third dose of 70, 140, or 210 mg dosesadministered every 2 weeks (with week 1 load) were 552, 4320, and 8230ug-hr/mL and the predicted steady state AUC_(0-672 hr) after the thirdand final dose of 280 mg administered every 4 weeks was 5280 ug-hr/mL.The 2-week margins based on AUC of the predicted human exposuresrelative to the exposures in the toxicity studies for 70, 140, and 210mg are 576, 74, and 39, respectively. For the 280 mg dose, the predicted4 week margin was 121.

Pharmacokinetic (PK) data (serum drug concentrations measured atpre-specified time points) of AM-14 were collected for each subject inStudy 1. Pharmacodynamic (PD) data (PASI score at baseline andpre-specified times post dose) were also collected for subjects in thefinal three cohorts (subjects diagnosed with moderate to severe plaquepsoriasis). Modeling was performed on preliminary data to characterizethe PK response in all subjects (based on actual dose administered) andto characterize the PD response (based on individual PK response).

A two compartment PK model with parallel linear and non-linear(Michaelis-Menten) elimination pathways and an added compartment forsubcutaneous dose absorption was determined to best fit the data (seeFIG. 10). Variance components were incorporated characterizingbetween-patient variability as well as residual variability. To modelthe PD, a peripheral effect site compartment was added to the modelcoupled with an indirect response model of inflammation synthesis anddegradation. Placebo absorption and time-course compartments werecompartment also added to model the time course of placebo response. Keyassumptions in the model included: inflammation was measured as PASIscore; drug concentrations in the effect site compartment inhibitedinflammation synthesis; placebo effect acted to stimulate reduction ofinflammation for all subjects; and endogenous synthesis (rate) ofinflammation occurred until dose administration. Other PD models werealso investigated but were found to be less optimal. The nonlinear mixedeffects software NONMEM VI (Icon Development Solutions, Ellicott City,Md., USA.) was used to fit all models to data.

FIG. 11 compares observed and predicted mean PASI response time-course(as percent change from baseline) after single dose administration ofAM-14 or placebo. The model characterizes well the actual PASI responsedata. Mean peak response for the highest dose (700 mg IV) was greaterthan 80% PASI improvement.

FIG. 12 presents predicted time course of mean PASI response for fourmultiple dose scenarios (over 12 weeks) including placebo effect basedon the model developed from single dose data. The modeled placeboresponse was assumed to act after only the first dose, this being aconservative estimate. The mean response for the 140 mg SC dose (at WK0, 1, 2, 4, 6, 8, 10) was expected to exceed 50% PASI improvement formuch of the study period including the 12 week (day 84) primary efficacyendpoint. The mean response for the 210 and 280 mg SC doses (at WK 0, 1,2, 4, 6, 8, 10) was expected to exceed 75% PASI improvement for much ofthe study period including the 12 week (day 84) primary efficacyendpoint. The predicted response for repeated 210 and 280 mg dosing issimilar to, but of longer duration than, that observed for the single700 mg IV dose, as shown in FIG. 11.

FIG. 13 depicts predicted week 12 dose responses for a range of doses(mg SC) given at WK 0, 1, 2, 4, 6, 8, and 10 based on the responsepredicted in FIG. 12 at day 84 (week 12). Dose-response curves (with 90%CI) are given for mean week 12 PASI response and percent of subjectsexpected to achieve PASI 50, 75, 90 at week 12.

Example 3 Gene Regulation in Psoriasis Patients with an IL-17Antagonistic Antibody

The following data demonstrates that inhibition of IL-17R activationstrongly influences gene regulation in psoriasis patients. Therefore,aspects of the invention include methods of regulating gene expressionin psoriasis patients using IL-17 antagonistic antibodies. An “IL-17antagonistic antibody” is an antibody that inhibits IL-17A or IL-17A/Ffrom activating its cognate receptor(s) including IL-17RA, IL-17RC, andIL-17RA/RC. IL-17 antagonistic antibodies includes antibodies againstIL-17RA or antibodies against IL-17A and/or IL-17A/F.

In patients from cohort 9 of Study 1 (see Example 2), predose 6 mm skinpunch biopsies were taken from a non-lesional location and from a lesionthat was large enough to support two further nearby biopsies afterdosing. Two subsequent biopsies were taken two weeks and six weeks aftertreatment with AM-14, at the predesignated lesional positions,regardless of skin lesional appearance at the time of biopsy. Thebiopsies were immediately sliced longitudinally, with one halfimmediately placed into liquid nitrogen, and the other half frozen instandard OCT medium for IHC (immunohistochemistry). Placement intoliquid nitrogen was specified to happen in less than two minutes afterinitial punch, and the OCT freezing specified to happen within fiveminutes of the initial punch. The frozen punches were maintained at −70C or in dry ice.

RNA was prepared using standard Qiagen® or Ambion® RNA isolation kitsfrom the punches without allowing them to thaw. The RNA was checked forquality and yield, and then processed with the NuGen Ovation® labelingkits for analysis on Affymetrix® U133plus2 microarrays. The data weretransferred as .CEL files into Rosetta Resolver for analysis.

Ratios (Resolver id numbers 69671, 69672, and 69673) were calculatedbetween the three sets of lesional samples (Predose, Day 15, and Day 43)versus the non-lesional baseline samples, to generate fold-changevalues, using only the Cohort 9 samples from patients receiving AM-14.Arrays used were barcodes skn47471, skn47475, skn48862, skn48866,skn48870, skn48876, skn48879, skn48883 (non-lesional), skn47470,skn47474, skn48861, skn48865, skn48869, skn48875, skn48878, skn48882(lesional), skn47472, skn47476, skn48863, skn48867, skn48871, skn48877,skn48880, skn48884 (Day 15 Lesional), skn47473, skn47477, skn48864,skn48868, skn51554, skn48881, skn51556, and skn51557 (Day 43 Lesional).A set of sequences were identified as being increased in lesional versusnon-lesional skin. Some of these sequences were selected for having highfold-change values, and others were selected from being commonlymentioned in the literature as being associated with the immunopathologyof psoriasis or being a known drug target for the treatment ofpsoriasis, such as IL-23 and TNF.

An additional Resolver Ratio Experiment (#68458) of non-lesional versuslesional psoriasis gene expression was created using samples frompsoriasis patients external to Study 1 (purchased through Asterand®,plc., Detroit, Mich.) These samples included microarray barcodesskn41609, skn41610, skn41611, skn41613, skn41614, skn41616, skn41617,skn41618, skn41619, skn41620, skn41621, skn41622, skn41623, skn41624,skn41625, skn41626, skn41698, skn41699, skn41702, skn47051, skn47052,skn47053, skn47054, skn47055, skn47056, skn47057, skn47058, skn47059,skn47060, skn47061, and skn47062. This ratio was used to confirm thatthe selected probe sets all represented sequences that were regulated inpsoriasis, and could be properly observed in the study. The ratio valuesin this comparison were not as high as in the comparison betweenpre-dose lesional and non-lesional samples from the Study 1, which maybe a result of various treatments being used by the individualsproviding the external samples, who may not have had the samerestrictions on medications.

TABLE 3.1 Psoriasis associated sequences have highly elevated expressionin lesional relative to non-lesional skin, and almost completely resolvein lesional skin after treatment with AM-14. Gene (primary sequence)names are the current annotated Entrez names for the Affymetrix ®sequences whose IDs are the sequence codes in the second column. 6967169672 69673 68458 Cohort Cohort Cohort External 9 Pre 9 Pre 9 Pre PsO NLNL vs. NL vs. NL vs. Primary vs. PsO Cohort Cohort Cohort SequenceSequence L 9 Pre L 9 D 15 9 D 43 Name Code Fold-Change CXCL13 205242_at9.3 20.9 6.6 6.5 GZMB 210164_at 3.7 7.8 2.6 1.6 IFNG 210354_at 6.3 8.52.5 3.0 IL12B 207901_at 10.0 4.3 0.8 1.0 IL17A 216876_s_at 5.0 9.3 1.80.8 IL17F 234408_at 3.2 3.4 0.9 1.0 IL19 220745_at 3.6 33.9 1.1 1.2 IL1B39402_at 6.5 24.0 1.4 0.9 IL20 224071_at 4.4 12.9 1.5 1.4 IL22 222974_at3.1 10.7 1.6 1.0 IL23A 220054_at 2.2 2.7 1.0 1.0 IL8 202859_x_at 3.958.9 1.1 0.7 KRT16 209800_at 4.4 6.5 1.0 1.5 KRT6A 209125_at 2.8 3.3 1.11.2 MMP12 204580_at 5.8 4.3 0.6 0.9 MX1 202086_at 3.6 3.5 1.9 1.5 NOS2210037_s_at 3.2 4.6 0.9 1.3 S100A7A 232170_at 11.0 33.1 0.9 1.2 S100A8202917_s_at 2.8 4.3 2.3 2.1 S100A9 203535_at 6.2 14.1 1.3 1.6 SERPINB13216258_s_at 3.8 24.5 1.7 3.0 SERPINB3 210413_x_at 11.5 55.0 1.7 2.3SERPINB4 211906_s_at 16.2 91.2 1.1 1.3 TNF 207113_s_at 1.5 1.5 1.0 0.9Average 5.6 18.5 1.6 1.6 PsO = psoriasis; NL = non-lesional; L =lesional; Pre = predose

Notably in Table 3.1, many of the genes reduce their expression almostto the non-lesional baseline within two weeks of treatment with AM-14,in some cases going below the pre-dose level seen in the non-lesionalskin. Notably, TNF is reduced to the non-lesional expression level(Fold-change=1.0), as is IL23A. IL19 is reduced to only 10 to 20% abovenon-lesional expression (Fold-change=1.1 to 1.2), while IL12B isactually reduced to below the non-lesional level (Fold-change=0.8 to1.0). These changes are achieved within two weeks and broadly maintainedat these low levels at six weeks. These unprecedented changes are veryrapid across a wide set of genes that are implicated in the pathogenesisof psoriasis. To further dissect the changes in gene expression intofunctional groups of genes, RNAs from cytokine-stimulated keratinocyteswere profiled on the Affymetrix® U133 chips. Triplicate stimulations forIL-17A and for IFN-gamma were averaged in ratios (#49933, and #49939)against triplicate controls. Profiles used were barcodes skn48829,skn48833, skn48837 (control), skn48830, skn48834, skn48838, (IL-17A),and skn48832, skn48836, skn48840 (IFN-gamma). Sequences (i.e., partialsequences of the designated genes) were selected from each stimulationexperiment that would allow preferential monitoring of the effect ofthat cytokine. For example, sequences selected for the IFN-gammasignature were highly statistically significant, all induced at least10-fold with IFN-gamma, and not induced more than 1.2 fold (20%increase) by IL-17A. Because IFN-gamma is such a strong stimulus, it wasmore difficult to select sequences for IL-17A that were unaffected byIFN-gamma, but in a similar fashion, IL-17A signature sequences were allstatistically significant, more highly induced than other sequences withsimilar expression and were not induced significantly more by IFN-gamma.For both sets, the sequences were required to have increased expressionin psoriasis lesional skin as compared to non-lesional. These two setscould then allow separate measurements of inflammation along each axisto dissect the effects of AM-14 treatment.

As shown below in table 3.2, eighteen sequences were selected for theIL-17 signature based on their elevation in the IL-17A keratinocytestimulation, without higher skewed expression in the IFN-gammastimulations. In both the external psoriasis samples and in the Cohort 9samples, the sequences are elevated in psoriatic lesional skin. As canbe seen in the last two columns, these sequences have a dramaticreduction in expression, returning close to non-lesional levels afterAM-14 treatment. From an average of over 28-fold higher expression inthe predose lesional biopsies, they return to an average of less thantwo-fold within two weeks after treatment with AM-14. Some, includingthe defensins S100A7 and DEF4B have expression levels below the originalnon-lesional levels.

TABLE 3.2 Expression of IL-17A inducible genes in keratinocytes treatedwith IL-17A or IFN-gamma, or in psoriasis skin samples. Eighteensequences were chosen as elevated with IL-17A stimulation for 24-hoursin human keratinocytes, and their fold-change values determined forinduction in keratinocytes after 24-hour cytokine stimulation,non-lesional versus lesional external samples, or from psoriatic lesions(with or without AM-14 treatment) in comparison to pre-dose non-lesionalsamples. Experiment ID 49933 49939 68458 69671 69672 69673 ExperimentName 20060279 Predose Non- 20060279 20060279 Neg lesional PredosePredose Neg Control PsO NL vs. Non- Non- Primary Control vs. vs. vs. PsOPreDose lesional lesional Sequence Sequence IL-17A IFNg L Lesional vs.D15 vs. D43 Name Code Fold-Change C15or148 223484_at 4.7 5.5 2.5 3.8 0.60.8 CCL20 205476_at 4.2 0.9 5.8 28.8 1.7 1.4 CXCL1 204470_at 3.4 1.7 4.438.9 4.6 4.1 CXCL6 206336_at 6.0 0.5 4.2 17.8 1.5 1.2 DEFB4 207356_at45.7 5.4 8.9 33.1 0.6 0.8 IL1F9 220322_at 5.4 2.8 4.9 22.9 1.6 2.9 LCN2212531_at 3.7 0.5 8.5 13.8 3.8 4.2 PDZK1IP1 219630_at 10.2 11.5 2.6 6.01.0 1.6 PDZK1IP1 1553589_a_at 9.8 10.7 2.6 7.1 1.1 1.4 RHCG 219554_at2.8 1.2 4.6 11.2 0.6 0.7 S100A12 205863_at 4.1 2.1 14.1 95.5 1.7 0.3S100A7 205916_at 6.8 2.1 1.9 2.9 1.3 1.4 SAA1 208607_s_at 4.3 3.7 1.63.7 3.5 4.9 SAA1 214456_x_at 2.9 2.8 2.0 3.6 4.0 3.7 SPRR2C 220664_at5.9 0.9 10.5 32.4 0.5 0.5 TMPRSS11D 207602_at 7.8 6.3 4.1 89.1 2.3 0.8VNN3 220528_at 83.2 11.0 8.9 100.0 2.9 1.7 ZC3H12A 218810_at 3.2 1.8 3.04.7 1.7 1.4 Average 11.9 4.0 5.3 28.6 1.9 1.9

As shown below in Table 3.3, thirty-three sequences were selected forthe IFN-gamma signature based on their elevation in the IFN-gammakeratinocyte stimulation, without higher expression in the IL-17Astimulations. In both the external psoriasis samples and in Study 1samples, the sequences are elevated in lesional skin. As can be seen inthe last two columns, these sequences have a substantial, but incompletereduction in expression, returning towards non-lesional levels followingtreatment with AM-14. Some, such as CCL2 and IRF1 have non-lesional orlower expression levels within two weeks of treatment with AM-14 whileothers such as CCL7 and TNFRSF9 continue to decrease over time.

TABLE 3.3 Expression of IFN-gamma inducible genes in keratinocytesstimulated with IL-17A or IFN-gamma, or in psoriasis skin samples.Thirty-three sequences were chosen as elevated with IL-17A stimulationfor 24-hours in human keratinocytes, and their fold-change valuesdetermined for induction in keratinocytes after 24-hour cytokinestimulation, non-lesional versus lesional external samples, or frompsoriatic lesions (with or without AM-14 treatment) in comparison topre-dose non-lesional samples. Experiment ID 49933.0 49939.0 68458.069671.0 69672.0 6967 

Experiment Name 20060279 Predose Non- 20060279 2006027 

Neg lesional Predose Predose Neg Control PsO NL vs. Non- Non- PrimaryControl vs. vs. vs. PsO PreDose lesional lesional Sequence SequenceIL-17A IFNg L Lesional vs. D15 vs. D43 Name Code Fold-Change1570541_s_at 1570541_s_at 1.0 100.0 5.5 6.5 2.1

239979_at 239979_at 0.8 17.0 4.2 3.3 2.4

ACE2 219962_at 1.0 31.6 4.9 8.5 1.5

AIM2 206513_at 0.8 100.0 5.5 4.3 1.9

APOL1 209546_s_at 0.9 63.1 2.7 2.6 1.3

APOL6 219716_at 0.9 17.8 3.3 2.7 1.1

APOL6 241869_at 0.7 41.7 4.1 1.9 1.1

CCL22 207861_at 0.9 22.4 3.5 3.5 0.9

CCL5 1405_i_at 0.2 22.4 1.5 1.4 2.2

CCL5 204655_at 0.3 20.0 1.4 1.3 2.3

CCL7 208075_s_at 0.5 89.1 3.8 5.4 1.6

CCL8 214038_at 0.8 100.0 1.7 1.8 1.3

CLEC7A 221698_s_at 0.9 21.4 2.8 3.6 1.9

EBI3 219424_at 0.4 21.4 3.6 3.1 1.3

GBP4 235175_at 1.0 100.0 1.8 1.2 1.3

GBP5 238581_at 0.8 100.0 6.6 4.6 3.1

GBP5 229625_at 0.8 91.2 3.0 3.3 2.6

IFIT3 204747_at 0.9 21.4 2.9 3.0 1.1

IL12RB1 1552584_at 0.6 61.7 2.0 2.3 1.7

IL2RG 204116_at 0.6 67.6 2.0 2.0 1.3

IL32 203828_s_at 0.5 19.5 2.1 1.4 1.5

IRF1 238725_at 0.8 83.2 1.9 1.3 1.0

ISG20 33304_at 1.0 53.7 3.2 3.2 1.3

ISG20 204698_at 1.2 45.7 2.9 2.8 1.3

LIPA 236156_at 0.7 27.5 2.9 2.3 1.4

RSAD2 213797_at 1.1 46.8 6.0 9.8 2.5

RSAD2 242625_at 1.1 52.5 4.5 3.9 1.3

RTP4 219684_at 0.6 100.0 4.3 6.0 3.2

SAMD9L 226603_at 0.8 19.1 1.7 1.5 1.4

SLC15A3 219593_at 1.0 100.0 1.3 1.0 1.0

TNFRSF9 211786_at 0.6 14.1 3.1 3.3 2.1

TRIM10 221627_at 0.7 21.4 4.2 13.8 3.6

XAF1 206133_at 0.9 16.6 2.3 1.8 1.6

Average 0.8 51.7 3.1 3.4 1.7

indicates data missing or illegible when filed

The gene sets for IL-17A and IFN-gamma response were further trimmed toremove two sequences each that had extremely high correlationcoefficients with another sequence from the same gene. The probe sets208607_s_at (SAA1) and 219630_at (PDZK1IP1) were dropped from the IL-17Asignature set in Table 3.2, and the probe sets 1405_i_at (CCL5) and213797_at (RSAD2) were excluded from the IFN-gamma signature set inTable 3.3. The remaining sequences were used to calculate a Mahalanobisdistance based on a core set of skin profiles from normal individualsfor each sequence set (Table 3.4). In this calculation, the set of basecase normal skin samples are used to define the mean for each sequenceand a sequence set covariance matrix, which is used in combination withthe normalized sequence intensities of each sample to define aMahalanobis distance metric for that sample on that gene set. Distanceswere also calculated for external non-lesional, and lesional samples,which are in a similar range to the pre-dose samples from Study 1. Notsurprisingly for these two sets of inflammatory cytokine-regulated genesets, the lesional skin samples have much higher signature distancesthan the non-lesional samples. This is true for both the external sampleset, and for the pre-dose samples for this study. Surprisingly, thelarge pre-dose signature distances are dramatically decreased with asingle dose of AM-14, with the IFN-gamma signature distance droppingmost of the way towards the non-lesional value, and the IL-17A signaturedistance dropping even below the non-lesional value.

TABLE 3.4 Average Mahalanobis Distance IFN-gamma IL17A Distance DistanceNonLesional PreDose 674 10403 Lesional PreDose 8465 627631 Lesional Day15 2338 4133 Lesional Day 43 1705 1329 NonLesional External 712 82285Lesional External 11122 649648

Overall these data show a dramatic molecular change (i.e.,downregulating genes that are implicated in the pathogenesis ofpsoriasis) in the psoriasis lesional skin as a result of AM-14 treatmentthat happens rapidly and is sustained or increased through six weeksafter dosing. The change is observed across a wide range of genes thatare involved in inflammation and recognized as being affected bypsoriasis. It is also observed in a set of genes that are upregulated byIFN-gamma in keratinocytes, and is most striking in a set of genes thatare upregulated by IL-17A. This genotypic response correlates with thepercent reduction in PASI scores shown in Example 2 for patients treatedwith AM-14. The rapidity of the morphological and genotypic responses inthe psoriasis patients treated with AM-14 is unprecedented and may beunique to AM-14 (and the other anti-IL-17RA antibodies disclosed herein)as well as IL-17RA antagonists, as defined herein, such as antibodiesthat bind IL-17A and block its binding to IL-17RA and/or IL-17RC and/orheteromeric receptors comprising IL-17RA and IL-17RC.

Example 4 Histological Analysis of Psoriasis Patients Treated with anAnti-IL-17 Receptor “A” Monoclonal Antibody

The following experiments demonstrate that inhibition of IL-17Ractivation strongly influences histopathological responses in psoriasispatients. Treatment with AM-14 (700 mg IV single doses) in subjects withpsoriasis led to significant improvements in multiple histopathologicparameters compared to placebo. These parameters including epidermalthickness, Ki-67 and Keratin-16 levels. These data are presented inFIGS. 14, 15, and 16. FIG. 14 shows the changes in epidermal thicknessover time in subjects receiving AM-14 (filled object). Administration ofAM-14 led to significant reductions in epidermal thickness in psoriasissubjects compared to placebo. compared to placebo (empty circles). FIG.15 depicts the changes in Keratin-16 (KRT16) over time in subjectsreceiving AM-14 (filled object) compared to placebo (empty circles).Administration of AM-14 led to significant reductions in KRT16 mRNA inpsoriasis subjects compared to placebo. FIG. 16 depicts the changes inKi67 counts over time in subjects receiving AM-14 (filled object)compared to placebo (empty circles). Administration of AM-14 led tosignificant reductions in Ki67 counts in psoriasis subjects compared toplacebo.

In addition, treatment with AM-14 as described in the precedingparagraph reduced the numbers of infiltrating dermal leukocyte subsets(CD3+, CD11c+, CD8+, DC-LAMP+) as described in Table 4.0. The reductionsin leukocyte subsets indicate that both T-cells (CD3+ and CD8+) andmature dendritic cells (CD11c+ and DC-LAMP+) were reduced by treatmentwith AM-14. Both of these cellular subsets have been implicated inamplifying and maintaining the pro-inflammatory milieu in psoriaticskin. The histopathologic data correlated with significant PASIimprovements, as 7 of 8 subjects achieved at least 75% improvement inPASI score at week 6. Together these data identify numerous histologicconsequences of IL-17 activation and subsequent inhibition in human skinby AM-14.

TABLE 4.0 Subject NL LS d 0 LS d 14 LS d 42 CD3+ AM-14A 92 305 258 149AM-14 B 171 139 144 83 PBO A 8 155 508 247 AM-14 C 27 368 253 105 AM-14D 50 507 0 176 PBO B 37 295 338 374 AM-14 E NA 600 284 201 AM-14 F 57143 153 168 AM-14 G 54 248 244 88 AM-14 H 46 177 102 54 mean 71 311 180128 sd 48 171 98 53 CD11c+ AM-14 A 189 478 336 168 AM-14 B 57 205 124167 PBO A 30 141 264 298 AM-14 C 85 322 696 85 AM-14 D 72 463 235 228PBO B 77 192 488 985 AM-14 E 358 156 156 AM-14 F 108 987 318 150 AM-14 G42 128 93 78 AM-14 H 79 204 285 109 mean 90 393 280 143 sd 48 271 191 50CD8+ AM-14 A AM-14 B 35 103 61 19 PBO A 11 64 92 43 AM-14 C 56 56 150 39AM-14 D 26 118 165 89 PBO B 7 30 60 172 AM-14 E 231 67 46 AM-14 F 6 28455 106 AM-14 G 47 28 64 48 AM-14 H 72 132 63 48 mean 40 136 89 56 sd 2392 47 30 DC-LAMP AM-14 A AM-14 B 10 48 19 11 PBO A 0 92 60 59 AM-14 C 567 148 8 AM-14 D 0 32 15 45 PBO B 0 98 142 250 AM-14 E 267 5 2 AM-14 F 0150 28 14 AM-14 G 0 42 6 4 AM-14 H 0 56 3 0 mean 3 95 32 12 sd 4 86 5215

Example 5 Glutamate Formulation Sting Study

Six formulation buffers were tested in a total of 72 healthy humanparticipants over a three-day period of time. None of the bufferscontained antibody. Participants assessed and recorded perceivedpain/stinging after each buffer injection using 100-mm visual analogscale where larger numbers represent more pain (referred to as VAS).After all injections were administered, participants ranked-ordered thebuffers by pain/stinging perceived from least to most painful (buffers1-6).

The following six buffers were assessed:

A: 10 mM sodium acetate, pH 5.2, 9% sucrose, 0.004% polysorbate 20;B: 10 mM sodium glutamate, pH 4.8, 9% sucrose, 0.01% polysorbate 20;C: 30 mM sodium glutamate, pH 4.8, 8% sucrose, 0.01% polysorbate 20;D: 10 mM sodium acetate, pH 4.8, 3% L-proline, 0.01% polysorbate 20;E: 30 mM sodium glutamate, pH 4.8, 3% L-proline, 0.01% polysorbate 20;andF: 20 mM sodium citrate, pH 5.0, 5% sorbitol.

Buffer A was the AM-14 formulation buffer used in the clinical studiesdescribed in Examples 2-4 and 6 and was designated as the “comparator”buffer. Buffer F was a citrate-based buffer and was considered a“positive control” buffer for assessing relative pain/stinging due toits reputation in the art for causing stinging in subcutaneousinjections.

The results of the study demonstrate that: (a) subcutaneous injection ofthe positive control buffer (F) resulted in measurable transientlocalized pain (stinging) at injection site (mean VAS score=56.9 mm(SD=±30.64), median VAS score=59.5 mm); (b) subcutaneous injection ofthe other buffers (A-E) resulted in significantly less reported stinging(mean VAS scores ranging from 12.1 mm to 28.4 mm, median VAS scores of4.5 mm to 15.0 mm, p<0.0001); (c) based on mean VAS scores, the order(least to worst) of reported stinging by the buffers was B<A<D<E<C<F;(d) based on median VAS scores, the order (least to worst) of reportedstinging by the buffers was B<A<D<C<E<F; (e) after all injections wereadministered, participants ranked the buffers (1-6) by sting perceivedfrom least to most painful. The median participant ranking of sting wasbuffers A=B=D<buffers C=E<buffer F; (f) pair-wise comparisons of VASscores demonstrated that sting induced by comparator buffer A andbuffers B and D were indistinguishable (p=0.47 and 0.07, respectively),however, stinging induced by buffer B was less than that for buffer D(p=0.01), and that buffers containing 30 mM glutamate (buffer C and E)caused somewhat more stinging than the buffer containing 10 mM glutamate(buffer B, p≤0.0005). The pair-wise comparisons are provided in Table5.0, below.

This data demonstrates the unexpected result that a 10 mMglutamate-based formulation does not induce an unacceptable degree ofstinging in humans upon subcutaneous injection.

TABLE 5.0 Summary of Pairwise Vehicle Comparison of Pain ScoresConfidence Treatments Interval Compared Difference Coverage Lower Upperp-value A vs F −42.3 90 −48.0 −36.6 <0.0001 B vs F −44.8 95 −51.6 −38.0<0.0001 C vs F −28.4 95 −35.3 −21.6 <0.0001 D vs F −36.0 95 −42.8 −29.2<0.0001 E vs F −32.6 95 −39.5 −25.8 <0.0001 A vs B 2.5 90 −3.2 8.20.4700 A vs D −6.3 90 −12.0 −0.6 0.0711 B vs D −8.8 95 −15.6 −2.0 0.0117B vs C −16.4 95 −23.2 −9.5 <0.0001 B vs E −12.2 95 −19.0 −5.3 0.0005

Example 6 AM-14 Phase 2 Psoriasis Study

A Phase 2 randomized, double-blind, placebo-controlled, multiple-dosestudy to evaluate the safety, tolerability, and efficacy of AM-14 insubjects with moderate to severe plaque psoriasis was performed toestablish a dose-response efficacy profile of AM-14 compared withplacebo as measured by the percent improvement from baseline inPsoriasis Area and Severity Index (PASI) score at week 12 and toidentify an appropriate dose regimen for future trials. For additionalinformation see ClinicalTrials.gov Identifier no. NCT00975637.

Inclusion Criteria:

-   -   Subject has had stable moderate to severe plaque psoriasis for        at least 6 months    -   Subject has received at least one previous phototherapy or        systemic psoriasis therapy or has been a candidate to receive        phototherapy or systemic psoriasis therapy in the opinion of the        investigator    -   Subject has involved BSA 10% and PASI 12 at screening and at        baseline.

Exclusion Criteria:

-   -   Subject diagnosed with erythrodermic psoriasis, pustular        psoriasis, medication-induced, or medication-exacerbated        psoriasis    -   Evidence of skin conditions at the time of the screening visit        (eg, eczema, guttate psoriasis) that would interfere with        evaluations of the effect of IP on psoriasis    -   Subject has any active CTCAE grade 2 or higher infection    -   Subject has a significant concurrent medical condition or        laboratory abnormalities, as defined in the study protocol    -   Subject has used the following therapies within 14 days of the        first dose: UVB therapy or topical psoriasis therapies other        than Class I or II topical steroids    -   Subject has used the following therapies within 28 days of the        first dose: Class I or II topical steroids, UVA therapy (with or        without psoralen), or systemic psoriasis therapies    -   Subject has used the following therapies within 3 months of the        first dose: adalimumab, alefacept, etanercept, infliximab,        certolizumab, or live vaccines    -   Subject has used an anti-IL12/IL23 inhibitor within 6 months of        the first dose    -   Subject has previously used an anti-IL17 biologic therapy,        efalizumab, or rituximab

The study evaluated the efficacy of AM-14 compared with placebo asmeasured by the percent improvement in PASI score at week 12. Aftersigning informed consent forms, completing all screening assessments,and meeting all eligibility criteria, approximately 175 subjects wererandomized in a 1:1:1:1:1 ratio and received AM-14 and/or placebo at day1 and weeks 1, 2, 4, 6, 8, and 10. Subjects were randomized to receiveAM-14 received 70, 140, or 210 mg at day 1 and weeks 1, 2, 4, 6, 8, and10 or 280 mg at day 1 and weeks 4 and 8. For approximately 50 subjects,additional samples at additional timepoints for PK analysis werecollected as a sub-study. For approximately 175 subjects in the mainstudy, PK assessments with sparse sampling were performed. Randomizationwas stratified to assure treatment balance in the PK substudy and bybody mass index (above and below 35). Skin samples were collected fromapproximately 32 subjects at a subgroup of participating sites at day 1(1 each, lesional and nonlesional), week 2 (lesional only), and week 12(lesional only). Serum, plasma, and blood RNA was collected for allsubjects.

AM-14 was provided as a sterile, preservative-free liquid containing 70mg/mL AM-14 formulated in 10 mM sodium acetate, 9% sucrose, 0.004% w/vpolysorbate 20 at pH 5.2. The formulation was supplied as a frozenliquid in glass vials containing 1 mL deliverable volume (single useonly). Placebo clinical supply was provided in glass vials as a frozen,sterile protein-free solution. The vials were single-use vialscontaining approximately 1 mL of vehicle solution per vial. The controlgroup received placebo at day 1 and weeks 1, 2, 4, 6, 8, and 10(Q2WK+week 1). Other subjects received one or more placebo shots asneeded to maintain the blinded nature of the study.

PASI assessments were performed by a blinded assessor. The blindedassessor was a healthcare professional who has been certified as trainedwith the standard PASI training material provided by Amgen. To maintainthe blind, the assessor did not have any other interaction with thesubjects other than the PASI, sPGA, and BSA involvement assessments. Theassessor did not discuss the subject's clinical status or have access tothe subjects' medical records or CRFs including prior assessment data.PASI assessments were performed by the same assessor throughout thestudy.

The PASI 75, 90, and 100 responses at week 12 are provided in Table 6.0,below. This study shows AM-14 is efficacious at treating psoriasis (inparticular, moderate to severe plaque psoriasis) at doses ranging from70 to about 300 mg, and specifically at doses of 70, 140, 210, and 280mg at the dosing regimens described above. These data show that AM-14showed efficacy over placebo at all doses tested (70, 140, 210, and 280)

TABLE 6.0 PASI 75, 90, 100 Responses at Week 12 AM-14 AM-14 AM-14 AM-1470 mg 140 mg 210 mg 280 mg Placebo q2W q2W q2W q4W (N = 38) (N = 39) (N= 39) (N = 40) (N = 42) n/N1 (%) n/N1 (%) n/N1 (%) n/N1 (%) n/N1 (%)PASI 75 0/38 13/39  30/39 33/40 28/42 Response (0.0%) (33.3%) (76.9%)(82.5%) (66.7%) P value <0.0001 <0.0001 <0.0001 <0.0001 PASI 90 0/387/39 28/39 30/40 24/42 Response (0.0%) (17.9%) (71.8%) (75.0%) (57.1%) Pvalue 0.0057 <0.0001 <0.0001 <0.0001 PASI 100 0/38 4/39 15/39 25/4012/42 Response (0.0%) (10.3%) (38.5%) (62.5%) (28.6%) P value 0.0452<0.0001 <0.0001 0.0003 N = Number of participants randomized n = Numberof responders N1 = Number of participants who were randomized and had avalid measurement value at week 12, after imputation % = n/N1*100 Pvalue is for comparison between each AM-14 dose group and placebo and isnominal without multiplicity adjustment P value was based on theCochran-Mantel-Haenszel Test stratified by BMI (Body Mass Index) group(≤35, >35) and adjusted for baseline PASI group (≤median(17.45), >median (17.49)) NRI (NonResponder Imputation) was used toimpute missing data

1.-16. (canceled)
 17. A method of treating Sjögren's syndrome,dermatomyositis, or systemic lupus erythematosus in a human patient inneed thereof, which method comprises administering to the patient aneffective amount of a formulation comprising (i) 30 mM glutamic acid,(ii) a pH of 4.8±0.2, (iii) 3±0.2% proline (w/v), (iv) 0.01±0.002% (w/v)polysorbate 20, and (v) a human monoclonal antibody, or anantigen-binding fragment thereof, wherein the human monoclonal antibodycomprises: (a) a heavy chain CDR1 comprising the amino acid sequence ofSEQ ID NO: 5, a heavy chain CDR2 comprising the amino acid sequence ofSEQ ID NO: 7, a heavy chain CDR3 comprising the amino acid sequence ofSEQ ID NO: 8, and a light chain CDR1 comprising the amino acid sequenceof SEQ ID NO: 9, a light chain CDR2 comprising the amino acid sequenceof SEQ ID NO: 10, and a light chain CDR3 comprising the amino acidsequence of SEQ ID NO: 11; (b) a heavy chain variable domain comprisingthe amino acid sequence of SEQ ID NO: 3 and a light chain variabledomain comprising the amino acid sequence of SEQ ID NO: 4; or (c) aheavy chain variable domain comprising the amino acid sequence of SEQ IDNO: 1 or SEQ ID NO: 12 and a light chain variable domain comprising theamino acid sequence of SEQ ID NO: 2; wherein the formulation comprises adose of human monoclonal antibody of about 70 mg, about 140 mg, about210, or about 280 mg, and whereby the human monoclonal antibodyspecifically binds to human IL-17 receptor A and inhibits the binding ofIL-17A to IL-17 receptor A, and the Sjögren's syndrome, dermatomyositis,or systemic lupus erythematosus is treated in the human patient.
 18. Themethod of claim 17, wherein the human monoclonal antibody orantigen-binding fragment thereof is selected from a single chainantibody, a diabody, a triabody, a tetrabody, a Fab fragment, a F(ab′)2fragment, an IgD antibody, an IgE antibody, an IgM antibody, an IgG1antibody, an IgG2 antibody, an IgG3 antibody; and an IgG4 antibody. 19.The method of claim 17, wherein the formulation is administered to thepatient once a week, once every two weeks, or once every four weeks. 20.The method of claim 17, wherein the formulation is administered to thepatient subcutaneously, intramuscularly, or intravenously.
 21. Themethod of claim 17, wherein the patient suffers from Sjögren's syndrome.22. The method of claim 17, wherein the patient suffers fromdermatomyositis.
 23. The method of claim 17, wherein the patient suffersfrom systemic lupus erythematosus.